Identification of biomarkers associated with cervical cancer: a combined in silico and molecular approach by Ludaka, Namhla
  
 
Identification of biomarkers associated with cervical 
cancer: A combined in silico and molecular approach  
 
 
 
 
 
 
Namhla Ludaka 
Thesis presented in the fulfilment of the requirements for the  
Magister Scientae 
Department of Biotechnology, DST/Mintek Nanotechnology Innovation Centre, 
University of the Western Cape, Cape Town, South Africa 
 
Supervisor: Dr. Ashley Pretorius 
Co-supervisors: Dr Mervin Meyer 
 
 
 
 
 
 
 
 
  
i 
 
DECLARATION OF AUTHORSHIP 
 
 
Last name: Ludaka      First name: Namhla 
 
I declare that the work presented here is, to the best of my knowledge and belief, original and 
the result of my own investigations, except as acknowledged, and has not been submitted, 
either in part or whole, for a degree at this or any other University. 
Formulations and ideas taken from other sources are cited as such and all work which was the 
result of joint effort, have been acknowledged by complete references. This work has not 
been published. 
 
…………………………      .......………………. 
Signature           Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ii 
 
ACKNOWLEDGEMENTS 
I would like to thank my father in heaven, the omnipresent God, for being the source of my 
strength and the strength of my life. Thank you God for everything, for all the answered 
prayers and always reminding me that I am a more than a conqueror through Christ my Lord. 
A special thanks to my supervisors Dr. A. Pretorius and Dr. M. Meyer for the unconditional 
support, guidance and help during my master‘s degree. Specially, I feel the need to 
acknowledge them for having believed in my capabilities and for making me believe in 
myself.  It has been a privilege working with them. Thank you very much. Thank you to 
NRF, NIC/MINTEK and MRC for the funding and making this project a reality. In addition, I 
would like to thank all of my group colleagues (BRG/NIC) for all the teaching, for  having 
supported me whenever I was feeling down, for all the laughs that made me feel good  and 
for all the experience shared during these months. Their friendship was, without any doubt, 
very important to overcome the difficulties faced. Big thanks to Mrs Potelwa for the love, 
support, encouragement and for unlocking my potential.  
 
From the bottom of my heart a big thank you to my family, especially my mother and 
grandmother (Sange Totose and Noluthando Ludaka), from the youngest to the elderly for the 
prayers, love, support, sacrifices and patience not only during the execution of this master 
thesis, but also through my entire academic course. They were truly important in all of my 
victories and they are definitely ‘the only love that doesn‘t make me weak‘. Thank You to my 
church family (DCF) for the love, laughs and more importantly their unending prayers. I 
could not end these acknowledgments without a special thanks to my best friend and partner 
for having appeared in my life when I needed him the most. For all the love, support, care 
and patience during the good and the bad days and for all the advices and for always 
listening, I do thank him a lot.   
 
 
 
 
 
 
 
  
iii 
 
ABSTRACT 
Cervical cancer is the leading cause of cancer mortality among black women in South Africa. 
It is estimated that this disease kills approximately 8 women in South Africa every day. 
Cervical cancer is caused by the human papillomavirus (HPV) with the most common 
screening method for cervical cancer being Papanicolaou (Pap) smear, test amongst others. 
However, less than 20% of South African women go for these tests. There are several reasons 
why women do not go for these tests but the invasiveness of the test is one of the major 
causes for the low rate of screening. Lateral flow devices offer medical diagnosis at the point-
of-care, allowing for the quick initiation of the appropriate therapeutic response. These tests 
are more cost-effective for the healthcare delivery industry, and can potentially be used by 
patients to self-test in the privacy of their homes and allow them to make informed decisions 
about their health. Therefore, the aim of this study was to use computational methods to 
identify serum biomarkers for cervical cancer that can be used to develop a point-of-care 
diagnostic device for cervical cancer.  
 
An in silico approach was used to identify genes implicated in the initiation and development 
of cervical cancer. Several bioinformatics tools were employed to extract a list of genes from 
publicly available cancer repositories. Multiple gene enrichment analysis tools were 
employed to analyze the selected candidate genes. Through this pipeline, ~28190 genes were 
identified from the various databases and were further refined to only 10 genes. The 10 genes 
were identified as potential cervical cancer biomarkers. A subcellular compartmentalization 
analysis clustered the proteins encoded by these genes as cell surface, secretory granules and 
extracellular space/matrix proteins. The selected candidate genes were predicted to be 
specific for cervical cancer tissue in a cancer tissue specificity meta-analysis study. The 
expression levels of the candidate genes were compared relative to each other and a graph 
constructed using gene expression data generated by GeneHub-GEPIS and TiGER databases. 
Further gene enrichment analysis was performed such as protein-protein interactions, 
transcription factor analysis, pathway analysis and co-expression analysis, with 9 out of the 
10 of the candidate genes showing co-expression.  
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A gene expression analysis done on cervical cancer cell lines, other cancer cell lines and 
normal fibroblast cell line revealed differential expression of the candidate genes. Three 
candidate genes were significantly expressed in cervical cancer, while the seven remaining 
genes showed over expression in other cancer types. The study serves as basis for future 
investigations to diagnosis of cervical cancer, as well as for cancers. Thus, they could also 
serve as potential drug targets for cancer therapeutics and diagnostics. 
 
 
Key Words: cervical cancer, early diagnosis, biomarkers, bioinformatics, gene 
enrichment analysis 
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CHAPTER 1: Literature Review 
     1.1. Cancer Overview 
Cancer is a very complex disease that develops due to the accumulation of genetic and 
epigenetic changes that allow for deviation from normal cellular and environmental control 
(Kumar et al., 2009). Cancer is a common term used for a group of more than 100 diseases 
that affect any part of the body and is also known as neoplasms or tumours. The most 
prominent characteristics of cancer are the uncontrolled proliferation of cells beyond their 
normal boundaries, the ability to invade and invade adjoining body tissue and that they can 
metastasize to other tissue. Cancer morbidity or mortality is a result of metastases (Kumar et 
al., 2009). Cancer is a disease that affects people of all races and age groups and is 
responsible for about 13% of all deaths.  According to the World Health Organisation (WHO) 
there were around 12 million new cases of cancer in 2008, and 7 million deaths resulting 
from cancer in the same year. Among the known cancer types, lung cancer is the most 
common cause of death in both genders, followed by breast cancer in females and prostate 
cancer in males (Iyoke and Ugwu, 2013). According to estimates by the International Agency 
for Research on Cancer (IARC), in 2008, 53% of the 12.7 million new cases of cancer and 
63% of the 7.6 million cancer deaths occurred in developing countries (Iyoke and Ugwu, 
2013).  
 
A portion of the cancer types are specific to a particular sex, such as uterine sarcoma, cervical 
and ovarian cancer in females and prostate cancer in males. There are more than a 100 
distinct types of human cancers that have been described and different tumour subtypes are 
found within specific organs (Grizzi and Chiriva-Internati, 2006). Cancerous cells are 
neoplastic and they proliferate in defiance to normal cell control, thus preventing normal 
cellular function, tissue, and organ formation with the potential of becoming malignant and 
colonising surrounding tissues (Abbott et al., 2006). Cancers are classified by the type of cell 
and tissue they originate from. Approximately 90% of cancers are characterised as 
carcinomas, which develop from epithelial cells with the most common sites being the breast, 
lung, prostate and colon (Petersen et al., 2003). The high prevalence of carcinomas is due to 
the fact that epithelial cells are the site of active cell proliferation and are constantly exposed 
to both physical and chemical carcinogens. Sarcomas are tumours that originate from 
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connective tissue or mesenchymal cells, whereas cancers that arise from hemopoietic cells 
are lymphomas and leukaemia. All the different types of cancers can be further subdivided 
based on specific cell type, location in the body and the structure of the tumour (Petersen et 
al., 2003). The majority of cancers occur as a result of initial somatic hypermutation of a 
single cell that must undergo a number of mutations in order to become cancerous, a process 
that is described in Hanahan and Weinberg’s hypothesis of 6 cumulative alterations (Hanahan 
and Weinberg, 2000). Surgery is used to remove benign tumours and they consist of 
neoplastic cells which remain clustered together in a single mass. When aggressive cancerous 
cells divide, they penetrate the basement membrane. The result of this local invasion is 
neoplastic cell adherence to adjacent tissue and through, production of proteolytic enzymes 
and factors such as matrix metalloproteinases (MMPs); degradation of the extracellular 
matrix (ECM) is caused in surrounding tissue. As a result cancer cells are able to cross tissues 
into neighbouring stroma, thus facilitating deeper invasion and metastasis. This process is 
responsible for tumours becoming malignant as the cells invade the surrounding tissue and 
cross the basal lamina to enter the blood stream (Laerum, 1997). Tumours that are metastatic 
are able to survive in circulation and have the ability to travel through blood vessels to other 
organs and through the lymphatic vessels to lymph nodes. As a consequence, the 
development of secondary tumours at a site far away from the primary tumour is a hallmark 
of cancers that are more aggressive and rendering them difficult to eradicate (Liotta and 
Kohn, 2001).  
 
1.1.1. Pathogenesis of Cancer 
There are 6 hallmarks of cancer that define malignancy as hypothesised by Hanahan and 
Weinberg: (i) sustaining proliferative signalling, (ii) evading growth suppressors, (iii) 
activating invasion and metastasis, (iv) enabling replicative immortality, (v) inducing 
angiogenesis and (vi) resisting cell death as shown in figure 1.1 (Hanahan and Weinberg 
2011).  It is believed that the majority of cancer cell genotypes are a manifestation of these 
six essential alterations in cell physiology that collectively dictate malignant growth.
 
 
 
 
   
 
 
Figure 1.1: The six hallmark capabilities of cancer, adapted from Hanahan & Weinberg 2011. 
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1.1.1.1. Sustaining Proliferative Signalling  
The ability of cancer cells to sustain chronic proliferation is the most fundamental trait of 
cancer cells. Normal tissues carefully control the production and release of growth-promoting 
signals that instruct entry into and progression through the cell growth-and-division cycle, 
thereby ensuring a homeostasis of cell number and thus maintenance of normal tissue 
architecture and function. Cancer cells, by deregulating these signals, become masters of their 
own destinies (Hanahan and Weinberg 2011). The tumor cells generate many of their own 
growth signals by altering extracellular growth signals, transcellular transducers of those 
signals, or intracellular circuits that translate these signals into action (Mees et al., 2009). The 
enabling signals are conveyed in large part by growth factors that bind cell-surface receptors, 
typically containing intracellular tyrosine kinase domains. The latter proceed to emit signals 
via branched intracellular signalling pathways that regulate progression through the cell cycle 
as well as cell growth (that is, increases in cell size); often these signals influence yet other 
cell-biological properties, such as cell survival and energy metabolism. Tumour cells are 
therefore less dependent on exogenous growth stimulation (Hanahan and Weinberg 2011).   
 
1.1.1.2. Evading Growth Suppressors 
Cancer cells have the ability to evade antiproliferative signals, such as soluble growth 
inhibitors and immobilized inhibitors, in order to progress (Hanahan and Weinberg 2000). 
These signals block proliferation by either forcing the cells out of the active proliferative 
cycle into the G0 phase of the cell cycle, or by inducing the cells to permanently give up their 
proliferative potential by making them enter into post mitotic states. At the molecular level, 
most antiproliferative signals are funnelled through retinoblastoma 1 (RB1) and its two 
relatives, retinoblastoma-like 1 (RBL1) and retinoblastoma-like 2 (RBL2) proteins. 
Disruption of the RB1 pathway allows proliferation, causing cells insensitive to antigrowth 
factors that normally operate along this pathway to block progression (Weinberg, 1995).  
 
Cancer cells also circumvent powerful programs that negatively regulate cell proliferation 
and many of these programs depend on the actions of tumour suppressor genes. The two 
prototypical tumour suppressors encode the RB (retinoblastoma) and tumor protein p53 
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(TP53 proteins); which operates as central control nodes within two key complementary 
cellular regulatory circuits that govern the decisions of cells to proliferate or alternatively, 
activate senescence and apoptotic programs (Hanahan and Weinberg 2011).   
 
1.1.1.3. Resisting Cell Death 
In the face of aberrant and potentially cancerous growth signalling, normal cells activate 
programmed cell death (Apoptosis). Apoptosis is also activated in response to DNA damage, 
although other cellular stresses can also be features of cancerous cells. Apoptosis thus 
represents a crucial mechanism to avoid accumulation of damaged cells and mutations that 
can culminate in cancer formation (Fulda, 2009). Programmed cell death, is triggered by a 
variety of physiological signals, and will unfold in a precisely choreographed series of steps, 
including disruption of cellular membranes, breakdown of cytoplasmic nuclear skeletons, 
degradation of chromosomes, and fragmentation of the nucleus (Fulda, 2009). Cancer cells 
acquire the ability to evade this induction of cell death and this ability is crucial for 
maintaining tumour growth and allowing cancerous cells to form in the first stage of disease 
development. Part of the ability of tumour cells to evade programmed cell death is derived 
from survival signals supplied by the stromal compartment (Hanahan and Weinberg 2011).  
Failure of apoptosis is essential to all types of cancer and the apoptotic program is present in 
a latent form in almost all cell types in the body (Hanahan and Weinberg 2011).   
 
Cells use a variety of ways to avoid cell death; some of these strategies are less clearly 
understood than others. One of the most commonly mutated tumour suppressor genes is the 
p53 gene. 50% of the tumour apoptosis evasive characteristics are a result of p53 protein 
inactivation.  More than half of all types of human cancers have a mutated or missing gene 
for p53, resulting in a damaged or missing P53 protein. As an alternative to achieving the loss 
of P53, cancer cells can compromise the activity of P53 by increasing the inhibitors of P53, 
or silencing the activators of P53. The P13 Kinase-AKT/ PKB pathway is another pathway 
used by tumour cells to evade programmed cell death. This pathway is concerned with the 
anti-apoptotic survival signals. This survival signalling circuit is found to be up-regulated 
either by extracellular factors such as IGF-1and IL-3, or by intracellular signals involving 
RAS, thus leading to evasion of apoptosis (Wong, 2011). 
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1.1.1.4. Inducing Angiogenesis 
Induced angiogenesis is the process by which cancer cells induce and sustain the growth of 
new blood vessels. Oxygen and nutrients are crucial for cell function and survival, they are 
supplied by the vasculature. Cells within aberrant proliferative lesions initially lack this 
angiogenic ability, reducing their capability to expand. Cancer cells on the other hand 
overcome this restriction by inducing and sustaining angiogenesis (Hanahan and Folkman 
1996). Tumour growth depends on angiogenesis to first provide oxygen and nutrients to 
proliferating cells and to then provide a physical route for metastasis transport. Tumours, like 
normal tissues also require sustenance as well as the ability to evacuate metabolic wastes and 
carbon dioxide. The tumour-associated neovasculature generated by the process of 
angiogenesis addresses these needs (Hanahan and Weinberg 2011).   
 
Tumour cells make use of the vascular network and penetrate into the blood using it as a 
transport channel, circulating through the intravascular channel and then proliferate to distant 
sites. Since nutrients and oxygen are a necessity for cancer cells, angiogenesis becomes an 
important factor for the progression of cancer. Angiogenesis therefore becomes a multistep 
process of which angiogenic factors (VEGF, bFGF TGF-alpha etc.) play a huge role. It 
involves degradation of the basement membrane in tissues; endothelial cells which are 
activated by angiogenic factors (Nishida et al., 2006). Upon further migration, they 
proliferate and stabilise and angiogenic factors will further continue the angiogenic process 
forming new blood vessels. Angiogenesis therefore creates a vascular support for cancer cells 
and absence thereof will result in tumours becoming necrotic or even becoming apoptotic. 
Angiogenic factors have thus received remarkable attention, with the VEGF family being one 
of the major angiogenic agents in neoplastic tissues (Nishida et al, 2006). 
 
1.1.1.5. Activating Invasion and Metastasis 
Invasion of normal host tissue by the tumour and metastasis ultimately leads to death of the 
cancer patient. Cancer cells acquire the ability to become motile and migrate from the 
original tumour site and this is the acquisition of the invasive and metastatic phenotype. 
Changes promoting invasion happens at the cellular level, including changes in the 
expression of surface markers which allow the cells to adhere to the surrounding tissues. 
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Metastasis is a particularly complex process, but usually occurs by cancer cells invading 
blood vessels and hitchhiking through the circulatory system to other sites of the body 
(Hanahan and Weinberg 2011).   
 
1.1.1.6. Enabling Replicative Immortality 
The ability of cancerous cells to avoid controlled growth often involves finding ways of 
repairing or lengthening the telomeres to prevent them from shortening, allowing indefinite 
replication (Hanahan and Weinberg 2011). About 10% of cancers develop as result of 
inherited genetic susceptibility; therefore a 90% risk of cancer development can be attributed 
to a combination of diet, environment, cultural and lifestyle factors (Bell, 2005). Mitogenic 
growth factors are required by normal cells to stimulate proliferation; however cancerous 
cells have developed autonomy from this mode of down-regulation. Cells that are cancerous 
have the ability to gain self-sufficiency for growth signalling by overexpression or 
constitutive activation of growth factor receptors, thus synthesising their own growth factors 
and deregulating downstream signalling targets (Peters et al., 2001). Cancerous cells evade 
negative anti-growth signals which act by forcing cells out of the cell cycle into a resting, 
quiescent state (G0), or by inducing cells to undergo differentiation into a post-mitotic state. 
This can also be achieved by abrogation of growth-inhibitory receptor function (Zeimet et al., 
2000). Cancerous cells have the ability to evade programmed apoptotic cell death by 
abrogation of pro-apoptotic sensor receptor signalling that monitors the extracellular and 
intracellular environment. Cells in every tissue survive by being in close proximity to a blood 
vessel to supply oxygen and nutrients. Cancer cells have developed mechanisms to encourage 
growth of new blood vessels from pre-existing vessels (angiogenesis) by changing the 
angiogenesis inducers such as vascular endothelial growth factor (VEGF) and inhibitors such 
as thrombospondin-1 (Hanahan and Folkman 1996). As previously mentioned cancer can 
originate in any part of the body and cancers that develop in the female reproductive system 
are known as women's reproductive cancers. These encompass cancer of the breast, cervix, 
ovaries, endometrium, vagina and vulva. The most persistently occurring cancers of the 
reproductive system in women worldwide are breast, cervical and ovarian cancer (Getahun, et 
al., 2013).  
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1.2. Cervical Cancer 
1.2.1. Global Cervical Cancer Burden 
Cervical cancer (CC) is the third most prevalent cancer amongst women globally, with 
approximated 83,195 new cases and 35,673 mortality cases in 2012 (Human Papillomavirus 
and Related Diseases Report, South Africa, 2014). More than 80% of the global burden 
occurs in developing countries, where cervical cancer accounts for 13% of all female cancers. 
However, cervical cancer is not limited to the developing world as it is considered in Europe 
as a significant public health problem with an incidence rate of 10.6 per 100 000. As a result 
of better developed prevention programmes, Western Europe has a lower incidence and 
mortality rate when compared to Central and Eastern Europe (Mareea and Moitse, 2014). In 
western countries, the incidence and mortality of CC have declined substantially over the past 
decades, whereas in developing countries there is a slight increase in mortality (Figure 1.2). 
This is probably due to the lack of screening and the greater impact of infectious cofactors in 
the latter regions. Age-adjusted incidence rates vary from about 10 per 100 000 per year in 
many industrialized countries to more than 40 per 100 000 in some developing countries. 
More than 88% of deaths occur in low-income countries and it is predicted to increase to 
91.5% by 2030 (Maree and Wright, 2010).  
 
 
 
 
  
Figure 1.2: Estimated cervical cancer incidence worldwide in 2008. GLOBOCAN 2008, International Agency for Research on Cancer (IARC). 
The red and dark highlighted areas have the highest incidence rates. 
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Cervical cancer is the second most frequently diagnosed cancer in women after breast cancer 
and the leading cause of cancer death in African women
 
(Jemal et al., 2012). Eastern and 
Western Africa are the highest risk regions with Age Standardised Rate (ASR) greater than 
30 per 100 000, Southern Africa with ASR 26.08 per 100 000, South-Central Asia (ASR 24.6 
per 100 000), and South America and Middle Africa with 23.9 and 23.0 ASRs respectively. 
Low-risk regions are Western Asia, Northern America and Australia/New Zealand with 
ASRs less than 6 per 100 000. Cancer of the cervix is most prevalent in women in Eastern 
Africa, Melanesia and South-Central (Globocan, 2008).Cervical Cancer was responsible for 
approximately 275 000 deaths in 2008 and 88% of these cases occurred in developing 
countries. Africa reported 53 000 death cases, 31 700 in the Caribbean and Latin America 
and Asia with 159 800 deaths (Figure 1.2) (Globocan, 2008).  
 
According to Globocan 2012, cervical cancer is the fourth most common cancer in women, 
and the seventh overall, with an estimated 528 000 new cases in 2012. There were an 
estimated 266 000 deaths from cervical cancer worldwide in 2012, accounting for 7.5% of all 
female cancer deaths. Almost nine out of ten (87%) cervical cancer deaths occur in the less 
developed regions. According to the IARC, there were 453 531 cases of cervical cancer in 
developing countries in 2008 representing 89% of global estimates. Also 273 000 deaths 
occur worldwide every year due to cervical cancer out of which 83% occur in developing 
countries ((Iyoke and Ugwu, 2013). It is estimated that 80-90% of cervical cancer cases in 
developing countries occur amongst women of age 35 and older. Cervical cancer develops 
very slowly from precancerous lesions to advance cancer.  On a global scale the incidence of 
cancer is low in women under the age of 25 years, however, the incidence increases at age 35 
to 40 years and reaches the maximum in women of ages 50 and 60 years  (Alliance for 
Cervical Cancer Prevention, 2005). It is estimated that about 83% of all new cases of cervical 
cancer and 85% of all deaths related to cervical cancer are occurring in developing countries 
as shown in Figure 1.2 (Anorlu, 2008).   
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1.2.2. Cervical Cancer Burden in Africa and South Africa 
In Africa, there is an absence of accurate information relating to the extent of cancer and this 
is mostly due to cancer registries being limited. However, this does not reflect the magnitude 
of the cancer problem on the African continent. The African continent has a population of 
267.9 million women from age 15 years and older who are at risk of developing cervical 
cancer, with an estimation of 80 000 women diagnosed with cervical cancer annually and 
over 60 000 women perishing from this disease (Denny, 2012). The incidence of cervical 
cancer in Africa varies substantially by region, with the highest rates in Africa (ASIR>40 per 
100 000) all found in Eastern, Southern and Western Africa as shown in figure 1.3 (Denny, 
2012). There are many compelling factors that contribute to the high prevalence of cervical 
cancer in Africa. These include limited human and financial resources, competing health 
needs, poorly developed healthcare systems, war and civil strife, women being uninformed 
and disempowered and the nature of cytological-based screening programmes (Mareea and 
Moitse, 2014). 
 
 
 
 
  
Figure 1.3: Incidents and mortality of cervical cancer in 2008. Source Jemal et al., 2011,  
http://onlinelibrary.wiley.com/doi/10.3322/caac.20107/pdf  
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Other factors include lack of access to preventative measures, late diagnosis, treatment and 
palliation for cancer related disease. The African continent has poor accessibility to cancer 
therapies (Denny, 2012). In South Africa, cervical cancer is the second most diagnosed 
cancer in women with, 7735 new cases being diagnosed yearly and is the most common 
cancer in women aged 15-44 years (Table 1.1 and Figure 1.4) (Human Papillomavirus and 
Related Diseases Report, 2014). Cervical cancer has the highest incidence rate in South 
Africa, followed by breast cancer, lung cancer, cancer of the trachea and bronchi (Maree and 
Wright, 2010). In South African women, cervical cancer is the primary cause of death with 
approximately 4248 new cancer deaths occurring each year with the highest death rate among 
black women between the ages of 66-69 years (Figure 1.4). South African women, 
particularly black women, most often present late with cancer that is already in an advanced 
stage (Francis et al., 2011). 
 
Table 1.1: Incidence of cervical cancer in South Africa (estimations for 2012) 
Indicator South Africa Southern Africa World 
Annual number of new cancer cases 7,735 8,652 527,624 
Crude incidence rate
ɑ
 30.2 29.3 15.1 
Age-standardized incidence rate
ɑ
 31.7 31.5 14.0 
Cumulative risk (%) at 75 years old 3.1 3.1 1.4 
*Adapted from Human Papillomavirus and Related Diseases Report, 2014.  
 
The total age-adjusted incidence rate (ASIR) of cancer in the black population is far lower 
than the corresponding white population. Black women are most at risk of developing 
cervical cancer when compared to their white and coloured counterparts. According to the 
Department of Health of KwaZulu-Natal, cancer of the cervix accounts for 18.5% of 
gynaecological cancers, with approximately 5000 new cases being reported annually (Walker 
et al., 2002).   
 
 
 
 
  
Figure 1.4: Cervical cancer mortality compared to other cancers in women of all ages in South Africa, adapted Human Papillomavirus and 
Related Diseases Report, 2014. 
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1.3. Physiology and Anatomy of the Cervix 
The cervix is the lower portion of uterus that connects to the upper portion of the uterus. It is 
cylindrical in shape and connects the vagina and the uterus as depicted in figure 1.5 
(Junqueira and Carneiro, 2005). There are two narrow openings present in the cervix namely 
the internal and external ostiums (os). The location of the internal os is the topmost portion of 
the cervix and opens into the uterus and the external os is located at the minor portion of the 
cervix and opens into the vagina (Stevens and Lowe, 2005). The endocervical canal or canal 
of the cervix, which can change in width and length, is the passageway between the external 
ostiums and the uterine cavity. The cervix is divided into two parts, the endocervix which is 
the portion proximal to the uterus and the ectocervix proximal to the vagina. The endocervix 
has a fusiform shape and is composed of a single layer of mucous-secreting columnar 
epithelium and the ectocervix has a convex, elliptical surface and is composed of 
nonkeratinized stratified squamous epithelium (Arends et al., 1998). The transformation zone 
(TZ) or squamo-columnar junction  is the portion adjacent to the edge of the endocervix and 
ectocervix, where the columnar epithelium is converted to squamous epithelium by a process 
known as metaplasia. The transformation zone is the area where the majority of abnormal 
changes occur and is susceptible to carcinogens and diseases (Ross and Pawlina, 2006).  
 
 
 
 
  
Figure 1.5: Diagram of the uterus indicating the cervix, internal and external ostiums and the cervical canal (Martini and Bartholomew, 2007). 
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1.4. Risk Factors for Cervical Cancer 
The majority of women will be exposed to the human papilloma virus (HPV) virus at some 
stage in their life, however, only a fraction develop persistence of infection and subsequent 
life-threatening cervical disease, thus implicating other factors in cervical cancer 
pathogenesis. Risk factors associated with squamous cervical cancer, besides infection with 
HPV, include early age of coitus debut, numerous sexual partners, hormonal contraceptives, 
high parity, smoking and other sexually transmitted infections (STIs) (Dahlstrom et al., 
2011). The daunting challenge is to determine to what extent these risk factors possess 
inherent capabilities to induce cervical cancer, or if they advance proxy measures for the risk 
for present and/or past  high-risk (HR) HPV infection. Infection with HPV is the main factor 
responsible for initiation of cervical cancer through sexual intercourse. Out of the 100 
different HPV types, about 40 of these affect the genital areas. The other types infect the skin 
on other areas of the body such as hands or feet. HPV 6 and 11 are responsible for causing 
warts which develop in a period of six to eight weeks (Likes and Itano, 2003). 
 
The HPV is very difficult to identify because it’s asymptomatic, hence there is a need for 
routine cervical check-ups and HPV testing (Godfrey, 2007). There are about 13 high risk 
HPV strains that cause high-grade cervical cell abnormalities, with the high risk strains 
detected in 90% of cervical cancer incidences, with 70% of these caused by HPV 16 and 18. 
Infection by one HPV strain does not necessarily guarantee that a person is not susceptible to 
infection by a second or more strains. Individuals infected with mucosal HPV, about 5% to 
30% get infected with more than one viral type simultaneously (Pink book, 2011). A woman 
that has multiple sexual partners is at an increased risk of contracting HPV which is dominant 
in men (Likes and Itano, 2003). Also at risk of HPV infection are women with three or more 
full term pregnancies and this is due to the different hormonal changes associated with 
pregnancy. Girls aged 17 years or younger are also at an increased risk when they have their 
first full term pregnancy and are more at risk of developing cervical cancer later on in life 
when compared to women who get pregnant at age 25 years and above (American Cancer 
Society, 2010).  
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The risk associated with hormonal contraceptives could be explained by their hormonal 
influence on the cervical mucosa, thus rendering it more susceptible to persistent/progressing 
infection. According to Appleby et al., 2007, this can also be attributed to a higher risk for 
HR-HPV due to a concurrent tendency to (1) the infrequent use of condoms since already on 
contraception and (2) more likely to indulge in sexual activity than those not using 
contraceptives. Therefore, it is important to adjust for information on these factors as far as 
possible, and with large scale analyses, an association to contraceptive use still needs to be 
demonstrated (Appleby et al., 2007). High parity has been consistently found to increase the 
risk of squamous cell cervical carcinoma among HPV positive women. It leads to direct 
exposure of the transformation zone in the cervix to HPV infection, thus increasing the risk of 
cervical cancer (Munoz et al., 2002).  
 
1.5. Human Papilloma Virus and Cervical Cancer 
Human papilloma virus is the most common sexually transmitted virus. HPVs are double 
stranded DNA viruses, which are very small, with their genomes encoded by approximately 
8000 base pairs. There are nearly 100 types of HPV, with different variations in their genetic 
and oncogenic potential. Cervical cancer is caused by HPV strains that belong to a few 
phylogenetically related “High-risk” (HR) species (alpha-5, 6, 7, 9, 11) of the mucosotropic 
alpha genus. The types found most frequently associated with CC (-16, -18, -31, -33, -35, -45, 
-52, -58) and four less-common types (-39, -51, -56, -59) are classified in Group 1. The 
remaining types of HPV in the HR alpha species are classified as “possibly carcinogenic” 
(Group 2. 2A: -68; 2B: -26, -30, -34, -53, -66,-67, -69, -70, -73, -82, -85, -97). Finally, HPV -
6 and -11, which belong to the alpha-10 species, were not classifiable as to their 
carcinogenicity in humans (Group 3) and were also described as low risk (LR) strains (Abreu 
et al., 2012). Worldwide, the most common HR-HPV strains are -16 and -18, and 
approximately 70% of CC is due to these genotypes. LR-HPV strains, principally -6 and -11, 
are predominantly involved in the development of genital warts (Abreu et al., 2012).  HPV 16 
accounts for about half of the cervical cancer cases in the United States and Europe (Gómez 
and Santos, 2007). The HPV 18 strain has been also associated with adenocarcinoma of the 
cervix, but the connection is less pronounced and is age dependent (Gómez and Santos, 
2007). 
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1.6. Development of Cervical Cancer 
More than 80% of the population is infected with HPV at some point in their life. In rare 
cases (1%), this infection will eventually lead to cervical cancer and simultaneous infections 
with multiple HPV types are common (Southern Africa Litigation Centre, 2012). The 
majority of HPV infections, irrespective of the type, are asymptomatic and resolve over a 
short period of time without treatment, as the woman’s immune system will usually suppress 
or eliminate the HPV infection. The HPV infection persists in a small percentage of women 
(Southern Africa Litigation Centre, 2012). Cervical cancer develops over time when 
persistent HPV infection triggers alterations in the cells of the cervix, called precursor lesions 
or cervical intraepithelial neoplasia (CIN), or recently referred to as squamous intraepithelial 
lesions (SIL) (Southern Africa Litigation Centre, 2012). When these pre-cancerous lesions 
are left untreated, they can eventually lead to cancer. The lesions can progress from low 
grade (CIN 1) to high grade (CIN 2 and CIN 3) as their size, shape and number increases. 
Following its natural course, progression of the disease is slow and can take as long as 10 to 
20 years from the initial infection with HPV to invasive cancer (Southern Africa Litigation 
Centre, 2012).  
 
There are four steps involved in the development of cervical cancer: (i) HPV transmission, 
(ii) viral persistence, (iii) progression of a clone of persistently infected cells to precancer and 
(iv) invasion. Backward steps can also occur such as clearance of HPV infection and 
regression of precancer to normality as indicated in figure 1.6 (Schiffman et al., 2007).  There 
is a high chance for progression to precancerous lesions and ultimately invasive lesions, when 
HPV acquisition is followed by HPV persistence instead of clearance. HPV 16 and 18 
account for about 70% of all Squamous Cell Carcinoma (SCC) and for up to 85% of all 
adenocarcinomas. HPV has the ability to incorporate into human DNA, with HPV 16, 18 and 
45 being predominant HPV types in cervical cancer as they are more likely to integrate into 
the human genome than other HPV types (Hoste et al., 2013). When these three types of 
HPV cause cervical cancer, the patients are diagnosed on average 4 to 5 years earlier than 
those caused by other high-risk types (Hoste et al., 2013). HPV 16 and 18 positive Low-grade 
Squamous Intraepithelial Lesion (LSIL) is more likely to progress to CC than LSIL 
containing other HPV genotypes. HPV 16 and 18 account for 35% of LSIL but nearly 70% of 
CC worldwide. HPV 16 is more persistent and more likely to progress to CIN3+ (CIN3, 
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carcinoma in situ and invasive CC) than other high risk HPV types (Hoste et al., 2013). The 
onco-proteins E6 and E7 deactivate essential processes associated with tumour genes like p53 
and pRb functioning (Botha and Dochez, 2012). This ubiquitous infection does not lead to 
disease progression in all infected individuals and certain processes make individuals more 
susceptible to the development of pre-malignant and malignant disease. Since HPV is almost 
exclusively an epithelial disease, the virus is poorly presented to the adaptive immune 
system, which is important for induction of long term immunity. Most natural infections of 
HPV do not cause significant immunoglobulin responses and therefore the immune response 
after natural infections is not very pronounced (Botha and Dochez, 2012). After the initial 
exposure to HPV there is an incubation period of between 1 and 8 months after which the 
first HPV-related lesions might appear. There is active growth of the virus for a period of 
between 3 and 6 months but usually there are host-immune responses that will in most cases 
clear the infection by about 9 months (Botha and Dochez, 2012). A large percentage of the 
population will have sustained clinical remission but a small proportion will develop chronic 
infection and become HPV-DNA positive on repeated testing. These are the individuals that 
will be at highest risk for the development of pre-malignant conditions and later invasive 
cancer (Botha and Dochez, 2012). 
 
 
 
 
  
Figure 1.6: Major steps in cervical cancer carcinogenesis. HPV infection followed by clearance by the immune system or progression to 
precancer and invasion. The top row shows cytology and the bottom row shows colposcopy (Schiffman et al., 2007).  
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1.7. Types of Cervical Cancer 
There are two types of cells that line the surface of the cervix: which are the glandular cells 
and the squamous cells. Glandular cells are found in the middle and upper third of the cervix 
close to the lining of the uterus and these cells have a column-shape or columnar appearance. 
Squamous cells are thin, flat cells that line the bottom third of the cervix. The transformation 
zone or the squamocolumnar junction is the borderline between the glandular cells and 
squamous cells and this is the area where cervical dysplasia and cancer usually occur 
(Jefferies, 2008). These cells eventually develop into different types of cancer which include 
the following:  
 Squamous cell carcinoma: Cancer that develops from the cells covering the outer 
surface of the cervix at the top of the vagina (ectocervix).  
 Adenocarcinoma: is the type of cancer that develops from the glandular cells lining 
the cervical canal or in the upper portion of the cervix (endocervix). 
 Adenosquamous carcinomas: these are rare, mixed cancer cell types which contain 
features of both squamous cells and adenocarcinoma.   
 Small cell carcinoma and cervical sarcoma: are the other rare cancer types that can 
develop in the cervix (<1% of all cervical cancers) (Jefferies, 2008). 
 
Squamous cell carcinoma and adenocarcinoma are the most frequent types of cervical cancer 
and they are responsible for 85-90 % and 10-15 % of all cervical cancer cases respectively. 
They develop from the distinctive precursor lesions CIN / SIL and adenocarcinoma in situ 
(AIS) respectively (Lax, 2011). Invasive cancer occurs when the abnormal cells invade the 
deep muscle, fibrous tissue and the organs surrounding the uterus. Staging is the process of 
finding out how far the cancer has spread and the stage of cervical cancer informs about the 
size of the tumour, how deeply the tumour has invaded tissues within and around the cervix 
and whether there is metastasis to lymph nodes or distant organs. Determining the stage of 
the cancer is critical in determining what type of treatment should be offered (Southern 
Africa Litigation Centre, 2012). 
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1.8. Classification and Stages of Cervical Cancer 
There are various cervical cancer stages that indicate the extent and site of infection. The 
International Federation of Gynaecology and Obstetrics (FIGO) system is used in staging of 
invasive cervical cancer based on clinical criteria like size, penetration depth within the 
cervix and spreading within and beyond the cervix as shown in figure 1.7. According to the 
FIGO system, cervical cancer is divided into 4 different stages, with 10 sub-stages from IA to 
IVB (Koyama et al., 2007). In stage I, the cancer cells are strictly limited to the cervix and 
are divided into stage 1A, 1B1 and 1B2 depending on the depth of penetration. Stage II 
cancerous cells extend beyond the cervix to the upper two thirds of the vagina (IIA) or the 
parametrial tissue (IIB) and not to the pelvic side wall. Furthermore, stage III describes a 
tumour that has spread to the lower third of the vagina (IIIA) or to the pelvic side wall (IIIB) 
and in stage IV, the cancer is advanced and has invaded the mucosa of the bladder or rectum 
(IVA) or has metastasised to distant sites outside the pelvis (IVB) (Koyama et al., 2007).
 
 
 
 
  
Figure 1.7:  Illustration of the various stages of cervical cancer according to FIGO, adapted from Fauci et al., 2008. 
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1.9. Current Therapy and Prognosis of Cervical Cancer 
Normally, cervical cancer early stages are either treated with surgery, including radical 
hysterectomy or pelvic lymph node dissection or a combination of chemotherapy and 
radiation (Rasty et al., 2009). Stage IA cervical cancers are treated with surgery with a  five-
year survival rate exceeding 95%, however, for stage IB or early stage IIA surgery and 
chemo radiotherapy are the choice of treatment with a five-year survival rate of 80%. The 
locally advanced stages IIB, III and IVA are treated with chemo radiotherapy, with both 
brachytherapy and external radiation being given in combination with adjuvant cisplatin-
based chemotherapy which has been demonstrated to increase the efficacy of radiotherapy 
(Klopp and Eifel 2011). The five-year survival rates are 65%, 40% and less than 20% for 
stage IIB, III and IVA respectively, with stage IVB benefiting from local radiotherapy, which 
is combined with carboplatin and 5-FU-based chemotherapy and the disease is not curable 
once it reached this stage (Klopp and Eifel 2011). There are other tumour characteristics that 
are not included in the FIGO staging system that also influence prognosis of cervical cancer 
such as tumour volume as determined with high accuracy using imaging techniques in 
particular Magnetic Resonance Imaging (MRI) (Chiang and Quek, 2003).  
 
The presence of lymph node metastases is another factor that influences survival of cervical 
cancer patients. The lymph node metastasis incidence correlates with other parameters of 
poor prognosis such as increasing stage, diameter of the tumour, lymphovascular space 
involvement and parametrial involvement with another important independent prognostic 
factor for cervical cancer being the presence of positive lymph nodes. Also of important 
prognostic significance is the number of positive lymph nodes, site and number of nodal sites 
(Creasman and Kohler, 2004). An important aspect of the treatment regime is the incidence of 
serious side effects after therapy. As a result of the anatomical location of the cervix in the 
pelvis, the lower uterus, bladder and posterior urethra are exposed to radiation during 
treatment of cervical cancer. A consequence of this is several urinary adverse effects (AEs). 
The probability of developing grade 1 and 2 AEs following radiotherapy for cervical cancer 
has been reported to be 28%, increasing by an additional 17.4% in five years (Elliott and 
Malaeb, 2011). The acute toxic effects caused by treatment last for a short time and may be 
resolved with medical management. However, the long term toxic effects may cause 
permanent impairment in the quality of life of the survivors.  
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Since the recurrence rate is very high and the incidence of side effects is quite frequent, there 
is still a great need for improved treatment strategies (Klopp and Eifel, 2011). 
 
1.10. Screening and Diagnosis of Cervical Cancer 
There are two approaches used for the control of cervical cancer: primary and secondary 
prevention. Primary prevention involves a risk-reduction approach through behavioural 
interventions for sexual health care seeking behaviour or through the mass immunization 
against high risk HPVs. These preventive methods can eliminate the probability of the 
development of the disease and, in the case of cervical cancer, one would prevent its onset by 
eliminating the risk of being infected with HPV. This can be achieved either by abstaining 
from sexual intercourse or through HPV vaccination (Sehgal and Singh, 2009). Secondary 
prevention includes screening for precancerous lesions and treating them. This stops the 
progression of the disease once the individual has already been infected. Routine screenings 
for cervical cancer precursors followed by appropriate treatment is an effective preventative 
measure in curbing the incidence of cervical cancer (Sehgal and Singh, 2009).  
 
1.10.1. Screening of Cervical Cancer 
The objective of screening programmes is to lessen the rate of mortality and morbidity due to 
cervical cancer and to reduce the number of patients suffering from cervical cancer.  Basic 
screening programmes can lead to down-staging of cervical cancer, which in its own right 
offers benefits for patients (Botha et al., 2010). The lack of efficient high quality precancer 
screening, treatment resources and poor or lack of infrastructure results in an increased 
number of deaths in developing countries as a result of cervical cancer (Alliance for Cervical 
Cancer Prevention, 2009). Cancer of the cervix is preventable and highly curable by 
screening especially for those women who are asymptomatic for precancerous cervical cancer 
lesions. Early detection leads to faster and more successful treatment. It has been 
demonstrated by various studies that women who have been screened at least once in their 
lifetime between the ages of 30 and 40 have a reduced cervical cancer risk by 25-36% 
(Cervical Cancer Action, 2007).  
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It has been recommend by the American Congress of Obstetricians and Gynaecologists that 
cervical cytology screening begins at age 21 years and thereafter be repeated every 2 years 
for women aged 21-29 years and every 3 years for women aged 30 years or older who have 
had three prior normal pap smears. It is recommend that women who are infected with human 
immunodeficiency virus (HIV), immunosuppressed, and women previously treated for CIN 
2, CIN 3 or cancer should undergo frequent screening. Women aged 65–70 years with three 
prior consecutively normal pap smears, and no abnormal pap smears over a period of 10 
years may discontinue screening (Brown and Trimble, 2012).  
 
1.10.2. Current Status of Cervical Screening in South Africa 
There are two healthcare systems in South Africa with 80% of the population depending on 
the public sector, providing cost-free healthcare and 20% utilises private health care as they 
have medical insurance or can afford to pay for it (SouthAfrica.Info 2012). However, the 
South African Department of Health, in 1999, developed and adopted a National Cancer 
Control Policy which included a national programme for cervical cancer screening. The 
screening programme allows asymptomatic women aged 30 years and older three Pap smears 
within a ten-year period in their lifetime. The cervical cancer screening programme is 
implemented at district level at nurse-led primary health care clinics, which serve as an 
entrance to the public health care service (Mojaki et al., 2010). The rationale behind the 
starting age was based on the fact that cervical cancer affects women in early to late middle 
age.  The goal of the programme was to screen 70% of women in the targeted age group 
within 10 years from the initiation of the programme and to decrease cervical cancer 
incidence by 64% (Smith et al., 2003).  
 
However, according to Gakidou, et al., 2008 only 20% of the target population was screened. 
In some areas of the country the screening programme has been implemented but not 
throughout the country. The outcome is that presently there is no population-wide screening 
programme in South Africa. However, in some areas partial screening does take place and in 
the private sector opportunistic screening is commonly practised (Botha et al., 2010). In 
South African women, cervical cancer remains the second most common cancer and is most 
common in black women, accountable for 31% of the cancer burden in this group.  The 
 
 
 
 
  
21 
 
reflection of these figures is debatable as the registry is an under-representation. There are 
far-reaching implications associated with not being screened, as women with micro-invasive 
cervical cancer may not experience noticeable signs and symptoms and only seek health care 
when symptoms are evident and the disease is advanced (Maree and Moitse, 2014).  
 
1.10.3. Cervical Cancer Screening Methods 
Screening of cervical cancer is a way of preventing the disease from developing and 
diagnosing it at an early pre-cancerous stage. The three screening modalities are cytology, 
HPV detection and visual inspection. 
 
1.10.3.1. The Papanicolaou Test 
The Papanicolaou (Pap) smear test, also known as exfolative cervicovaginal cytology, is the 
most common technique used for screening and diagnosis of cervical cancer in its early 
stages. Women who are 18 years and older and sexually active are encouraged to undergo 
annual Pap smear tests. Cells are collected from the cervix by inserting a speculum inside the 
vagina and removing cells using a cotton swab or a small brush (Duraisamy et al., 2011).  
The cells are fixed on a glass slides and are sent to a cytology laboratory and evaluated by a 
trained cytologist or cytotechnician who determines the cell classification as atypical 
squamous cells of undetermined significance, low grade squamous intraepithelial lesions and 
high grade squamous intraepithelial lesions. Should abnormalities be encountered, additional 
tests will be performed (Duraisamy et al., 2011).  The value of the Pap smear in screening of 
cervical cancer cannot be disputed as the method has resulted in a reduction in cervical 
cancer related mortalities. However, there are several limits to this test such as sensitivity to 
detect precursors of cervical cancer which is less than 50%, inadequate collection and transfer 
of cells to the slide, presence of obscuring blood, inhomogeneous distribution of abnormal 
cells and inflammation or thick areas of overlapping epithelial cells. There is an occurrence 
of false-negative results associated with the Pap test and it is said that it is unlikely to detect 
60% of the general cervical cancer cases (Duraisamy et al., 2011).  
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1.10.3.2. Pelvic Examination 
The pelvic examination is also an important technique in cervical cancer detection and is very 
similar to the Pap smear. A speculum is inserted into the vagina and the doctor examines the 
vagina and surrounding organs both visually and manually. The doctor inserts gloved hands 
into the vagina and feels the cervix and surrounding areas with the fingers (Duraisamy et al., 
2011).  
 
1.10.3.3. HPV DNA Screening 
This procedure is targeted at identifying high risk HPV strains 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 59 and 68 which are commonly associated with high grade cervical intraepithelial 
neoplasia (HSIL) and invasive cancer of the cervix. Various methods such as southern blot 
hybridation are used with this screening method, however they are very laborious and tedious 
and are not suitable for clinical usage because they demand use of fresh tissue and not easy to 
conduct in mass screening programmes (Kerkal and Kulkarni, 2006). However, Hybrid 
capture 2 assay is a more suitable technique used and is utilised mostly in HPV-DNA 
screening. Samples that are used for screening are obtained from cell suspensions acquired 
from liquid based cytology or use of the cytocervical brush (Kerkal and Kulkarni, 2006).  
 
The FDA has approved three types of tests to detect oncogenic HPV DNA: Hybrid Capture 2 
test, Cervista_ HPV HR test and Cervista® HPV 16/18. The Hybrid Capture 2 test was 
approved in 2003 and it detects 13 oncogenic HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, and 68) by making use of full genome probes complementary to HPV DNA, 
specific antibodies, signal amplification, and chemiluminescent detection. The Cervista_ 
HPV HR test was approved in 2009 and detects 14 HR HPV types (16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 66, and 68) using a signal amplification method for detecting specific 
nucleic acid sequences. This method uses a primary reaction that occurs on the targeted DNA 
sequence and a secondary reaction that produces a fluorescent signal. There are two 
limitations associated with these tests. Firstly, neither test can differentiate between single 
HPV genotype infections and multiple concurrent HPV genotype infections and secondly, 
they cannot quantitate viral load. The third HPV DNA test, Cervista_ HPV 16/18 was 
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approved in 2009 and it only detects HPV 16 and 18, the genotypes most commonly 
associated with cancer, using a similar method to the Cervista_ HPV HR assay (Brown and 
Trimble, 2012).  
 
1.10.4. Visual Approaches to Screening 
Cervical cancer screening is limited by social infrastructure of the society being screened and 
financial resources, relying on methods that are low-cost and require fewer visits to the clinic. 
Therefore, alternative methods of screening may be implemented quickly and cheaply, such 
as visual inspection alone or with a magnifying device are presently utilised in low resource 
settings (Brown and Trimble, 2012). There are three approaches involved: (i) Visual 
inspection of the cervix with acetic acid (VIA), (ii) visual inspection after application of 
Lugol’s iodine (VILI) and (iii) visual inspection with magnification (VIAM) (Duraisamy et 
al., 2011).  
 
1.10.4.1. Visual Inspection with Acetic Acid  
For this procedure the cervix is examined following the application of acetic acid. A bivalve 
speculum is used to expose the cervix and 4% dilute solution of acetic acid is applied to the 
cervix. Lesions that stain acetowhite are regarded as positive for VIA and those with dull 
white plaques and faint borders are considered low grade VIA, whereas those with sharp 
borders are considered high grade VIA. If no acetowhite lesions are detected, the test is 
considered negative. Various studied have demonstrated VIA to be reliable, sensitive and cost 
effective in comparison with Pap smear testing, especially in low resource countries 
(Duraisamy et al., 2011). Visual inspection using acetic acid wash has a sensitivity of 79% 
(95% CI 73 to 85%) and a specificity of 85% (95% CI 81 to 89%) for the detection of CIN2+ 
lesions (Brown and Trimble, 2012). 
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1.10.4.2. Visual Inspection with Lugol's Iodine (VILI)   
After the cervix is examined using VIA, it is painted with Lugol's iodine solution and 
examined with the naked eye. Small high-grade lesions are easier to identify within the larger 
low-grade area. Abnormal areas of squamous epithelium (CIN or inflammation) does not 
stain brown. VILI is believed to be more accurate and more reproducible than VIA and to be 
much better than a Pap smear in identifying CIN (Duraisamy et al., 2011). The use of Lugol’s 
iodine solution can increase sensitivity marginally, by 10% compared to other screening 
methods, and does not change the specificity (Brown and Trimble, 2012). 
 
1.10.4.3. Visual Inspection with Magnification  
This is the technique that visualises the cervix under low magnification after application of 
acetic acid. Using a magnifying device to aid in evaluating the cervix has comparable 
sensitivity and specificity to VIA only. The sensitivity and specificity of visual detection are 
dependent on the skill of the provider and vary widely (Brown and Trimble, 2012). 
 
1.10.5. Cervical Cancer Diagnostic Methods 
If an abnormal result is obtained following a screening process, often additional tests needs to 
be performed to determine the extent of the pre-cancer or cancer. 
 
1.10.5.1. Colposcopy 
Colposcopy is magnified visual examination of the ectocervix, squamous columnar junction 
(SCJ) and endocervical canal. It is accompanied by a biopsy of any abnormal-looking tissue 
and is also similar to a Pap smear (Duraisamy et al., 2011). A solution that stains abnormal 
cells white is applied to the cervix and the doctor views the cells using a high-powered 
microscope to detect abnormal cancerous cells. Colposcopy is used as a diagnostic test and 
not a screening test. Other techniques that are used include Cone biopsy, Endocervical 
Curettage, Loop electrosurgical procedure (LLETZ/LEEP) and imaging (Duraisamy et al., 
2011). 
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1.10.5.2. Cone Biopsy 
Cone Biopsy is a procedure that is also known as conization, where a cone-shaped piece of 
tissue is removed from the cervix. The cone base is formed by the exocervix and the apex of 
the cone is from the endocervical canal with the transformation zone (the area in the cervix 
where pre-cancers and cancer are likely to develop) is contained within the cone specimen. 
Cone biopsy is also used as treatment to remove many pre-cancers and some very early 
cancers completely. If a huge amount of tissue is removed, the result is a higher risk of giving 
birth prematurely if the individual it to become pregnant (Duraisamy et al., 2011). 
 
1.10.5.3. Endocervical Curettage 
Endocervical curettage also called endocervical scraping is a procedure where a curette is 
inserted into the endocervical canal to scrape the inside of the canal to remove some of the 
tissue which is sent to the laboratory for analysis. Side effects associated with this procedure 
include light bleeding and abdominal cramping pain (Duraisamy et al., 2011). 
 
1.10.5.4. Loop Electrosurgical Procedure 
The Loop Electrosurgical Procedure also called loop excision of the transformation zone 
(LLETZ). This is a procedure where a thin wire loop heated with electrical current is used to 
remove tissue. Mild cramping during and after the procedure and mild-to-moderate bleeding 
for several weeks are some of the side effects associated with this method (Duraisamy et al., 
2011). 
 
1.10.5.5. Imaging 
Certain imaging techniques are performed in order to determine if the cancer has spread 
beyond the cervix. These include Magnetic Resonance Imaging (MRI) and Computed 
Tomography (CT) scans. The usefulness of a CT scans is to help identify if the cancer has 
spread to the lymph nodes in the abdomen and pelvis (Duraisamy et al., 2011). 
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1.10.6. HPV Vaccines 
The most cost-effective method to prevent cervical cancer against infectious agents is through 
vaccination. The primary goal of HPV vaccination is to reduce the incidence of cervical 
cancer and precancerous lesions. The other objective is to decrease the rate of cancers and 
other benign lesions related with HPV infection (Zarchi et al., 2009). There are two vaccines 
available Gardasil® (Merck, Sharpe and Dohme) and Cervarix® (GlaxoSmithKline). The 
vaccines are based on the virus-like particle (VLP) technology, where viral genes encoding 
surface proteins are used to produce empty virus shells, capable of inducing effective immune 
responses without any infectious or malignant potential. Both vaccines have prophylactic 
properties and do not clear existing HPV infection or treat HPV-related disease (Souter, 
2012). The purpose should be to administer both vaccines before the start of sexual activity 
and the first exposure to HPV infection as this is when the individual would derive the most 
benefit from these vaccines (Souter, 2012). Both vaccines are highly immunogenic and nearly 
all individuals develop an antibody response one month after completing the three-dose 
series. It is not yet known how long these vaccines protective efficacies last; however, to date 
it has been maintained for the duration of the observation periods: 9.4 years for Cervarix® 
and five years for Gardasil® (Souter, 2012). 
 
1.10.6.1. Gardasil
®
 
Gardasil
®
 is a quadrivalent vaccine that contains virus-like particles for HPV subtypes 6, 11, 
16 and 18. It is designated for prevention of cervical, vaginal and vulva pre-cancers and 
cancers as well as anogenital warts that are caused by HPV types 6, 11, 16 and 18 in females 
aged 9-26 years. The vaccine is administered as a series of three intramuscular injections at 
0.2 and 6 months. It is delivered into the deltoid muscle or in the higher anterolateral area of 
the thigh (Souter, 2012). Internationally, Gardasil® is used up to the age of 26 years in men 
and 45 years in women. In South Africa, Gardasil® is also registered for use in boys aged 9-
17 years for the prevention of anogenital warts (Souter, 2012). 
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1.10.6.2. Cervarix
®
 
Cervarix® is a bivalent vaccine that contains virus-like particles for HPV subtypes 16 and 18. 
It is indicated for the prevention of cervical pre-cancers and cancers caused by HPV types 16 
and 18 in females from nine years of age. Cervarix® is given as a series of three 
intramuscular injections at 0, 1 and 6 months, delivered into the deltoid muscle (Souter, 
2012).  Both Gardasil and Cervarix vaccines are preventive, not curative for HPV infection or 
HPV-related diseases. Therefore, HPV vaccine is most useful when given to girls and women 
prior to infection. Vaccination is able to reduce up to 70% of cervical cancer related to HPV 
infection and even prevents precancerous and cancerous lesions of the genitalia. It must be 
remembered that the HPV vaccine does not eliminate the need for continued Pap smears as 
30% of cervical cancers are caused by HPV types that are not included in these vaccines 
(Souter, 2012).  
 
1.10.7. Limitations of Current Screening Methods 
The major challenge for cervical cytology is the need to detect rare events. A specimen 
collected by liquid-based cervical cytology contains a minimum of 5 000 normal squamous 
cells, with most samples containing 50 000 or more normal cervical squamous epithelial cells 
as well as benign endocervical cells and inflammatory components. On the other hand, HSILs 
may often be based on the detection of only a very small number of abnormal cells; 
frequently in the range of 10–100 dysplastic cells per slide (Ling et al., 2008). Current 
methods for cervical cancer screening are not only labour-intensive but are also highly 
subjective and have a relatively low sensitivity and specificity rate for the detection of some 
high-grade clinically significant lesions. With the liquid-based Pap test, the sensitivity of 
cervical screening has increased to about 80% from 65% compared to the conventional Pap 
smear, resulting in an improvement of the overall clinical, economic, and patient outcomes. 
However, the specificity of liquid-based Pap test dropped from 95% with conventional Pap 
smear to about 75% (Ling et al., 2008). Unfortunately only a small percentage of cervical 
cancer patients are diagnosed in the early stages (stage 0 and 1). This has prompted the search 
for cervical cancer biomarkers, although biomarkers have been identified, these have not yet 
been successful in the detection of CC.  
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1.11. Biomarker Applications in Cancer  
The discovery of biomarkers in cancer is becoming extremely important and it is very clear 
that people would benefit tremendously by a greater availability of such effective molecular 
indicators that can be monitored non-invasively from readily accessible body fluids. A widely 
accepted and comprehensive medical definition describes a biomarker as a characteristic that 
can be objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes and pharmacologic responses to a therapeutic intervention (Aebersold 
et al., 2005). The National Cancer Institute (NCI) defines a biomarker as a biological 
molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal 
process, or of a condition or disease. Cancer biomarkers can be messenger ribonucleic acid 
(mRNA), deoxyribonucleic acid (DNA), proteins, metabolites or processes such as apoptosis, 
angiogenesis or proliferation (Kulasingam and Diamandis, 2008). The markers are produced 
either by the tumour itself or by other tissues in response to the presence of cancer or other 
associated conditions such as inflammation. Such biomarkers can be found in a variety of 
fluids, tissues and cell lines. Contrary to common belief, biomarkers are not only or 
necessarily molecules, they are any type of measurable change which may have clinical 
relevance (Kulasingam and Diamandis, 2008).  
 
For instance biomarkers can be certain proteins present on the tumour or released by the 
tumour in the blood, which serves as an indication for recurrence of the disease after curative 
surgical intervention. A biomarker can also be the expression level of mRNA or the presence 
of a gene mutation targeted by a drug (Kulasingam and Diamandis, 2008). Various 
characteristics are used to classify biomarkers such as molecular biomarkers or imaging 
biomarkers, with molecular biomarkers being tumour-associated proteins, mRNA or DNA 
fragments which are used either individually or in signatures of multiple molecules. 
Additionally, different functional subgroups of proteins, such as enzymes, glycoproteins, 
oncofetal antigens and receptors, may serve as useful biomarkers. Furthermore, tumour 
changes such as genetic mutations, amplifications, translocations and changes in microarray 
profiles (signatures) may also be utilized as tumour markers (Smith et al., 2003). Imaging 
biomarkers are anatomical, physiological, biochemical or molecular characteristics which are 
detectable using certain parameters or features from imaging modalities such as MRI, CT or 
Positron Emission Tomography (PET) (Smith et al., 2003). There are various advantages in 
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discovery of new biomarkers, such as improved diagnosis and predicting response to both 
current treatment regimens and to novel molecularly targeted agents (Eifel, 2006). Cancer 
biomarkers have several applications such as early diagnosis of cancers, improved 
reproducibility of the histopathological diagnoses, surveillance of individuals at risk and post 
therapy monitoring (Wentzensen and von Knebel Doeberitz, 2007).  
 
1.12. Classification of Biomarkers 
Biomarkers are classified based on the sequence of events from the onset of exposure to 
disease detection and they play an essential role in providing some insights into prognosis, 
disease progression and response to treatment (Manne et al., 2005). There is a variety of 
biomarkers available; they are utilized in experimental research and clinical settings.  
Biomarkers are grouped in to different categories such as early detection, diagnostics, 
prognostics and predictive biomarkers. Other types are classified based on biomolecules such 
as DNA, RNA and proteins (Mayeux, 2004). Therefore, biomarkers are invaluable tools for 
cancer detection, diagnosis, patient prognosis and treatment selection. They can also function 
in localizing the tumour and determine its stage, subtype and response to therapy. 
Identification of such signatures in surrounding cells or at more distal and easily sampled 
sites of the body viz., cells in the mouth (instead of lung) or urine (instead of urinary tract) 
can also influence the management of cancer (Bhatt et al., 2010). A significant focus of 
clinical research, as evident by the large number of publications, has been the discovery and 
validation of biomarkers with the primary aim of facilitating disease diagnosis (Bhatt et al., 
2010). 
 
1.12.1. Diagnostic Biomarkers 
Diagnostic biomarkers are used to assist in making a specific diagnosis and in relation to 
cancer these biomarkers may be assessed on tumour specimens; however, diagnostic 
biomarker research is performed on serum or plasma. The ideal source material for biomarker 
analysis is the blood, because it is easy to sample and relatively cheap. Furthermore, in 
preclinical research, it is common to encounter molecules of interest, which can be actively 
released in the bloodstream by tumour cells or leak out as a result of the high cell turnover 
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rates typical of tumours (Kulasingam and Diamandis, 2008). The ultimate goal of diagnostic 
biomarkers would be to apply them in a disease screening setting or in suspected cancer 
patients, those that are at higher risk of developing the disease. For example, the presence of 
Bence–Jones protein in urine remains one of the strongest diagnostic indicators of multiple 
myeloma (Kulasingam and Diamandis, 2008). Novel or putative biomarkers may be 
developed into simple diagnostic tests assaying one or two biomarkers or more complex tests, 
where multiple biomarkers are assayed. Based on improved knowledge at the molecular 
level, such tests can provide faster, more accurate or information-rich diagnostics of many 
diseases (Hempel et al., 2008).  
 
Biomarker-based tests can confirm clinical diagnosis and may provide other information 
concerning prognosis and best treatment options. These diagnostic tests may enable 
identification of disease or disease susceptibility in its early stages, before it can be diagnosed 
by other means, providing opportunities for prevention of disease progression or better 
disease management leading to better patient outcomes and a reduction in the direct and 
indirect costs of disease (Hempel et al., 2008). Improved diagnostics to detect cancer at an 
early stage, when it is curable with current methods would provide the greatest benefit to 
cancer patients. For the majority of cancers, 5-10 year survival often approaches 90% for 
cancers detected at an early stage, whilst it may drop to 10% or less for cancers detected at a 
later stage. It is well established that screening to detect cancer earlier saves lives. For 
instance, the Pap smear strongly reduces mortality through early detection of pre-neoplastic 
cervical cancer lesions; moreover, the test is employed widely despite its significant 
inconvenience, unpleasantness, cost and requirement for clinical expertise (Aebersold et al., 
2005). 
 
1.12.2. Prognostic Biomarkers 
The role of prognostic biomarkers is to acquire knowledge about the natural history of the 
disease in terms of metastatic potential, likelihood of tumour progression and probability of 
patient survival independently of treatment. Prognostic biomarkers are relevant in cancer 
research for various reasons such as, when it is used to determine that the expression of a 
protein, gene or other molecules is directly correlated with an aggressive phenotype. This 
may give important information about the biology of the disease and which pathways are 
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activated when the phenotype is more aggressive. Furthermore, from a clinical aspect, 
availability of validated strong and independent prognostic tumour markers may be used to 
stratify patients in randomized clinical trials aiming at evaluating the effect of diverse drugs 
(Kulasingam and Diamandis, 2008). 
 
1.12.3. Predictive Biomarkers 
The function of predictive biomarkers is to determine in which subset of patients with a 
particular disease, drug treatment will be more effective. It is indeed a common clinical 
observation that the same treatment may induce excellent responses in some patients while in 
others it will not have any effect. Ideally, after testing for a panel of predictive biomarkers for 
different treatment regimens, one could administer the most effective drug only to those 
patients who, on the basis of the results from the biomarker analysis, will benefit most likely 
from that specific treatment. Biomarkers can also be used to predict toxicity and be 
particularly valuable for choosing between drugs with the same activity, but different toxicity 
profiles (Kulasingam and Diamandis, 2008).  
 
1.13. Non-invasive Monitoring of Biomarkers 
People at risk for development of cancer or with cancer would benefit tremendously by 
superior methods for determining cancer risk, detecting and localising cancer at its earliest 
stage, profiling for therapeutic decision making and monitoring response to therapy in real 
time. For some of these applications, it will not be known whether a tumour exists or, if it 
does its anatomical site. Thus, there is a need for biomarkers that can be monitored 
noninvasively in readily available bodily fluids (Aebersold et al., 2005). Tumours seep DNA 
and proteins into circulation and they also induce dramatic alterations of the surrounding 
stroma (e.g. alterations in basement membranes, angiogenesis and lymphogenesis) and 
release proteases that digest normal tissues and plasma proteins (Aebersold et al., 2005). 
Therefore, it is rational to expect many biomarkers to be present in blood and other fluids. 
Indeed, several individual plasma proteins (i.e., prostate-specific antigen (PSA), cancer 
antigen 125 (CA125), Carcinoembryonic antigen (CEA), and alpha fetoprotein (AFP) 
antigen) are in clinical use as markers of the presence of a tumour, response to therapy or of 
tumour recurrence (Aebersold et al., 2005). Any proteins that are differentially expressed in 
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cancer tissue when compared to normal tissue, or any proteins that are known to be involved 
in the cancer process, are good sources of candidate biomarkers for cancer. 
 
1.14. Characteristics of an Ideal Biomarker 
An ideal biomarker ought to explain the occurrence of a moderate proportion of the disease in 
the community and must have several qualities in order to be clinically applicable. Firstly, the 
biomarker test must be safe and easy to perform, meaning it must be as non-invasive as 
possible using external body fluids or blood (Fathi et al., 2014). The biomarker test should be 
done at the bedside or as a relatively simple laboratory test using a rapid and reliable 
standardised platform. Secondly, a biomarker should be highly specific for the disease and 
preferably be able to identify subtypes and causes of the disease. Thirdly, a biomarker should 
be sensitive for early detection as possible. Additionally, the sensitivity and specificity of the 
biomarker should be relatively high, thus reducing false-positive and false-negative values 
(Fathi et al., 2014). An ideal cancer biomarker should be measured easily, reliably and cost-
effectively using an assay with high analytical sensitivity and specificity. An ideal biomarker 
should be present in detectable quantities at early or preclinical stages and the quantitative 
levels of the cancer biomarker should reflect tumour burden (Hanash et al., 2008).  
 
1.15. Cancer Biomarkers in Clinical Use 
Cancer biomarkers are present in tumour tissues or serum and they include a wide range of 
molecules such as DNA, mRNA, transcription factors, secreted proteins and cell surface 
receptors. Proteins designated as clinical cancer biomarkers are those offered commercially 
by ARUP or by Mayo Medical Laboratories, also offered for internal use by either NIH or the 
Fred Hutchinson Cancer Research Centre (Hanash et al., 2008). Table 1.2 contains cancer 
biomarkers that are approved by the Food and Drug Administration (FDA) (Sahab et al., 
2008), and table 1.3 shows certain types of biomarkers and their applications.  
 
Table 1.2: FDA Approved Biomarkers 
Cancer Biomarker 
Prostate PSA 
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Breast CA15.3, Her-2/neu, CA27-29 
Ovarian CA125 
Testicular Human corionic 
Thyroid Thyroglobulin 
Pancreas CA19–9 
*Adapted from Sahab et al, 2007 
 
Table 1.3: Different types of Cancer Biomarkers 
Cancer 
Biomarker 
Tumour Application Typical Sample 
AFP Hepatocellular carcinoma, 
Hepatoblastoma 
Diagnostic and 
prognostic 
Blood 
BRCA-1, BRCA-2 Breast cancer Diagnostic  
CA125 Epithelial ovarian carcinoma, 
Fallopian tube cancer 
Diagnostic and 
prognostic 
Blood 
CA 15-3 Breast cancer Diagnostic and 
prognostic 
Blood 
CA 19-9 Pancreatic cancer, Bladder 
cancer 
Diagnostic and 
prognostic 
Blood 
CEA Colorectal cancer Diagnostic and 
prognostic 
Serum 
hCG Germ cell  tumours (ovarian, 
Testicular) 
Diagnostic Serum 
PSA Prostate cancer Diagnostic and 
prognostic 
Blood 
Thyroglobulin Papillary and follicular thyroid 
cancer 
Diagnostic and 
prognostic 
Serum 
*Adapted from Fathi et al., 2014 
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1.16. Mechanisms of Biomarker Elevation in Biological Fluids 
The levels of proteins are physiologically maintained in body fluids and thus, in disease states 
proteins may become elevated as a result of the disease by various mechanisms. These 
include and not limited to gene over-expression, angiogenesis, invasion and destruction of 
tissue architecture and lastly increased protein secretion and shedding (Jarjanazi et al., 2008). 
Firstly, increased quantities of proteins may be a result of increases in the specific gene or 
chromosome copy number (gene amplification), epigenetic modifications such as DNA 
methylation and increased transcriptional activity. The imbalance between gene repressors 
and activators causes an increase in transcriptional activity (Jarjanazi et al., 2008). Secondly, 
invasion of tissues by the tumour may allow release of molecules into the interstitial fluids 
directly, reabsorbed by the lymphatics and subsequently into the blood. In the case of 
epithelial cancer types, proteins must break through the basement membrane of the invading 
tumour before entering the circulation (Jarjanazi et al., 2008). Thirdly, approximately 20-25% 
of proteins are secreted, thus elevated protein levels may occur as a result of aberrant 
secretion or shedding of membrane-bound proteins containing an extracellular domain (ECD) 
(Jarjanazi et al., 2008). 
 
Furthermore, single nucleotide polymorphisms may cause alterations in the signal peptide of 
proteins resulting in atypical secretion patterns. Cancer-associated glycoproteins may be 
released into circulation due to the change in the polarity of the cancer cells. Also, increased 
protease expression may lead to increased ECD cleavage of membrane bound proteins, 
resulting in increased circulating levels of these cleaved products (Jarjanazi et al., 2008). 
There are five major mechanisms by which molecules can be elevated in biological fluids 
during initiation and progression of cancer. Such molecules could serve as effective cancer 
biomarkers. A representation of the different human body fluids that could be used as a 
source of biomarkers for specific types of cancers is shown in table 1.4. The various 
mechanisms of elevation are outlined below.  
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Table 1.4: Human biological fluids: a source for biomarker discovery 
Human biological fluid Cancer type 
Plasma Broad spectrum of diseases 
Serum Broad spectrum of diseases 
Cerebrospinal fluid Brain 
Nipple aspirate fluid Breast 
Breast cyst fluid Breast 
Ductal lavage Breast 
Cervicovaginal fluid Cervical and endometrial 
Stool Colorectal 
Pleural effusion Lung 
Bronchoalveolar lavage Lung 
Saliva Oral 
Ascites fluid Ovarian 
Pancreatic juice Pancreatic 
Seminal plasma Prostate and testicular 
Urine Urological 
*Adapted from Jarjanazi et al., 2008 
 
1.16.1. Gene Overexpression 
The protein encoded by the gene can be expressed in increased quantities as a result of 
increases in gene or chromosome copy number (i.e. gene amplification) or through increased 
transcriptional activity. The latter process could be the result of imbalances between gene 
repressors and gene activators. Epigenetic changes, such as DNA methylation, are also 
known to affect gene expression. On a larger scale, chromosomal translocations can result in 
gene regulation by promoters that are sometimes enhanced by steroid hormones; transposons 
can serve a similar role (Kulasingam and Diamandis, 2008). 
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1.16.2. Increased Protein Secretion and Shedding 
Another way by which molecules can be elevated in biological fluid is aberrant secretion or 
shedding of membrane-bound proteins with an extracellular domain, given that 20-25% of all 
proteins are secreted. Alterations in the signal peptide of proteins as a result of single 
nucleotide polymorphisms can result in atypical secretion patterns (Kulasingam and 
Diamandis, 2008). The release of cancer-associated glycoproteins into circulation is caused 
by change in polarity of cancer cells, this result in elevation of molecules in biological fluids. 
Increased circulating levels could also be caused by increased expression of proteases that 
cleave the ECD portion of membrane proteins. Alfa-fetoprotein is one of the many proteins 
secreted into circulation, it is rapidly released from both normal and cancer cells. Human 
epidermal growth factor receptor 2 (HER2) currently serving as a breast cancer biomarker is 
a classic example of shedding of membrane proteins into bodily fluids (Kulasingam and 
Diamandis, 2008). 
 
1.16.3. Angiogenesis, Invasion and Destruction of Tissue Architecture 
Invasion of tissue by the tumour might allow direct release of molecules into the interstitial 
fluid and subsequent delivery by the lymphatics into the blood. For epithelial cancer types, 
the proteins must break through the basement membrane of the invading tumour before they 
appear in the blood. For instance PSA is abundantly expressed by prostatic columnar 
epithelial cell and secreted into the glandular lumen (Kulasingam and Diamandis, 2008). 
 
1.17. Bioinformatics 
Bioinformatics is the application of computer technology to the management of biological 
information. It is the science of storing, extracting, organizing, analysing, interpreting and 
utilizing information from biological sequences and molecules. Bioinformatics has been 
driven by advances in sequencing of DNA and mapping techniques. Rapid developments 
over the past few decades in genomic, other molecular research technologies and 
developments in information technologies have combined to produce remarkable amounts of 
information related to molecular biology. The main aim of bioinformatics is to increase the 
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understanding of biological processes (Raza, 2010). One of the numerous ways to apply 
bioinformatics methods to cancer, relating to signalling, proliferation, communication and 
specificity of disease metabolisms is through cancer bioinformatics. Another developing 
science is clinical bioinformatics, merging medical informatics, clinical informatics, 
bioinformatics, mathematics, omics science and information technology together. Clinical 
bioinformatics is considered as one of the crucial factors for addressing important clinical 
challenges in early diagnosis, predictive prognosis and effective therapies in cancer patients. 
The development of cancer bioinformatic-specific methodologies or the introduction of new 
and advanced bioinformatics tools is strongly desired to address the specific challenge of 
cancer (Wu et al., 2012). The application, specificity and integration of methodologies, 
computational tools, software and databases which can be utilised to explore the molecular 
mechanisms of cancer and identify and validate novel biomarkers, network biomarkers and 
individualized medicine in cancer should be seriously considered (Wu et al., 2012).   
 
Cancer bioinformatics is anticipated to play a vital role in identifying and validating 
biomarkers specific to clinical phenotypes connected to early diagnosis, measurements to 
monitor the progress of the disease and the response to therapy and predictors for the 
improvement of a patient’s quality of life. The first and critical step in discovering and 
developing new diagnostic and therapies for disease is to understand the interaction between 
bioinformatics and clinical informatics (Wu et al., 2012). Bioinformatics can enable 
clinicians to answer fundamental questions based on individual patient details including 
disease characteristics, laboratory results, proteomic, genomic and metabolic information. 
The progression of biomarker discovery is impossible without bioinformatics, which 
connects individual discovery processes, including experimental design, study execution and 
bioanalytic analysis. Bioinformatics has supported translational research, which has provided 
critical tools for transforming data into medical practise and has prompted biomarker 
breakthroughs and drug development. The development of cheaper, less invasive tests that 
will benefit both clinicians and patients can be permitted by the use of clinically validated 
biomarkers (Suh et al., 2013).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
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1.17.1. Analysis of Gene Expression 
Expression of various genes can be determined by measuring mRNA levels with various 
techniques such as microarrays, expressed cDNA sequence tag (EST) sequencing, serial 
analysis of gene expression (SAGE) tag sequencing, massively parallel signature sequencing 
(MPSS), or various applications of multiplexed in-situ hybridization and so forth (Raza, 
2010). 
 
1.17.2. Analysis of Protein Expression 
There are various ways to measure gene expression including mRNA and protein expression; 
however protein expression is one of the best indicators of actual gene activity since proteins 
are generally final catalysts of cellular activity. Protein microarrays and high throughput mass 
spectrometry (HTMS) can provide a preview of the proteins present in a biological sample. 
Bioinformatics plays a major role in making sense of protein microarray and HT MS data 
(Raza, 2010). 
 
1.18. Sources of Biomarkers  
One of the major concerns in biomarker research is the accessibility of the source of 
biological matrix. Amongst a wide variety of available body fluids, blood is considered the 
most promising and other fluids such as urine, amniotic fluid, synovial fluid, saliva, nipple 
aspirate fluid, and cerebrospinal fluid to mention a few cannot offer a protein profile as 
representative as that of blood and availability of these samples may be restricted. Blood as a 
source of biomarkers is easily accessible; its collection is minimally invasive, low risk and 
cheap (Tambor et al., 2010).  
 
1.18.1. Blood 
Blood is the most commonly used biological fluid for biomarker analysis in clinical practice. 
The advantages of using blood, serum and plasma as a source to mine for biomarkers is that it 
can be obtained through a minimally invasive procedure, it is abundantly available and some 
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constituents of blood reflect diverse pathological states. The prime importance of blood is 
that it is in contact with virtually all cells of the organism and due to specific secretion, 
shedding from the surface or non-specific leakage, tissue-related proteins are released into the 
blood stream. Thus, pathologically affected cells with deregulated proteomes may create a 
specific barcode by releasing disease-related proteins into circulating blood. Furthermore, the 
barcode can also be represented by molecules resulting from the organism’s response to the 
disease (Zhang et al., 2007). 
 
1.18.2. Proximal Fluids and Tissue 
Exploring biological fluids proximal to tumours is an attractive strategy for the identification 
of tumour-secreted proteins. Various types of fluid and effusion offer access to the proteins 
from tumour tissue that may be released into extracellular fluids through secretion or through 
cell and tissue breakdown (Hanash et al., 2008). Proximal fluids are an alternative to blood as 
a source of biomarkers, even though they are not as representative as blood, their expedience 
increases if the nidus of a disease is in close proximity with the particular body fluid. For 
instance, urine may be a prospective source of kidney disease biomarkers or cerebrospinal 
fluid for central nervous system diseases (Quintana et al., 2009). According to Jurisicova et 
al, certain proteins originating from the tissue could subsequently appear and be monitored in 
the bloodstream. The secretion and shedding of tumour proteins into the bloodstream are 
expected to occur as a result of leaky capillary beds, protease cleavage and high rates of cell 
death within the tumour mass. However, these samples are often complex incorporating many 
different types of cells. Often, tumour biopsies may not simply contain tumour tissues but 
also include blood components as well as normal tissue (Jurisicova et al., 2008).  
 
Urine has been used for hundreds of years as a source for biomarker discovery and has 
become an extremely valuable body fluid for the discovery of biomarkers. Urine is able to 
provide important diagnostic information about certain biological disorders and conditions. It 
is a powerful diagnostic fluid utilized in point-of-care devices and biomarkers for various 
cancers have become evident in urine. For instance urinary protein biomarkers for prostate 
cancer and breast cancer are calgranulin B/MRP-14 and ADAM 12 respectively. The use of 
urinary biomarkers to diagnose diseases is a long-standing practice. Proteins that are found to 
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be differentially expressed can be used as biomarkers for the diagnosis and prognosis of the 
disease and may be used as therapeutic targets for future treatment and management of the 
disease (Tantipaiboonwong et al., 2005).   
 
1.19. Methods for Cancer Biomarker Discovery 
The discovery of biomarkers have proven to be one of the most broadly applicable and 
successful means of translating molecular and genomic data into clinical practise. The 
comparisons between healthy and diseased tissues have highlighted the importance of tasks 
such as class discovery (detecting novel subtypes of a disease) and class prediction 
(determining the subtype of a new sample) (Segata et al., 2011). There are various 
advantages of identifying a biomarker or a panel of biomarkers based on the expectation that 
it will lead to the development of a sensitive and reliable assay that is easily readable. That 
capability developed and validated in a platform, leads to the ability to develop an assay that 
is able to detect biomarkers (i.e. proteins) at extremely low concentrations (Larner, 2008).  In 
order to ensure long-term and widespread success the assay platform needs to be as non-
invasive as possible. Following the development of an assay kit, the ultimate goal would be 
to translate this assay into a user friendly, hand-held point-of-care (POC) device which is able 
to monitor this panel of biomarkers in body fluids such as blood or urine with minimal 
invasive procedures (Larner, 2008). Advances in genomics, proteomics, transcriptomics, and 
metabolomics have generated many candidate biomarkers with the potential for diagnostic 
and clinical value. 
 
1.19.1. Genomics 
Genomics is the study of all nucleotide sequences in the genome of an organism.  The widely 
used genomic technologies in cancer research include single nucleotide polymorphism (SNP) 
array, next‑generation sequencing (NGS) technologies, such as Roche 454, ABI SOLiD, 
Illumina Solexa and Helicos. Genomics is applied in cancer biomarker discovery to seek 
specific biomarkers related to genome alterations caused by cancer, for instance DNA 
sequence changes, copy number aberrations, chromosomal rearrangements and epigenetic 
modifications such as DNA methylation. There are various advantages for DNA methylation 
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since it has emerged as highly promising biomarkers offering stability and easy detection 
using PCR or array-based approaches in blood, sputum and urine thus making it suitable for 
non-invasive clinical detection (Zhang et al., 2011). The human leukaemia antigen (HLA) 
was found to be associated with renal cell carcinoma subsequent to cytokine therapy. 
Furthermore, haplotypes are observed in most key genes thus contributing to cancer 
progression by creating allelic imbalances. Srinivas et al, 2001 noted that SNPs can be mostly 
present at the initiation of many epithelial tumours thus causing loss in heterozygosity in 
many tumour suppressor genes. All these serve as possible gene markers for cancer. Wang et 
al used integrative transcriptomics and proteomics for identification of novel liver cancer 
biomarkers. 
 
1.19.2. Transcriptomics 
Transcriptomics is a technique that measures the relative amount of all mRNAs in an 
organism in order to determine the patterns and levels of gene expression. DNA microarray is 
a power technique used in Transcriptomics. Microarray-based gene expression profiling of 
human cancers has generated hundreds of novel diagnostic and prognostic biomarkers as well 
as therapeutic targets (Zhang et al., 2011).  
 
1.19.3. Proteomics 
Proteomics is used to study proteins expressed in a cell, tissue or organism, including all 
protein isoforms and posttranscriptional modifcations. There are two proteomic approaches: 
gel-based and gel-free proteomics. In the gel-based technique, proteins are separated and 
quantified using two-dimensional polyacrylamide gel electrophoresis (2D-Gel), with mass 
spectrometry to identify molecules of interest (Zhang et al., 2011). In the gel-free approach, 
“shotgun" proteomics are employed in the combined use of multidimensional liquid 
chromatography (MDLC) combined with tandem mass spectrometry. The basic strategies 
include digesting proteins into peptides and sequencing them using tandem mass 
spectrometry and identifying the generated sequences using automated database searches. In 
an attempt to identify cancer biomarkers, proteomics has been widely applied to analyse 
serum, saliva, cerebrospinal fluid and nipple-aspirated fluid (Zhang et al., 2011).  
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Recent proteomics studies in pancreatic cancer have identified proteins differentially 
regulated in cancer samples and have led to the discovery of several candidate biomarkers. 
An example of a known biomarker discovered through the use of proteomic technologies is 
CA19-9. This is the only widely used marker for pancreatic cancer and is frequently elevated 
in pancreatic cancer but can also be expressed in other malignancies. Moreover, CA19-9 
levels can be elevated in such benign conditions as acute and chronic pancreatitis, hepatitis, 
and biliary obstruction. The sensitivity and specificity of CA19-9 are 80–90%, limiting its 
value as a screening marker for the general populace (Chen et al., 2005).  
  
1.19.4. Secreted Protein Approach 
A candidate biomarker should be a secreted protein, because secreted proteins have the 
highest probability of entering the circulation. Examining tissues or biological fluids near to 
the tumour site of origin could facilitate identification of candidate molecules for further 
investigation. This approach is supported by the increasing evidence that tumour growth and 
progression is dependent on the malignant potential of the tumour cells as well as on the 
microenvironment surrounding the tumour e.g. stroma, endothelial cells and immune and 
inflammatory cells (Kulasingam and Diamandis, 2008). Some of the widely used cancer 
biomarkers such as CEA, CA125 and HER2 are membrane-bound proteins, which are shed 
into the circulation. However, the identification of secreted proteins in tissues or other 
biological fluids does not necessarily mean that the proteins will be detectable in the sera of 
cancer patients. Serum-based diagnostic tests rely on the stability of the protein, its clearance, 
its association with other serum proteins and the extent of post-translational modifications 
(Kulasingam and Diamandis, 2008).   
 
1.19.5. Cancer Biomarker Family Approach 
The cancer biomarker family approach is based on the premise that if a member of a protein 
family is already an established biomarker, then other members of that family might also be 
good cancer biomarkers. For instance, PSA is a member of the human tissue kallikrein family 
and kallikreins are secreted enzymes with trypsin-like or chymotrypsin-like serine protease 
activity. This enzyme family consists of 15 genes clustered in tandem on chromosome 
19q13.4.63. Currently PSA (KLK3) and KLK2 have important clinical applications as 
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prostate cancer biomarkers. KLK6 has been studied as a novel biomarker for ovarian cancer. 
Similarly, KLK3, KLK5 and KLK14 have been shown to be increased in the serum of 
patients with breast cancer, thereby potentially serving as diagnostic markers (Kulasingam 
and Diamandis, 2008). 
 
1.20. Serum Markers for Cervical Cancer 
The Pap smear test has resulted in a remarkable decline in cervical cancer incidence and 
mortality rates; however it has its imperfections. The Pap smear has an average sensitivity of 
51% to detect CIN and average specificity of 98%. In order to improve these qualitative 
parameters several attempts have been made amongst them the use of liquid-based cytology, 
repetition of Pap smears every 1-3 years and also the addition of HR-HPV detection. 
Regardless of these efforts, the number of false-positive and false-negative results is 
considerably high (Litjens et al., 2013). Increasing the rate of screening among groups of 
women who are at a higher risk of cervical cancer will reduce the incidence and mortality 
associated with this malignancy. Another approach would be to establish appropriate serum 
testing for early diagnosis of cervical cancer. Additional disease markers are thus needed to 
identify women at risk. The most commonly used serum marker for squamous cell cervical 
carcinoma, which makes up 85–90% of all cervical carcinomas, is the squamous cell 
carcinoma antigen (SCC). Elevated levels of serum SCC have been detected in 28–85% of 
cervical squamous cell carcinomas (Ueda et al., 2010).  
 
Table 1.5 outlines cervical cancer diagnostic serum markers in clinical use, with the positive 
rates (elevated serum levels) detected for the indicated serum markers, in cases of squamous 
cell carcinoma (squamous), adenocarcinoma (adeno), or for all histological types. In some 
studies elevated levels of SCC were demonstrated to have a predictive value for prognosis. 
Pre-treatment levels of SCC have been shown to be related to the stage of the disease, size of 
the tumor, depth of the stromal invasion, the lymph-vascular space involvement, and lymph 
node metastasis. The SCC marker has been used also in cervical cancer patients for follow-up 
examination and increased levels were shown to precede the clinical detection of recurrence 
of the disease (Ueda et al., 2010). 
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Table 1.5: Diagnostic serum markers for cervical cancer in clinical use 
Serum markers Positive rate 
SCC Squamous  28–85% 
CYFRA 21-1 Squamous 42–52% 
CA 125 Adeno 27–75% 
                            CA 19-9   
 
Adeno 35–42% 
CEA Adeno 26–48% 
IAP 43–51% 
*Adapted from Ueda et al., 2010 
 
The serum tumour marker CYFRA 21-1 1 (serum fragments of cytokeratin 19) is used for 
squamous cell carcinoma of the uterine cervix. Elevated levels have been detected in 42–52% 
of patients. Pre-treatment levels of CYFRA 21-1 are related to stage of the disease, size of the 
tumor, depth of the stromal invasion, the lymph-vascular space involvement, and lymph node 
metastasis. Elevated levels of CYFRA 21-1 do not have predictive value for prognosis and 
have been reported to be useful in monitoring response to radiotherapy and chemotherapy. It 
is used also in follow-up examination of cervical cancer patients (Ueda et al., 2010). Raised 
serum CA 125 levels are associated with the stage of the cervical disease and are of some 
prognostic significance. Immunosuppressive acidic protein (IAP) marker is elevated in 
cervical carcinomas. IAP levels are linked to disease stage and lymph node metastasis and are 
of predictive value for prognosis (Ueda et al., 2010). The number of candidate biomarkers for 
the diagnosis of cervical cancer is overwhelming. However, the majority of these biomarkers 
have been tested on histological samples only. A lack of sensitivity and specificity has, so far, 
given most of the tumor markers in current use an unsatisfactory predictive value. 
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1.21. Problem Identification  
Development of cervical cancer involves sequential progression from normal cervical 
epithelium to preneoplastic cervical intraepithelial neoplasia and finally invasive cervical 
cancer. It has been shown by increasing evidence that early detection by testing for HR HPV 
and cervical papilloma smears have declined mortality rate associated with cervical cancer. 
However, these methods lack the capability to detect directly the development of cervical 
cancer. Therefore new and less invasive biomarkers are desired for the improvement of 
detection and prognostic outcome of cervical cancer (Ma et al., 2014).  Consequently, there is 
a need for a diagnostic tool that is non-invasive by allowing for the detection of cervical 
cancer in bodily fluids. It should be sensitive enough to detect cancer in its early as well as 
pre-invasive stages and it should be consistently accurate across all ethnicities and ages. 
Additionally, it should be specific for cervical cancer with minimal generation of false 
positives or false negative results (Kumar and Sarin, 2009). The most significant molecular 
signatures implicated in cervical cancer are the HPV oncogenes E6 and E7. Unfortunately, 
they are ambiguous (non-specific) because they have been found to be associated with subset 
of head and neck cancers. If molecular signatures are used to signal the disease, ideally they 
should be present when the individual has cervical cancer and absent when the individual is 
healthy (Mishra and Verma, 2010).  Discovering molecules that are solely expressed in the 
cervix tissue is not always feasible since cancerous cells are renegade normal cells. 
Henceforth, there is ongoing research for molecules differentially expressed or altered in a 
manner that discriminates them from normal cells (Tiffin et al., 2005). Considering the 
importance of the issue, the current study was initiated with the aim to identify potential 
biomarkers that can help in cervical cancer diagnosis, as well as a parallel study to identify 
biomolecules that can detect HPV infections with high specificity as well as sensitivity. 
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CHAPTER 2: Identification of Biomarkers Using an in silico Approach 
2.1. Background 
Advancement in DNA microarray technologies has made it possible for the differential 
expression levels of up to tens of thousands of genes to be effectively and efficiently 
measured under various conditions simultaneously. The information gained from these 
experiments is successfully implemented in gene function prediction, drug development, 
disease diagnosis and patient survival analysis (Raza and Parveen, 2012). Priority for the 
discovery of candidate biomarkers has always been granted to differential quantitative 
proteomic studies; however, candidate biomarkers can also be selected by in silico analysis 
starting with various publicly available databases. Through this route, the search can be 
established for candidate biomarkers that result from experiments and/or knowledge in 
scientific literature and/or the public domain (i.e. websites) (Rodríguez-Pérez et al., 2008).  
 
2.1.1. Data Mining 
Data mining (DM) is extracting or “mining” knowledge from large amounts of data. It is the 
science of discovering new interesting patterns and relationships in huge amounts of data. 
Data mining can defined as the process of discovering significant new correlations, patterns 
and trends by exploring large amounts of data stored in warehouses (databases). Thus Data 
Mining is also referred to as Knowledge Discovery in Databases (KDD). Mining of 
biological data assists in extracting useful knowledge and trends from massive datasets 
gathered in biology and in other life science areas such as medicine (Raza, 2010). There are 
numerous applications of data mining in bioinformatics such as gene discovery, protein 
function domain determination, functional motif detection, diagnosis of diseases, protein 
function inference, disease prognosis, optimization of disease treatment, reconstruction of 
protein and gene interaction networks, protein sub-cellular location prediction and data 
cleansing (Raza, 2010). 
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2.1.2. Microarray Data Mining 
Microarray data mining is the application of Bioinformatic approaches in microarray data 
analysis in order to discover biological entities and pathways that define a phenotype such as 
human diseases. Microarray data mining has proved to be a productive approach to discover 
target genes associated with human diseases and has been increasingly used to detect 
diagnostic or prognostic marker genes. Supervised classification and unsupervised clustering 
are the two basic approaches broadly applied in microarray data mining. In the latter 
approach a group of genes that share coherent expression across a subset of conditions is 
determined using clustering methods such as hierarchical clustering, principal component 
analysis (PCA) and self-organising maps (SOM) (Kapushesky et al., 2011). A supervised 
analysis approach searches for genes that can distinguish between known samples and 
conditions. In a typical example of supervised analysis, the global gene expression profiles of 
disease tissues or fluids will be compared to those in normal tissues or fluids (e.g. cancer vs. 
healthy tissues/fluids) from which a list of target genes or biological pathways that are 
important in a particular disease will be identified (Kapushesky et al., 2011). 
 
2.1.3. Gene Expression Profiling using Microarrays 
Various techniques have been developed for using microarray gene expression data to study 
several aspects of cancer biology, with an accumulation of microarray data suitable for cancer 
target discovery. Many gene expression studies on numerous types of cancers are connected 
with entire datasets that can be downloaded from public repositories specifically dedicated to 
the dissemination of this valuable data. These include websites such as the Stanford 
Microarray Database (http://genome-www5.stanford.edu/MicroArray/SMD), the NCBI’s 
Gene Expression Omnibus repository (http://www.ncbi.nlm.nih.gov/geo), the EBI’s 
ArrayExpress (http://www.ebi.ac.uk/arrayexpress) and the MIT Cancer Genomics Program 
(http://www.broad.mit.edu/cancer/), making these databases valuable resources for target 
gene discovery (Desany and Zhang, 2004). Interesting targets are not solely defined by their 
expression patterns, other criteria such as type of molecule (e.g. kinase), subcellular 
localization (e.g. cell surface) and biological pathway (e.g. angiogenesis) are of importance in 
the decision to follow-up on a potential new target. To this end, resources such as the Gene 
Ontology Project (http://www.geneontology.org), the Kyoto Encyclopaedia of Genes and 
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Genomes Pathways Project (http://www.genome.ad.jp/kegg) attempt to place genes in the 
context of biological function, location and pathway (Desany and Zhang, 2004). 
 
2.1.4. Digital Expression Profiling using EST and SAGE 
Gene expression profiling is not only applicable with microarrays, however, digital 
expression based on either expressed sequence tags (ESTs) or serial analysis of gene 
expression (SAGE) is also complementary to microarrays and can be just as powerful. Both 
EST-derived expression and SAGE are centred on the principle that the frequency of 
sequence tags sampled from a pool of cDNAs is directly proportional to the expression level 
of the corresponding gene (Desany and Zhang, 2004). There are three key advantages of EST 
and SAGE over microarrays; firstly, the simple digital data format in sequence clone counts 
and frequencies enables direct and platform-independent data comparison among different 
data collections from multiple tissues. Secondly, since there is no need for designing any 
DNA chips, no prior knowledge of gene sequence is required and therefore many novel genes 
not covered by microarrays are represented (Desany and Zhang, 2004). 
 
Lastly, since the expression levels are represented by mRNA abundance relative to all 
transcripts and it is thus independent of probe selection and hybridization biases. Through 
these advantages digital expression becomes a more quantitative measurement of gene 
expression than microarrays (Desany and Zhang, 2004). A significant fraction of these ESTs 
are derived from cancer tissues as a result of the large-scale efforts of the Cancer Genome 
Anatomy Project (CGAP; http://www.ncbi.nlm.nih.gov/ncicgap) at the National Cancer 
Institute (NCI) to generate EST libraries from tumour samples. ESTs present an attractive 
resource for differential expression analysis between normal and cancer tissues (Desany and 
Zhang, 2004). 
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2.2. Biological Databases 
In the past decade, genome-wide gene expression assays, the majority using microarrays and 
more recently high throughput sequencing have become common tools in biomedical and 
biological research. Most assays are performed to answer specific questions, for example to 
determine which genes are differentially expressed in a particular disease state in comparison 
to a healthy condition in a tissue or cell type (Kapushesky et al., 2011). The accessibility of 
biological data is of paramount significance for bioinformatics applications and fortunately 
there are innumerable biological databases that gather data and organize it in such a way that 
their content is easily accessible. Biological databases are grouped into three categories 
depending on the type of stored data: (i) primary databases, which contain DNA and protein 
sequences, (ii) secondary databases, derive their information from a primary database and 
(iii) composite database, combine numerous sources from primary databases (Kapushesky et 
al., 2011). 
 
This section of the study aimed at identifying proteins/genes implicated in cervical cancer, by 
extracting gene lists from various databases namely Oncomine, Gene Expression Atlas, and 
TiGER to name a few. The gene lists will be functionally characterised by assigning GO 
terms suitable for gene products that could be detected in bodily fluids. It is objectively 
targeted at prioritising these genes through literature mining using databases such as PubMed, 
iHOP and Google Scholar etc. It not feasible to cover all the available biological databases 
due to their high number, however, major databases of interest will be covered in this thesis. 
 
2.2.1. Gene and Gene Expression Databases 
    2.2.1.1. Gene Expression Atlas  
Gene expression atlas (GEA) (http://www.ebi.ac.uk/gxa/) is a database launched by the 
European Bioinformatics Institute (EBI). This database allows users to query gene expression 
under various biological conditions, including different cell types, developmental stages, 
physiological states, phenotypes and disease states. The database contains information about 
more than 200 000 genes from nine species and almost 4500 biological conditions studied in 
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over 30 000 assays from over 1000 independent studies. GEA can help investigators 
determine which conditions or where in the organism is a gene of interest differentially 
expressed and which genes are differentially expressed in a condition or site for example in a 
disease or in an organ (Kapushesky et al., 2011).  
 
2.2.1.2. Oncomine 
Oncomine (http://www.oncomine.org) is a cancer microarray database and web-based data-
mining platform aimed at facilitating discovery from genome-wide expression analyses. 
Oncomine contains 65 gene expression datasets comprising nearly 48 million gene 
expression measurements from over 4700 microarray experiments. Differential expression 
analyses comparing most major types of cancer with their respective normal tissues as well as 
a variety of cancer subtypes and clinical-based and pathology-based analyses are available for 
exploration. Data can be queried and visualized for a selected gene across all analyses or for 
multiple genes in a selected analysis (Rhodes et al., 2004). Oncomine is designed from a 
collection of microarray studies focusing on published literature using sophisticated data 
normalization and statistical methods to enable comparison of results across multiple 
platforms and experiments (Rhodes et al., 2007). This database also provides tools that 
enable organisation and visualisation to prioritise and identify certain patterns from the 
processed and integrated experimental information collected on literature that has been 
published. The objective of Oncomine is to provide the public with micro-array data that has 
been identified from literature studies that have composed data of gene expression patterns of 
different disease states, cancer stages and experimental populations and conditions with 
statistical support for all genes in the experiment (Rhodes et al., 2004).  
 
Oncomine to date has accumulated over 18 000 cancer gene expression experiments and 
automated analysis has identified the genes, pathways, regulatory networks and functional 
networks that are activated and/ or repressed in human cancers (Rhodes et al., 2007). 
Oncomine produces different types of outputs, i.e. a search using a gene can produce 
different experiments, and one can search by cancer types and disease property. Amongst 
other types of outputs Oncomine also produces list of authors that have done similar studies 
confirming the users query (Rhodes et al., 2004). 
 
 
 
 
  
61 
 
2.2.1.3. Integrative Oncogenomics  
The Integrative Oncogenomics (intOGen) database (http://www.intogen.org/) is a cancer 
analysis tool database designed to facilitate the integration, analysis, exploration and 
interpretation of oncogenomic data for the identification of genes and groups of genes 
involved in cancer development. This database aims at facilitating the detection of the most 
recurrent alterations that drive tumourigenesis. It collates, annotates and analyses high-
throughput data regarding transcriptional, genomic and mutational changes taking place in 
tumours from different studies annotated with specific cancer types. Currently, intOGen 
contains 118 studies for mRNA expression profiling and 188 studies for genomic alterations, 
covering in total 64 different tumor topographies (Perez-Llamasy et al., 2011).  
 
2.2.1.4. Cancer Genome Anatomy Project 
The Cancer Genome Anatomy Project (CGAP) (http://cgap.nci.nih.gov/) of the National 
Cancer Institute (NCI) is an attractive starting point for cancer-specific gene discovery. 
CGAP is a collaborative network of cancer researchers with a common goal to decipher the 
genetic changes that occur during cancer formation and progression. This database sought to 
determine the gene expression profiles of normal, precancer and cancer cells, which 
ultimately leads to improved detection, diagnosis and treatment of patients. This database 
consists of expression information (mRNA) of thousands of known and novel genes in 
diverse normal and tumour tissues. By monitoring the electronic expression profile of many 
of these sequences making it possible to compile a list of genes that are selectively expressed 
in the cancers (Strausberg, et al., 1997).  
 
2.2.1.5. C-It  
C-It (http://c-It.mpi-bn.mpg.de) is a knowledge database focusing on uncharacterized genes 
to build a starting point for biologists to study genes with unknown functions. The database 
implements literature information from the PubMed database to identify genes that lack 
publication records. Based on the assumption that genes are likely to fulfil important 
functions when their expression is enriched in a certain tissue, C-It uses the tissue expression 
information of UniGene, ESTs profiles to identify tissue-enriched genes (Gellert et al., 2010). 
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C-It combines microarray and SAGE data to give users integrated access to comprehensive 
transcriptional profiles. The database is designed to include additional expression studies, 
which might provide more comprehensive coverage of gene expression patterns and tissue-
enriched splicing isoforms. C-It is thus an excellent starting point to study uncharacterized 
genes (Gellert et al., 2010). 
 
2.2.1.6. Tissue-specific Gene Expression and Regulation 
TiGER (Tissue-specific Gene Expression and Regulation) is a web database that gives 
comprehensive information of human gene specificity using three types of data: the gene 
expression profile (EST), combinational gene regulation (based on transcription factor 
binding sites) and a cis-regulatory module (CRM) (http://bioinfo.wilmer.jhu.edu/tiger/). The 
database is also a good example for comparison of EST data and Microarray data.  At present 
the database contains expression profiles for 19,526 UniGene genes, combinatorial 
regulations for 7,341 transcription factor pairs and 6,232 putative CRMs for 2,130 RefSeq 
genes (Liu et al., 2008). For comparison of this research predicted result, only the record 
from gene expression profile will be used. 
 
2.2.1.7. VeryGene  
VeryGene (http://www.verygene.com/) is a web-accessible database for the annotation of 
human tissue-specific genes, with a primary focus on integration with disease association and 
drug targets. A significant effort was made to integrate tissue-specific genes (TSGs) from two 
large-scale data analyses with information on subcellular localization, Gene Ontology, 
Reactome terms, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, Mouse 
Genome Informatics (MGI), Mammalian Phenotype, disease association, and drug targeting 
(Yang et al., 2011). To date there are 3960 annotated TSGs derived from 127 normal human 
tissues and cell types, including 5672 gene-disease and 2171 drug-target relationships. This 
database can be used as a discovery tool by generating novel inferences and a potentially 
useful resource for many applications, for instance, screening for therapeutic targets or 
biomarkers by tissue, subcellular localization, or gene-drug relationship or looking for 
functional enrichment of similarly localized genes or genes participating in a common 
pathway/disease or vice versa (Yang et al., 2011). 
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2.2.1.8. Gene Expression Barcode 2.0  
The Gene Expression Barcode 2.0 (GEB) is the first database to provide reliable absolute 
measures of expression for most annotated genes for 131 human and 89 mouse tissue types, 
including diseased tissue (http://barcode.luhs.org/). This is made possible by a novel 
algorithm that leverage information from Gene Expression Omnibus (GEO) and 
ArrayExpress public repositories to build statistical models that permit converting data from a 
single microarray into expressed/unexpressed calls for each gene (McCall et al., 2011). The 
database can create a gene expression barcode for a single microarray that provides 
information about the expression states of all genes. GEB has combined thousands of gene 
expression barcodes to create vast catalogs of transcriptome information spanning hundreds 
of cell types and tens of thousands of genes. These catalogs are easily accessible via a series 
of web tools that allow an investigator to readily access gene and/or cell type specific 
information (McCall et al., 2011). 
 
2.2.1.10. Database for Annotation, Visualization and Integrated Discovery 
DAVID (Database for Annotation, Visualization and Integrated Discovery) is a database that 
has numerous features (http://david.abcc.ncifcrf.gov/). DAVID is a publicly available high-
throughput annotation tool that systematically maps a large number of interesting genes to a 
list of associated Gene Ontology terms and then statistically highlights genes that are over 
enriched for those terms (Ashburner et al., 2000). This increases the likelihood that the 
researcher will identify the biological process most pertinent to the biological phenomena 
under study (Khatri and Draghici, 2008). The annotation tool in DAVID provides several 
gene annotation options including; GenBank, Unigene, LocusLink, RefSeq, Gene Symbol, 
Gene Name, OMIM, Affymetrix description, Summary and Gene Ontology. Each of these 
tools can be used for various reasons or functions, for this study the Gene Ontology (GO) 
annotation tool will be of interest since Gene Ontology is a controlled vocabulary that is 
applied to the functions of genes and proteins. The functional classifications that are used in 
DAVID are those included in the Locus Report provided by NCBI (Dennis et al., 2003). This 
feature will categorize the genes that have been identified into three categories namely, 
Biological Processes, Molecular Function and Cellular Components. The cellular component 
category is of particular importance to this study as the objective is to identify genes that are 
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expressed on the cell surface of the cervix as this will indicate their shedding into biological 
fluid for diagnostic purposes (Huang et al., 2008).  
 
2.2.1.11. Human Protein Atlas  
The Human Protein Atlas (HPA) (http://www.proteinatlas.org/) uses high-resolution images 
to show protein expression profiles in 46 normal tissues, 20 cancer types, and 47 cell lines for 
the human species. The gene-centric manner of HPA enables the comparison of proteomic 
data (antibody) and genomic (microarray) data. The expression intensity is marked as “level 
of antibody staining” with Strong, Moderate, Weak and Negative levels. Only genes marked 
as “Strong” will be considered as specific/selective for the purpose of this project and only 46 
normal human tissues will be used for comparison (Uhlen et al., 2010).  
 
2.2.1.12. Cervical Cancer Gene Database  
The Cervical Cancer gene Database (CCDB, http://crdd.osdd.net/raghava/ccdb) is a manually 
curated catalog of experimentally validated genes that are thought, or are known to be 
involved in the different stages of cervical carcinogenesis. The database have compiled 537 
genes that are linked with cervical cancer causation processes such as methylation, gene 
amplification, mutation, polymorphism and change in expression levels, as evident from 
published literature. Each record contains details related to gene like architecture (exon–
intron structure), location, function, sequences (mRNA/CDS/protein), ontology, interacting 
partners, and homology to other eukaryotic genomes, structure and links to other public 
databases, thus augmenting CCDB with external data (Agarwal et al., 2011). Also, manually 
curated literature references have been provided to support the inclusion of the gene in the 
database and establish its association with cervical cancer. In addition, CCDB provides 
information on microRNA altered in cervical cancer as well as a search facility for querying-
several browse options and an online tool for sequence similarity searches, thereby providing 
researchers with easy access to the latest information on genes involved in cancer of the 
cervix (Agarwal et al., 2011). 
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2.3. Text Mining 
Text mining (TM) is the computational discovery of new, previously unknown information 
by automatically extracting information from different written sources. There are two major 
steps involved in text mining, information retrieval (IR) and information extraction (IE). 
Information retrieval finds literature or abstracts associated to a specific topic with the help of 
general search engines or specifically designed IR searching tools such as google scholar, 
GoPubMed, iHOP, PolySearch and GeneWays just to mention a few (Yang et al., 2009).   
There are two search methods in IR: rule-based or knowledge based and statistical or 
machine learning. The first approach uses patterns that rely on basic biological insights, for 
instance <cervical> and <cell surface>, to find literature or abstracts of interest on genes 
implicated in cervical cancer and simultaneously found on the surface of the cell. The second 
approach utilises synthetic parse trees (which can also be rule-based) or classifiers to classify 
the related biomedical literature (Yang et al., 2009). A prerequisite for IE is named entity 
recognition (NER), which relies on tools or methods for automatic term recognition in order 
to extract entities such as genes, proteins, drugs or other molecules. Text mining has been 
broadly applied to identify disease-associated entities (genes/proteins) and to understand their 
roles in diseases. The goal of text mining is to filter knowledge and present information to 
users in a concise and an understandable format (Faro et al., 2012). 
 
2.3.1. Text Mining Databases 
2.3.1.1. Universal Protein Knowledgebase 
Universal Protein Knowledgebase (UniProt) (http://www.uniprot.org) is a database formed 
by multiple sources such as the Swiss-Prot, TrEMBL and PIR protein database activities, in 
order to provide the scientific community with a single, centralized, authoritative resource for 
protein sequences and functional information. The database provides a comprehensive, fully 
classified, richly and accurately annotated protein sequence knowledgebase, with extensive 
cross-references and query interfaces (Apweiler et al., 2004).  
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2.3.1.2. Human Gene Navigator  
Human Gene Navigator (HuGENavigator) (http://www.hugenavigator.net/) is a searchable 
and a continuously updated knowledge base (KB) in human genome epidemiology, including 
information on population prevalence of genetic variants, gene-disease associations, gene-
gene and gene- environment interactions, and evaluation of genetic tests (Yu et al., 2008).  
 
2.3.1.3. GoPubmed   
GoPubMed (www.gopubmed.org) is a web server knowledge-based search engine for 
biomedical texts. The database allows users to explore PubMed search results with the GO 
annotation approach, a hierarchically structured vocabulary for molecular biology. 
GoPubMed provides the following benefits: firstly, it gives an overview of the literature 
using abstracts by categorizing these abstracts according to their GO term annotations and 
thus allowing users to quickly navigate through the abstracts by category (Doms and 
Schroeder, 2005). Secondly, it automatically shows general ontology terms related to the 
original query, which often do not even appear directly in the abstract. Thirdly, it enables 
users to verify its classification since the GO terms are highlighted in the abstracts and as 
each term is labelled with an accuracy percentage. Lastly, exploring PubMed abstracts with 
GoPubMed is useful as it shows definitions of GO terms without the need for further reading 
of additional literature (Doms and Schroeder, 2005). 
 
2.3.1.4. PolySearch 
PolySearch (http://wishart.biology.ualberta.ca/polysearch) is a web accessible tool that is 
designed specifically for extracting and analyzing text-derived relationships between human 
diseases, genes/proteins, mutations, drugs, metabolites, pathways, tissues, organs and sub-
cellular localizations. It also displays links and ranks text, as well as sequence data in 
multiple forms and formats (Cheng et al., 2008). A feature that distinguishes PolySearch 
from other biomedical text mining tools is the fact that it extracts and analyses not only 
PubMed data, but also text data from multiple databases (DrugBank, SwissProt HGMD, 
Entrez SNP, etc.). This integration of current literature text and database ‘factoids’ allows 
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PolySearch to extract and rank information that is not easily found in databases or in journals 
alone (Cheng et al., 2008). PolySearch supports >50 different classes of queries against 
nearly a dozen different types of text, scientific abstract or bioinformatic databases. 
PolySearch also exploits a variety of techniques in text mining and information retrieval to 
identify, highlight and rank informative abstracts, paragraphs or sentences. This database 
consists of seven basic components: (i) a web-based user interface for constructing queries; 
(ii) a collection of internal and external biomedical databases; (iii) a collection of biomedical 
synonyms (custom thesauruses and all entity lists); (iv) a general text search engine for 
extracting data from heterogeneous databases; (v) a schema for selecting, ranking and 
integrating content; (vi) a display tool for displaying and synopsizing results and (vii) a PCR 
primer-designing tool to facilitate SNP and mutation studies (Cheng et al., 2008). 
 
2.3.1.5. Information Hyperlinked over Proteins 
Information Hyperlinked over Proteins (iHOP) (http://www.ihop-net.org/ ) is an online text-
mining service that provides a gene-guided network to access PubMed abstracts. The concept 
underlying iHOP is that by using genes and proteins as hyperlinks between sentences and 
abstracts, the information in PubMed can be converted into one navigable resource 
(Hoffmann and Valencia, 2004). Navigating across interrelated sentences within this network 
rather than the use of conventional keyword searches allows for stepwise and controlled 
acquisition of information. Moreover, this literature network can be superimposed onto 
experimental interaction data to facilitate the simultaneous analysis of novel and existing 
knowledge. The network presented in iHOP contains 28.4 million sentences and 110,000 
genes from over 2,700 organisms, including the model organisms Homo sapiens, and many 
more (Hoffmann and Valencia, 2004).  
Aims of this chapter 
1) Explore several databases (as outlined above) for the extraction of potential 
biomarkers for the early diagnosis of cervical cancer using in silico methods 
2) Refinement of the compiled gene list obtained from method 1 using literature mining 
tools. 
 
 
 
 
2.4. Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Outline of the in silico methodology for biomarker discovery 
Data Extraction from various public cancer databases 
 
Cross referenced gene lists against experimentally verified 
cervical cancer genes 
 
Combined datasets and eliminated overlapping genes 
 
Identify cellular localization of gene products- DAVID 
 
Candidate list of genes 
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2.4.1. Extraction of Candidate Biomarkers 
The focus of this research analysis approach was to retrieve and filter genes differentially 
expressed in cervical cancer compared to normal tissues, to a manageable gene list. A 
bioinformatics pipeline was used to interrogate different databases and in this study eight 
databases were mined to identify proteins highly specific to or strongly expressed in the 
cervix tissue and genes differentially expressed in cervical cancer. The pipeline was divided 
into three sections: i) Data-mining of publicly available databases, ii) Literature- mining, and 
iii) Gene enrichment analysis (Figure 2.1). 
 
 2.4.1.1. Oncomine Database  
The first set of genes was searched on Oncomine with the following input query: 1. Analysis 
type: Cancer vs. normal, cervical cancer vs normal, differential analysis and outlier analysis. 
2. Cancer type: Cervical cancer. 3. Data type: mRNA and 4. Pathology subtype: Stage and 
grade type. The second set of genes was searched with the above mentioned criteria, 
however, with the addition of Human Papillomavirus (HPV) infection status selected under 
molecular subtype. 
 
2.4.1.2. Gene Expression Atlas Database  
The GEA database was searched for genes differentially expressed in cervical cancer using 
the following parameters, <all genes >< up/down in ><homosapiens>< cervical cancer. The 
following GO terms were also used as a search criteria, cell surface, membrane, integral to 
membrane and plasma membrane to filter the up/down regulated genes identified. 
 
2.4.1.3. intOGen Database  
The Integrative Oncogenomics database was queried using the search criteria, all experiments 
were selected in the browser. The tumor type cervix uteri C53 (Adenocarcinoma and 
squamous cell carcinoma) was chosen and genes/modules was left as default “all”. 
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2.4.1.4. CGAP Database  
The Cancer Genome Characterization Initiative database was searched using the gene finder 
function, using the default setting: tissue, function, location or keyword. The cervix tissue 
type was selected as Homo sapiens.  
 
2.4.1.5. C-It Database 
The database was searched for proteins enriched in cervix tissue (human data only). 
Literature information search parameters of fewer than five publications in PubMed and 
fewer than three publications with the Medical Subject Headings (MeSH) term of the 
searched tissue were used.   
 
2.4.1.6. TIGER Database 
The Tissue-specific Gene Expression and Regulation (TiGER) database was searched for 
proteins preferentially expressed on the cervix tissue based on ESTs by using “Tissue View”.  
 
2.4.1.7. VeryGene Database 
The database was searched for the cervix tissue using “Tissue View” for tissue-selective 
proteins.  
 
2.4.1.8. Gene Expression Barcode 2.0 Database 
Gene expression barcode was searched for genes expressed in >95% samples of cervical 
cancer tissue by selecting gene expression. The consensus input type was chosen, using the 
affymetrix human genome U 133A (HGU 133a). 
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2.4.2. Analysis of Gene Lists 
A command line script using Ubuntu software was used to eliminate duplicates per list of 
genes from each of the databases and  to combine the list of genes together using the 
following command line (cat FILE NAMES |sort -u > OUTPUT FILE NAME) in Ubuntu. A 
total of 27 datasets were combined and thereafter, the genes were submitted to DAVID for the 
same enrichment analyses. 
 
2.4.3. Functional Characterisation using DAVID 
The candidate gene lists was then submitted to The Database for Visualization and Integrated 
Discovery (DAVID) Version 6.7 for gene enrichment through the following steps.  
 Step 1: Gene List Submission: start analysis was selected and a gene list was uploaded. 
Gene identifiers were selected as “official_gene_symbol”. In the list type “gene list” was 
chosen and the gene list was submitted. Homo sapiens were the selected as the organism from 
which the protein products were derived. 
 
 Step 2: Analyze gene list using DAVID tools: Functional annotation clustering was selected 
from the functional annotation tools. The classification stringency was set to high or left at 
default “medium”. On the “options” setting the following were selected, display, fold change 
and Bonferroni analysis. Using the same setting “option” re-run was chosen. 
 
Step 3: Choose annotation clusters: different clusters were searched by identifying the 
following GO terms: cell surface, secreted, secretory granules, extracellular matrix, 
extracellular space and extracellular membrane. The newly derived list of genes were 
exported and saved. Gene Ontology was selected and the cellular component with the highest 
percentage (100%) was chosen. The classification data was displayed with a count of the 
number of genes annotated to be “cell surface, secretory granules, extracellular matrix and 
extracellular space” as the output. When selected, the genes were displayed with gene 
identifier, gene name and class of species. 
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2.4.4. Comparison to Reference Lists 
After gene enrichment in DAVID, the list of genes were cross-referenced against the genes 
from HPA and CCDB, to ascertain the ability of Bioinformatics to correctly identify genes 
that were implicated in cancer through experimental studies and to gauge its 
reproducibility/variability. CCDB was mined for the extraction of a reference gene list 
containing documented experimentally verified cervical cancer genes. Genes were 
individually entered into HPA to search for a moderate to strong association with cervical 
cancer expression. Genes were also cross-referenced with each other to identify overlapping 
genes. No genes were eliminated at this point, but all candidate genes were further subjected 
to literature mining to ascertain if genes were already experimentally verified as cervical 
cancer genes, despite not being found in the reference gene lists. 
 
2.4.5. Literature Review of the Candidate Entities 
A text mining approach was used to search each gene from the output obtained from DAVID 
against literature. Uniprot, PolySearch, Google Scholar, HuGENavigator, GoPubmed and 
iHOP were used to search for abstracts or journal articles using the “gene symbols” the 
Boolean term “AND” and terms that imply neoplastic cervical cancer tissue e.g. <cervical 
cancer> AND <gene name>. A search was then done through the relevant literature for any 
information or data that links the gene as a biomarker for cervical cancer. All genes found to 
have been validated or inferred as biomarkers for cervical cancer were recorded and these 
genes will be eliminated from further analysis. Subsequent to these mining approaches, a 
final list of putative genes was compiled and the genes were subjected to tissue specificity 
analysis.  
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2.5. Results and Discussion 
2.5.1. Identification of Eligible Cancer Biomarkers 
The approach presented here was designed to exploit several cancer databases to identify 
genes encoding proteins with differential expression that could be secreted into bodily fluids 
and subsequently be used as potential biomarkers for the early diagnosis of cervical cancer.  
The methods that were used are complementary to the extent that they query fundamentally 
different aspects of biological knowledge stored within these databases. A series of data 
mining steps was used to increase the stringency such that the huge number of entities 
(genes/proteins) present in various databases and in literature was reduced to a manageable 
size. At each step, the criteria, choice of tool, and databases were selected to reduce the list of 
identified hits. From the Oncomine platform, data mining of 5 microarray datasets: (i) 
Bachtiary cervix, (ii) Biewenga cervix, (iii) Bittner cervix, (iii) Pyeon Multi-Cancer and (iv) 
Scotto cervix for genes differentially expressed in cervical cancer compared with their 
expression in normal tissues led to the identification of a list of 16023 differentially expressed 
gene profiles. The output was five seed lists which varied from 1%, 5% to 10% fold 
expression derived from each dataset. This means that from the five datasets, a total of 15 
seed lists were presented as an output.  
 
The second set of genes consisted of three datasets, Bittner Cervix, Scotto Cervix and Pyeon 
Multi-cancer with a total of 49674 genes as outlined in section 2.4.1.1. The results was 3 seed 
lists which varied from 1%, 5% to 10% fold expression derived from each dataset.  This 
means that from the three datasets, a total of 9 seed lists were presented as an output.  Each 
dataset is titled according to the first author, which is used as a classifier. The selected 
datasets were categorised based on the different folds/levels of gene expression as compared 
to the normal as per condition of each study. Table 2.1 depicts a summary of all genes that 
were extracted from all datasets presented as percentage fold (1%, 5% and 10%) irrespective 
from the study it was obtained. Each dataset represent a study that has been conducted, under 
certain experimental conditions and each gene list extracted from each dataset represents the 
outcome of that study. It was therefore pivotal that the sampling strategies and conditions at 
which these studies were conducted were well understood. All the seed lists in Oncomine 
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produced 24185 genes, after combining all the seed lists and eliminating redundant genes, a 
total of 16023 genes remained. 
 
Table 2.1: Summary of the genes extracted from Oncomine 
Fold Expression % No. of genes Extracted 
1% 
5% 
10% 
10483 
53548 
99316 
 
Conversely GEA a general microarray database generated an output based on all data 
available to support the query as outlined in section 2.4.1.2. This database can be queried for 
datasets from functional genomic experiments using the meta-analysis of microarray and high 
throughput sequencing data. Two sets of gene lists were extracted from GEA, first dataset 
consisting of all genes up/downregulated in cervical cancer and the second set included genes 
queried with various GO terms such as cell surface etc. (refer to section 2.4.1.2). This was 
done to increase the sample size and also include genes that may not appear in the 
background. The first set produced 13431 genes using the query term up/downregulated in 
cervical cancer, and set 2 resulted in 11996 genes using GO terms with a summary of the 
number of genes extracted from the various GO terms shown in table 2.2. In summary the 
total number of genes mined from GEA were 6696 following curation.  
 
Table 2.2: Summary of gene set 2 mined from GEA based on GO terms 
GO Terms No. of genes extracted 
Cell surface 2288 
Membrane 5116 
Integral to membrane 2288 
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Plasma membrane 2304 
 
For clarification the set of genes extrapolated from GEA were not particularly from one study 
but from multiple experiments combined in a global repository. Thus, one gene list from 
GEA is extrapolated from multiple experiments. IntOGen allows for the extraction of genes 
involved in expression changes and copy number variations across multiple tumours and 
cancer types. This database generated 22686 genes. However, the actual number of genes 
extracted using this database was 836 genes after duplicates were removed. VeryGene, a 
curated database containing tissue specific enriched genes identified 20 tissue-selective 
proteins. C-It focuses on tissue-enriched gene variants and differentially expressed genes that 
are still uncharacterised and identified 1075 tissue-enriched proteins after filtering of genes 
according to the set parameters and the TiGER database identified 209 proteins preferentially 
expressed in tissue. The gene expression barcode database produced 836 genes found in 
cervical cancer and the CGAP database identified 8216 genes after removal of common 
genes. A summary of all the genes extracted from the various databases as well as the number 
of common genes that were removed in each database are indicated in table 2.3 with the total 
number of genes identified. 
 
Table 2.3: Total number of genes identified from mining gene and protein databases 
Databases No. of genes 
identified 
 No. of genes 
duplicated 
No. of unique 
genes 
Oncomine 24185 8162 16023 
Gene Expression Atlas 18458 11762 6696 
intOGen 22686 21850 836 
Gene Expression 
barcode 
1099 263 836 
CGAP  8337 121 8216 
C-It 1601 526 1075 
TIGER 281 72 209 
VeryGene 20 0 20 
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Total  number of  
combined genes 
Total number  of 
eliminated genes 
Final number of 
genes after curation 
34033 5398 28190 
 
2.5.2. Gene Enrichment Analysis 
A total of 28190 genes were uploaded to DAVID for enrichment bioinformatics analysis and 
the output was 113 genes. The enrichment analyses of GO terms including biological process, 
cellular component and molecular function were performed on the 113 genes by using the 
functional clustering annotation tools as highlighted by figure 2.2, 2.3 and 2.4 respectively. 
The default options with medium/high classification stringency were used, and finally cluster 
names were extracted from the most biologically relevant GO term assigned to that cluster. 
 
 
 
 
  
Figure 2.2: Functional Characterisation of genes in DAVID based on their biological process using GO analysis.  
 
 
 
 
  
 Figure 2.3: Functional Characterisation of genes in DAVID based on their cellular component using GO analysis. 
 
 
 
 
 
 Figure 2.4: Functional Characterisation of genes in DAVID based on their molecular function using GO analysis 
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2.5.3. Literature Review of the Candidate Entities 
Subsequent to functional characterisation in DAVID, the list of candidates were further 
investigated in order to select a subset of higher priority genes that will be further validated as 
putative biomarkers for cervical cancer. Further analysis and assessment of the resulting hits 
were performed retrospectively using various databases such as Uniprot, PolySearch, Google 
Scholar, HuGENavigator, GoPubmed and iHOP. To find links and cited articles to 
genes/proteins and identify the particular gene product if the gene name or synonym is 
known. The entities obtained were checked by carefully reading the associated literature 
references or original publications. This subset of candidates included genes that have not yet 
been inferred as putative biomarkers in cervical cancer or have not yet been experimentally 
validated to be connected to cervical cancer. From the 28190 genes that were investigated in 
DAVID, only 113 genes matched the stringent criteria imposed in this work and these were 
further investigated using literature mining. The genes were searched in literature using the 
selected GO terms, a total of 36 genes were identified and 7 genes were found to be common 
amongst the list and these were eliminated from the study as highlighted in table 2.4. Thus 
after review of literature, only 29 candidate genes remained and these were not 
experimentally linked to cervical cancer to date. As depicted in table 2.4, a number of these 
genes had been implicated in cervical cancer through various experimental studies.  
 
Table 2.4: Gene Categorisation based on literature 
Go Terms No. of genes identified No. of genes experimentally 
validated 
Cell surface 14 2 
Secretory granules 7 1 
Extracellular space 7 3 
Extracellular matrix 8 1 
 
Biomedical literature in this research study ensured that extensive information was 
investigated prior making conclusions. The literature search confirmed the database mining 
route impressing confidence in the candidate genes, thus indicating that out of more than 28 
000 genes extracted from databases, the study managed to prioritise these genes and also 
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obtained a subset of genes that have been experimentally validated to be implicated in 
cervical carcinogenesis. After literature studies, a total of 29 genes remained as candidate, 
after experimentally validated genes were eliminated and only those genes showing no 
relation to cervical cancer were deemed as novel biomarkers.  
 
2.6. Discussion and Conclusion 
Cervical cancer continues to represent a major health problem for women from developing 
countries. Cervical cancer lethality occurs because most patients are first diagnosed in 
advanced stages. Even if early stages are successfully treated, advanced cervical cancer 
represents a major problem due to increased rates of recurrence and distant metastasis 
(Balacescu et al., 2014). Cancer is an intricate disease whereby many proteins, genes and 
molecular processes are involved. Genes and proteins do not work independently, but are 
organised into co-regulated units that perform a common biological function. The alteration 
of these functional elements leads to the development of a particular cancer phenotype and 
subsequently their study cannot be undertaken from the classical one-gene approach (Sanz-
Pamplona et al., 2012). A systems biology approach, the analysis of the molecular 
relationship between the implicated genes and proteins as a whole, is required to understand 
the disease phenotype. Research on biomarkers will help in understanding diseases at the 
initial stages of development. Therefore the introduction of bioinformatics has improved 
ways in which new hypothesis is generated for knowledge discovery (Sanz-Pamplona et al., 
2012). 
 
In this chapter several in silico methodologies were employed to interrogate microarray 
databases in order to unearth the affluence of information that goes unnoticed in databases. 
Various bioinformatics tools were utilised to excerpt a list of genes based on input queries. 
The databases chosen for this study were based on several factors (i) the number of times 
they are curated (verify the accuracy of the information held by these databases) (ii) how 
often they are referenced as reliable source of data for biomarker discovery studies. The data 
that was retrieved from all databases was effectively refined to ascertain that each step is 
treated as an independent validation step thus enhancing the signal-to-noise ratio (Baron et al, 
2011). This research aimed at identifying tissue-specific biomarkers by making use of 
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publicly available gene and protein databases. According to Prassas et al (2012), mining 
protein expression databases for the identification of candidate biomarkers seems more 
relevant since serological biomarkers are protein-based. Using gene expression databases also 
has limitation since the considerable variation between mRNA and protein expression and 
gene expression does not account for post-translational modification events. Thus, mining 
both gene and protein expression databases minimizes the limitations of each platform 
(Prassas et al., 2012). The databases were searched for genes and proteins highly specific to 
or strongly expressed in cervical tissue. The search criterion was designed to accommodate 
the design of the databases. In the gene expression databases the criteria used were set for 
maximum stringency for candidate identification to identify a manageable number of 
candidates. Through the methods that were employed in this study, ~ 361122 genes and 1902 
proteins highly specific to or strongly expressed in the cervical tissue and cervical cancer 
were filtered from the microarray databases and further refined to 113 genes using DAVID.  
 
As with the candidate lists, most array or sequencing databases generate large sets of gene 
lists that may contain thousands of candidate genes (Huang et al., 2008). The integration and 
interpretation of these heterogeneous data in order to draw meaningful scientific inference 
from can be a challenging task (Huang et al., 2008). Furthermore, it can be difficult to 
evaluate the biasedness of results and whether gene lists from multiple databases are 
reproducible or whether they generate overlapping genes. Enrichment analysis allows one to 
take a data-driven approach to framing results in a functional context (Huang et al., 2008). 
Functional annotation allows for the clustering of putative genes according to their cellular 
component, molecular function and biological process by using sequence similarity 
techniques. Gene Ontology provides ontology of a large number of terms which are 
representative of the gene product properties or the functions of the gene products. The Gene 
Ontology covers three domains; Cellular component, the parts of the cell or its environment; 
Molecular function, the activities of the gene product at the molecular level; and Biological 
processes, molecular events pertaining to function of integrated living units. Most of the 
genes in a genome are annotated with the ontology terms relevant to the gene products. Each 
gene is associated with many ontology terms and each term is associated with more than one 
gene. Genes that are similar in their functioning, share many common ontology terms. A GO 
Enrichment analysis on a set of genes analyses the GO terms associated with the set and 
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returns the enriched terms in the order of decreasing significance as described in section 
2.4.3. In this study, Gene ontology cellular localization annotations of ‘extracellular space’, 
‘cell surface ’, ‘secretory granules’ and ‘extracellular matrix’ (Figure 2.3) were selected to 
identify a protein as secreted or shed. Many groups in biomarker discovery use Gene 
Ontology protein cellular localisation annotations of ‘extracellular space’, ‘plasma 
membrane’ and so forth to identify a protein as secreted or shed, hence, this study was able to 
identify such biomarker candidates thus making this research valuable and this pipeline can 
be integrated in other biomarker discovery studies for other types of cancer. Proteins 
interacting with cancer-related proteins have a higher probability of being related with the 
cancer process than non-interacting proteins. Hence, the study of those proteins may be an 
efficient way to discover novel cancer genes and cancer biomarkers. The significance is given 
by the p-values, which is the probability that of a term occurring in the set by chance or a true 
hit. If the GO enrichment analysis on a particular set of genes returns many terms with very 
high significance i.e. very low p-values, then that set of genes is highly similar in its 
properties. When the clustering of the genes was analysed (which combined totalled 113), 
most of the genes were projected to be enriched for cell surface receptor-linked signal 
transduction as their primary biological process as shown in figure 2.2. The results for 
molecular function categorization were consistent with the biological process assigned to 
these genes, whereby the great majority of the genes were predicted to participate in signal 
transduction, 17 of the gene variants were allocated to receptor binding (Figure 2.4).  
 
Aberrations in signal transduction have been linked to the characteristics of cancer such as 
increased proliferation and inhibition of apoptosis (Rowinsky, 2003), the latter being one of 
the categories the genes was allocated to by DAVID, while 12 of the genes were predicted to 
function in secretion (Figure 2.2). The majority of the genes were predicted to be intrinsic 
and integral to membrane and 16 of the genes were enriched for the cell surface (Figure 2.3). 
This is promising since the targeted biomarkers for this study were those that are easily 
detectable in bodily fluids. Many of the functional categories such as apoptosis, signalling 
and focal adhesion were compatible with similar Bioinformatics cancer studies, such as the 
analyses carried out by Romaschin et al (2009) and Zang et al (2011). The dissimilarities in 
this study compared to others can be attributed to this study’s focusing on retrieving secreted 
cancer genes as opposed to any significant genes in cervical cancer. Determining the 
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subcellular localization of a protein can provide insights into how it functions and the 
pathways that are involved, as well as highlighting whether the protein could either provide a 
therapeutic target or act as a biomarker. In many biomarker studies secreted proteins are 
targeted because they are more likely to be present in body fluids and eventually measured by 
non-invasive assays (Klee and Sosa, 2007). After extensive literature studies, 29 genes 
remained as candidate biomarkers. Inclusion parameters were well defined for each selection 
method so as to attain a list of candidate genes that were differentially expressed in cervical 
cancer and can be located in biological fluids. Secreted or shed proteins have the highest 
chance of entering the circulation and being detected in the serum (Prassas et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
81 
 
2.7 References  
1. Agarwal, S.M., Raghav, D., Singh, H., and Raghava, G.P.S. 2011. CCDB: a curated 
database of genes involved in cervix cancer. Nucleic Acids Research, 39:975-979.  
2. Apweiler, R., Bairoch, A., Wu, C.H., Barker, W.C., Boeckmann, B., Ferro, S., 
Gasteiger, E., Huang, H., Lopez, R., Magrane, M., Martin, M.J., Natale, D.A., 
O'Donovan, C., Redaschi, N., and Yeh, L-S. L. 2004. UniProt: the Universal Protein 
knowledgebase. Nucleic Acids Research, 32:115-119.  
3. Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, 
A.P., Dolinski, K., Dwight, S.S., Eppig, J.T. et al. 2000. Gene Ontology: tool for the 
unification of biology. Nature Genetics, 25(1):5. 
4. Balacescu, O., Balacescu, L., Tudoran, O., Todor, N., Rus, M., Buiga, R., Susman, S., 
Fetica, B., Pop, L., Maja, L., Visan, S., Ordeanu, C., Berindan-Neagoe, I., and Nagy, 
V. 2014. Gene expression profiling reveals activation of the FA/BRCA pathway in 
advanced squamous cervical cancer with intrinsic resistance and therapy failure. BMC 
Cancer, 14(246):1-14.  
5. Baron, D., Dubois, E., Bihouée, A., Teusan, R., Steenman, M., Jourdon, P., Magot, 
A., Péréon, Y., Veitia, R., and Savagner, F. 2011. Meta-analysis of muscle 
transcriptome data using the MADMuscle database reveals biologically relevant gene 
patterns. BMC genomics, 12(1):113. 
6. Cheng, D., Knox, C., Young, N., Stothard, P., Damaraju, S., and Wishart, D.S. 2008. 
PolySearch: a web-based text mining system for extracting relationships between 
human diseases, genes, mutations, drugs and metabolites. Nucleic Acids Research, 
36:399-405.  
7. Dennis, G. Sherman, B.T., Hosack, D.A., Yang, J., Gao, W., Lane, H.C. and 
Lempicki, R.A. 2003. DAVID: Database for Annotation, Visualization, and 
Integrated Discovery. Genome Biology, 4(5):3. 
8. Desany, B., and Zhang, Z. 2004, Bioinformatics and cancer target discovery. Drug 
discovery today, 9(18):795-802. 
 
 
 
 
  
82 
 
9. Doms, A., and Schroeder, M. 2005. GoPubMed: exploring PubMed with the Gene 
Ontology. Nucleic Acids Res. 33 (Web Server issue): W783–6. 
doi:10.1093/nar/gki470. 
10. Faro, A., Giordano, D., and Spampinato, C. 2012. Combining literature text mining 
with microarray data: advances for system biology modelling. Briefings in 
bioinformatics, 13(1):61-82. 
11. Gellert, P., Jenniches, K., Braun, T., and Uchida, S. 2010. C-It: a knowledge database 
for tissue-enriched genes. Bioinformatics, 26(18): 2328-2333. 
12. Hoffmann, R., and Valencia, A. 2004. A gene network for navigating the literature. 
Nature Genet, 36:664. 
13. Huang, D.W., Sherman, B.T., and Lempicki, R.A. 2008. Systematic and Integrative 
Analysis of Large Gene Lists Using DAVID Bioinformatics Resources. Nature 
Protocol. Accessed 09/09/2013. Available from 
http://david.abcc.ncifcrf.gov/manuscripts/protocol/np_manuscript.pdf 
14. Kapushesky, M. Adamusiak, T., Burdett, T., Culhane, A., Farne, A., Filippov, A., 
Holloway, E., Klebanov, A., Kryvych, N., Kurbatova, N., et al. 2011. Gene 
Expression Atlas update -a value-added database of microarray and sequencing-based 
functional genomics experiments. Gene Expression (6):1 
15. Khatri, P. and Draghici, S. 2008. Ontological analysis of gene expression data: current 
tools, limitations and open problems. Bioinformatics, 21(18):3587-3595. 
16. Klee, E.W., and Carlos, C.P. 2007. Computational classification of classically 
secreted proteins. Drug Discovery Today, 12(5/6): 234-240. 
17. Liu, X., Yu, X., Zack, D.J., Zhu, H., and Qian, J. 2008. TiGER: A database for tissue-
specific gene expression and regulation. BMC Bioinformatics, 9(271):1-7. 
18. McCall, M.N., Uppal, K., Jaffee, H.A., Zilliox, M.J., and Irizarry, R.A. 2011. The 
Gene Expression Barcode: leveraging public data repositories to begin cataloging the 
human and murine transcriptomes. Nucleic Acids Research, 39:1011-1015.  
19. Perez-Llamasy, C., Gundemy, G., and Lopez-Bigas, N. 2011. Integrative Cancer 
Genomics (IntOGen) in Biomart. Database, Article ID bar039. 
 
 
 
 
  
83 
 
20. Prassas, I., Chritoja, C.C., Makawita, S., and Diamandis, E.P. 2012. Bioinformatic 
identification of proteins with tissue-specific expression for biomarker discovery. 
BMC Medicine, 10(39):1-13. 
21. Raza, K., 2010. Application of data mining in bioinformatics. Indian Journal of 
Computer Science and Engineering, 1(2):114-118. 
22. Raza, K., and Parveen, R., 2012. Evolutionary algorithms in genetic regulatory 
networks model. Journal of Advanced Bioinformatics Applications and Research, 
3(1): 271-280. 
23. Rhodes, D. R., Kalyana-Sundaram, S., Mahavisno, V., Varambally, R., Yu J., Briggs, 
B.B., Barrette, T.R., Anstet, M.J., Kincead-Beal, C., Kulkarni, P., Varambally, S., 
Ghoshy, D., and Chinnaiyan, A.M. 2007. Oncomine 3.0: Genes, Pathways, and 
Networks in a Collection of 18,000 Cancer Gene Expression Profiles. Neoplasia, 9(2): 
166-180.  
24. Rhodes, D.R., Yu, J., Shanker, K., Deshpandez, N., Varambally, R., Debashis Ghosh, 
D., Barrette, T., Pandey, A., and Chinnaiyan, A.M. 2004. Oncomine: A Cancer 
Microarray Database and Integrated Data-Mining Platform. Neoplasia, 6(1):1-6. 
25. Rodríguez-Pérez, M.A., Medina-Aunon, A., Encarnación-Guevara, S.M., Bernal-
Silvia, S., Barrera-Saldaña, H., and Albar-Ramírez, J.P. 2008. In silico analysis of 
protein neoplastic biomarkers for cervix and uterine cancer. Clin Transl Oncol, 
10:604-617. 
26. Romaschin, A.D., Youssef, Y., Chow, T.F., Siu, M., DeSouza, L.V., Honey, J., 
Stewart, R., Pace, K.T., and Yousef, G.M. 2009. Exploring the pathogenesis of renal 
carcinoma: pathway and bioinformatics analysis of dysregulated genes and proteins. 
Biological Chemistry, 390:125-135. 
27. Rowinsky, E.K. 2003. Signal Events: Cell Signal Transduction and its Inhibition in 
Cancer. The Oncologist, 8(3):5-17. 
28. Sanz-Pamplona, R., Berenguer, A., Sole, X., Cordero, D., Crous-Bou, M., Serra-
Musach, S., Guinó, E., Ángel Pujana, M., Moreno, V. 2012. Tools for protein-protein 
interaction network analysis in cancer research. Clin Transl Oncol, 14:3-14. 
 
 
 
 
  
84 
 
29. Strausberg, R. L., Dahl, C. A., and Klausner, R. D. 1997. New opportunities for 
uncovering the molecular basis of cancer. Nat. Genet, 17: 415-416. 
30. Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., 
Zwahlen, M., Kampf, C., Wester, K., Hober, S., Wernerus, H., Björling, L., Ponten, F. 
2010. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol, 
28(12):1248-50. 
31. Yang, X., Ye, Y., Wang, G., Huang, H., Yu. D., Liang, S. 2011. VeryGene: linking 
tissue-specific genes to diseases, drugs, and beyond for knowledge discovery. Physiol 
Genomics 43:457-460. 
32. Yang, Y., Adelstein, S.J., and Kassis, A.I. 2009. Target discovery from data mining 
approaches, Drug discovery today, 14(3):147. 
33. Yu, W., Gwinn, M., Clyne, M., Yesupriya, A., and Khoury, M.J. 2008. A Navigator 
for Human Genome Epidemiology. Nat Genet, 40:124-125. 
34. Zang, W-D., Liu, J., Wang, L.S., and Pan, T-W. 2011. Identifying genes related with 
non-small cell lung cancer via transcription factors- target genes relationships. 
International Journal of Physical Sciences, 6(28):6450-6457. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
85 
 
CHAPTER 3: In Silico Expression Analysis of Putative Biomarkers 
3.1. Introduction 
In order to extract most key features from the data, methods for visualization and analysis of 
large-scale data are of utmost importance (Hastie et al., 2009). Enrichment analysis allow for 
the biological interpretation of large gene and protein lists by investigation of the functional 
categories present in the data. Tools that allow construction of biological networks are 
utilised for visualizing relationships such as protein-protein interactions, and are valuable for 
extracting meaningful information from extensive data sets (Hastie et al., 2009). The large 
amounts of data generated by high-throughput strategies in genomics and proteomics often 
results in long lists of interesting genes, which are challenging to interpret. The biological 
knowledge stored in the vast number of databases described can be exploited to allow for a 
systematic functional analysis of these lists to summarize the most relevant properties. 
Bioinformatic tools for enrichment analysis have been successful in adding valuable 
information to large-scale biological studies (Huang et al., 2009). 
 
Biological processes and functions within a cell are seldom dependent on a single gene, 
however most often made up of a group of genes and this is the principal basis behind 
enrichment analysis. Co-functioning genes are likely to be selected together if a certain 
process or function is atypical in a biological study (Huang et al., 2009).  Once a certain 
functional term has been associated with a set of genes, a test has to be performed to 
determine if the enrichment based on the proportion of associated genes is significantly 
different than what would be expected by chance alone. Thus, an enrichment of a gene set 
uses a statistical model such as binomial, hyper-geometric or a chisquare or Fisher’s exact 
test for equality of proportions to calculate overrepresented or enriched terms, where a p-
value examines the significance of the enrichment (Draghici et al., 2003). To determine 
whether a functional term is overrepresented in a set of genes or not, a reference or 
background list is used for comparison and for determination of the degree of enrichment. A 
reference set can for example consist of the entire genome of the species being analyzed, or 
the complete set of genes with the potential of being part of the annotation category in 
question. When many categories are considered and hence a large number of tests are 
performed, a multiple-testing correction such as False Discovery Rate, Bonferroni or 
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Benjamini-Hochberg can be useful to correct for false rejections of the null hypothesis. Some 
examples of bioinformatic enrichment analysis tools include GoMiner, Onto-Express, GSEA 
and DAVID (Huang et al., 2009). Gene ontology (GO) terms have been the most primarily 
used annotation data to date, however, recently several of the new or updated tools have 
started to comprise a larger assortment of underlying information, such as data on KEGG 
pathways, Online Mendelian Inheritance in Man (OMIM) disease associations, protein 
domains and gene-expression result in their annotation databases (Huang et al., 2009). The 
differences between the many available methods lie mainly in their supported gene 
identifiers, choice of statistical model, reference data, annotation data, mapping between 
databases and many other aspects that can have a great impact on the results. Therefore it is 
highly important to be aware of the strengths and drawbacks of each method when deciding 
which one to use (Huang et al., 2009). 
 
3.1.1. GeneHub-GEPIS 
GeneHub-GEPIS (http://www.gepis.org/./) is a web application that performs digital 
expression analysis on human and mouse tissues based on an integrated gene database, using 
aggregated EST library information and EST counts. The application calculates the 
normalized gene expression levels across a large panel of normal and tumor tissues, thus 
providing rapid expression profiling for a given gene (Zhang et al., 2007). The backend 
GeneHub component of the application contains pre-defined gene structures derived from 
mRNA transcript sequences from major databases and includes extensive cross references for 
commonly used gene identifiers. ESTs are then linked to genes based on their precise 
genomic locations as determined by Genomic Mapping and Alignment Program (GMAP). In 
addition, the gene-centric design makes it possible to add several important features, 
including text-searching capabilities, the ability to accept diverse input values, expression 
analysis for microRNAs, basic gene annotation, batch analysis, and linkage between mouse 
and human genes (Zhang et al., 2007).  
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3.1.2. Genecards 
Genecards (http://www.genecards.org/) is an integrated database of human genes that 
provides concise genome related information on all known and predicted human genes. It 
extracts and integrates a carefully selected subset of gene related transcriptomics, genetic, 
proteomic, functional and disease information, from dozens of relevant sources. The 
information is automatically mined and integrated from a variety of data sources, resulting in 
a web based card for each of the 7000 human genes that currently have an approved gene 
symbol published by the  HUGO/ Genome Database (GDB) nomenclature committee (Stelzer 
et al., 2011). The aim of the database is to provide immediate current knowledge on a given 
gene. Source databases, mined to compile information stored by GeneCards, include SWISS-
PROT, OMIM, Gene Atlas and GDB. This composite database aims to integrate information 
fragments, scattered over a variety of specialised databases into a coherent picture. Genecards 
is a freely accessible web resource that offers one hypertext card for each of the genes in the 
database and the recent version features both novel infrastructure and an improved search 
engine (Stelzer et al., 2011).  
 
3.1.3. GeneMania 
GeneMania (http://pages.genemania.org/) uses a heuristic algorithm derived from ridge 
regression to predict the function of a set of input genes. It functions by finding directly 
interrelated/interacting genes and uses functional association from multiple genomics and 
proteomics network data to link genes/proteins of interest in real-time (Mostafavi et al., 
2008). Two genes are linked if their expression levels are similar across a specific condition 
in a gene expression study. The data is collected from publications within Gene Expression 
Omnibus (Mostafavi et al., 2008). 
 
3.1.4. STRING 
The database STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) aims to 
provide comprehensive, yet quality controlled collection of protein-protein associations for a 
large number of organisms (http://string-db.org/). The associations are derived from high 
throughput experimental data, from the mining of databases and literature, and from 
 
 
 
 
  
88 
 
predictions based on genomic context analysis (Von Mering et al., 2005). STRING integrates 
and ranks these associations by benchmarking them against a common reference set, and 
presents evidence in a consistent and intuitive web interface. Importantly, the associations are 
extended beyond the organism in which they were originally described, by automatic transfer 
to orthologous protein pairs in other organisms, where applicable. STRING currently holds 
730 000 proteins in 180 fully sequenced organisms (Von Mering et al., 2005).  STRING 
specializes in three ways: (i) it provides uniquely comprehensive coverage, with >1000 
organisms, 5 million proteins and >200 million interactions stored; (ii) it is one of very few 
sites to hold experimental, predicted and transferred interactions, together with interactions 
obtained through text mining; and (iii) it includes a wealth of accessory information, such as 
protein domains and protein structures, improving its day-to-day value for users 
(Franceschini et al., 2013) 
 
3.2. Network Analysis 
The majority of processes in the cell are dependent on various proteins working together in 
signalling cascades or larger complexes and co-operating inside organelles. The interaction 
partners of a protein can contribute to defining its function and it is known that co-expressed 
genes are more likely to interact and be involved in the same biological pathway than genes 
that are not expressed at the same time (Bader et al., 2003). Thus protein interactions and 
other relationships between biological molecules are important areas to study. Such 
interactions are often visualised by networks or more formally two-dimensional graphs 
consisting of vertices (nodes) connected pair wise by edges. The connections can express 
various forms of relationships such as proteins known to interact with one another or be co-
expressed sharing a domain belonging to the same protein family or being evolutionary 
related (Pavlopoulos et al., 2008). 
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3.3. Methods and Materials 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Representation of the in silico enrichment analysis 
 
 
 
 
 
 
 
Tissue Specificity Meta-analysis in TiGER and GeneHub databases 
Literature mining to exclude experimentally validated genes 
Co-expression in GeneMania 
Transcription factor analysis in DAVID and GeneCards 
 
Protein-protein interaction in STRING and Pathway Analysis 
 
Pathway Analysis in KEGG 
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3.3.1. Verification of In Silico Expression Profiles 
The TIGER and GeneHub-GEPIS databases were used to manually verify the expression 
profiles of the proteins and genes identified as “potentially” being secreted for strength and 
specificity of expression (figure 3.1). These databases were chosen above others as they offer 
a gene expression chart based on ESTs. These databases were also used as a source of 
elimination. The rationale was to determine whether the genes were expressed in other types 
of female cancers apart from cervical cancer and whether the proteins were expressed in other 
female tissues besides the cervix. The female cancers/tissues chosen were: cervix, breast, 
ovary, uterus, colon, lung and skin. For each tissue, proteins with gene expression profiles 
showing similar values of expression or high expression in more than the selected tissue were 
eliminated. If the gene or protein was absent in the cervix but was present in the other tissues, 
that protein or gene was eliminated from further study. If high expression was observed in the 
tissue of interest (cervix), but not in the other tissues, the protein or gene was not eliminated.  
If a protein was observed to be highly expressed in another tissue distinct from the criterion 
set for elimination, that particular protein was not eliminated. For data accuracy the lack of 
specificity had to be observed in both databases before non-specific genes were officially 
eliminated. The TIGER database was used to manually check for the expression of each gene 
individually across different cancer types by using “Gene View” and GeneHub-GEPIS 
database: was used to search each gene individually by using “Search by Accession/Gene 
Symbol”. In addition to accounting for tissue specificity, a co-expression analysis was carried 
out.  
 
3.3.2. Co-Expression Analysis 
To ascertain if these genes shared a similar expression pattern, a co-expression analysis was 
performed using GeneMania (http://www.genemania.org/). The genes of interest (GOI) were 
searched for co-expression in Homo sapiens.  
 
3.3.3. Transcription Factor Analysis 
To confirm if the putative genes had any connection to cancer through their regulatory 
network, a transcription factor (TF) analyses was carried out. All possible TFs regulating a 
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specific gene were extracted from Genecards and DAVID and validated for an association 
with cervical cancer development using literature mining. The TFs predicted to be associated 
with 80% or more genes were carried forward for further analysis. 
 
3.3.4. STRING Analysis 
An analysis in STRING 9.0 (http://string-db.org/) was carried out with the intention to view 
the most common pathway via Kyoto Encyclopedia of Genes and Genomes (KEGG) 
(http://www.genome.jp/kegg/pathway.html). By performing the analysis in STRING via 
KEGG it was easier to observe the actual number of GOI enriched for a specific pathway. 
STRING also grouped the genes of interest according to their biological process, molecular 
function and cellular component via their protein-protein interaction network. 
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3.4. Results and Discussion 
3.4.1. In silico Tissue Specificity Expression Analysis 
The 29 candidate genes were subjected to a cross cancer analysis in TiGER and GeneHub-
GEPIS according to their specificity for cervix tissue. The figures 3.2-3.11 provide a 
graphical display of the individual candidate genes. In TiGER, the profile expression level is 
normalized with tissue-library size. Each value for a gene in a tissue is a ratio of observed 
ESTs to the expected one in that particular tissue. The expected number of ESTs is the 
product of total ESTs of the genes and the fraction of total ESTs in the tissue among all ESTs 
in 30 tissues. In GeneHub-GEPIS, Digital expression unit (DEU) is the number of matching 
clones per 1 million library clones and is directly proportional to the copy number of mRNA 
per cell. Statistical significance was measured by the Z- test (p<0.025). A cross-cancer 
analysis in TiGER and GeneHub-GEPIS was used to characterize the 29 remaining genes 
according to their specificity for the cervical cancer tissue. Figures 3.2-3.11 gives a graphical 
display of the 10 candidate genes that showed expression in the cervix tissue for both 
databases, with GeneHub-GEPIS displaying expression between cancerous and normal 
tissue. A drawback of using only functional association data of DEGs is that it does not take 
into account any physical interactions between genes or proteins (Glaab et al., 2012). This 
prompted further analysis of the 10 candidate genes by submitting these candidate genes to 
STRING to investigate gene-gene (protein-protein) interactions or possible co-expression and 
co-regulation in cancer-related metabolic pathways. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Expression profile of Gene 1, Adapted from TiGER (A) and GeneHub-GEPIS (B), 2013. Normal expression is shown in blue while 
over-expression in tumour tissue is shown in yellow.    
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Figure 3.3: Expression profile of Gene 2, Adapted from TiGER (A) and GeneHub-GEPIS (B), 2013. Normal expression is shown in blue while 
over-expression in tumour tissue is shown in yellow.  
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Figure 3.4: Expression profile of Gene 3, Adapted from TiGER (A) and GeneHub-GEPIS (B), 2013. Normal expression is shown in blue while 
over-expression in tumour tissue is shown in yellow.  
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Figure 3.5: Expression profile of Gene 4, Adapted from TiGER (A) and GeneHub-GEPIS (B), 2013. Normal expression is shown in blue while 
over-expression in tumour tissue is shown in yellow. 
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Figure 3.6: Expression profile of Gene 5, Adapted from TiGER (A) and GeneHub-GEPIS (B), 2013. Normal expression is shown in blue while 
over-expression in tumour tissue is shown in yellow. 
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Figure 3.7: Expression profile of Gene 6, Adapted from TiGER (A) and GeneHub-GEPIS (B), 2013. Normal expression is shown in blue while 
over-expression in tumour tissue is shown in yellow. 
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Figure 3.8: Expression distribution of Gene 7, Adapted from TiGER (A) and GeneHub-GEPIS (B), 2013. Normal expression is shown in blue 
while over-expression in tumour tissue is shown in yellow. 
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Figure 3.9: Expression distribution of Gene 8, Adapted from TiGER (A) and GeneHub-GEPIS (B), 2013. Normal expression is shown in blue 
while over-expression in tumour tissue is shown in yellow. 
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Figure 3.10: Expression distribution of Gene 9, Adapted from TiGER (A) and GeneHub-GEPIS (B), 2013. Normal expression is shown in blue 
while over-expression in tumour tissue is shown in yellow. 
A 
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Figure 3.11: Expression distribution of Gene 10, Adapted from TiGER (A) and GeneHub-GEPIS (B), 2013. Normal expression is shown in blue 
while over-expression in tumour tissue is shown in yellow.   
A B 
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3.4.2. STRING Analysis  
The results from the STRING database indicated that the ten genes were not all linked as 
measured by parameters such as co-expression in STRING, with only one interaction 
observed as illustrated in figure 3.12. However, 50% (5/10) of the genes were shown to be 
enriched for receptor binding when classified based on their molecular function. Due to the 
fact not much scientific inference was drawn from protein interactions between the genes of 
interest, further analysis were done by conducting a co-expression analysis in order to search 
for a possible link between the putative genes and a common pathophysiological process. 
 
 
 
 
  
 
Figure 3.12: STRING showed that five (shown in red) out of the ten putative genes are 
implicated in receptor binding (gene names not shown) (Adapted from STRING, 2013). 
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3.4.3. Co-Expression Analysis  
According to GeneMania, 90% (9/10) of the putative genes are co-expressed as depicted in 
figure 3.13. Therefore, it can be deduced that there is a strong probability that the candidate 
genes co-function in the same pathophysiological process/disease. Following co-expression 
analysis, the putative genes were further subjected to TF analysis. It has been documented 
that co-expression analysis may also reveal information regarding the regulatory system of 
the candidate genes. Genes that are shown to have similar expression patterns, generally they 
are also controlled by the same underlying regulatory system (Heyer et al., 1999). 
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Figure 3.13: Co-expression analysis display of the putative genes, adapted from GeneMania, 2013. 
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3.4.4. Transcription Factor Analysis 
Relevant TFs for the ten candidate genes were extracted from Genecards and DAVID and 
these were validated for their association with cervical cancer through published literature. 
Genecards is a web based database that extracts data from genetics, proteomics, 
transcriptomics, functional and disease information to provide a complete summary of a 
specific gene. It was discovered that the putative genes are associated with multiple TFs 
implicated in cervical carcinogenesis such as c-Myc, c-Jun, NFkB and E2F. However, 100% 
(10/10) of the putative genes were projected to be modulated by perixosome proliferator-
activated gamma (PPARγ), while 80% (8/10) were predicted to be regulated by 
TAL1BETAITF2, p53 and CCAAAT enhancer binding protein alpha (C/EBPα). PPARγ is a 
ligand-dependent transcription factor that belongs to the nuclear hormone receptor family and 
is known to regulate cell differentiation and apoptosis (Han et al., 2003, Smith et al., 2001). 
With the TF analysis, the genes were analysed individually with their associated TFs, yet no 
real association between the genes of interest and their TFs could be visualized. Hence, a 
gene-gene interaction analysis considering the putative genes and their three TFs of interest 
(which together totalled 13 genes) was carried out in STRING to observe a network view of 
their interactions. 
 
STRING analyses indicated that when a wider view of the 13 genes/proteins was considered, 
they were remarkably all re-centred around Proliferating cell nuclear antigen (PCNA) as 
shown in figure 3.14. The E7 oncoprotein of high-risk HPV has been shown to activate 
PCNA, causing its up-regulation in cervical intraepithelial neoplasia, the premalignant 
condition of cervical cancer (Branca et al., 2006). Since PCNA is up-regulated in pre-
invasive cervical cancer and the candidate genes are linked to PCNA, they could potentially 
serve as early diagnostic molecular markers. Similarly, the relationship of p53 and the GOI 
were once again reaffirmed via PCNA. The p53 is known to induce and up-regulate PCNA 
(Paunesku et al., 2001). When PCNA and p53 are both up-regulated, they function in DNA 
repair. However, when p53 is down-regulated (or absent) due to degradation via the HPV E6 
oncogene and PCNA is up-regulated due to E7 induction, cell proliferation occurs instead 
(Paunesku et al., 2001). Hence the two viral oncogenes, E6 and E7 function together to 
promote cervical carcinogenesis by inversely modulating PCNA and p53. PCNA and p53 in 
combination have been suggested as valuable diagnostic biomarkers in low-grade cervical 
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intra-epithelial neoplasia (CIN - the first stage of cervical cancer when a diagnosis is ideal) 
(Goel et al., 2011). Henceforth, the genes directly interacting with p53 and PCNA could act 
as molecular signatures in the early diagnosis of cervical cancer. Although this information 
was promising in possibly implicating the putative genes in cervical cancer, the co-expression 
analysis demonstrated the significance of considering genes interacting with the putative 
genes. Hence, the ten putative genes, their interacting genes (extracted from GeneCards) and 
their TFs (which altogether totalled 79 genes) were once more assessed in STRING. 
 
 
 
 
  
Figure 3.14: The ten putative genes and their corresponding 3 cervical cancer-associated transcription factors were all linked to Proliferating cell 
nuclear antigen (PCNA) (PCNA is shown in the red rectangle, while p53 is shown in the blue rectangle). Disconnected nodes are not shown 
(Adapted from STRING, 2013). 
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3.4.5. STRING analysis with GOI, interacting genes and TFs 
STRING explores and assigns functions of genes based on gene-gene interactions; it 
confirmed the results obtained by the GO analysis carried out in DAVID. The categories 
enriched with the highest number of genes were selected. STRING showed that of the 79 
genes, 27 were enriched for cell surface receptor signalling pathways, while 17 genes were 
predicted to participate in G-protein coupled receptor (GPCR) signalling when clustered 
according to biological process (Figure 3.15). The molecular functions showed corresponding 
categorization with the majority of the genes involved in receptor binding (19 genes) and 
signal transducer activity (19 genes) (Figure 3.16). The highest proportion of genes was 
found in the plasma membrane component of the cell (Figure 3.17). The logical and 
systematic next step was to carry out a pathway analysis on the genes of interest. 
 
 
 
 
  
Figure 3.15: Distribution of genes according to their biological process. The images on the left show the genes (red) involved in cell surface 
receptor signalling (A) and G-protein coupled receptor signalling (B). The partial table on the right shows the number of genes predicted to 
participate in the most enriched biological process and their corresponding statistical values (Adapted from KEGG, 2013). 
 
 
 
 
  
 
 
 
Figure 3.16: Distribution of genes according to molecular function. The images on the left show the genes (red) involved in receptor binding (A) and signal 
transducer activity (B). The partial table on the right shows the number of genes predicted to participate in the most enriched molecular functions and their 
corresponding statistical values (Adapted from KEGG, 2013). 
 
 
 
 
  
Figure 3.17: Distribution of genes according to their cellular component. The images on the left show the genes (red) localized in the plasma 
membrane (A) and the extracellular space (B). The partial table on the right shows the number of genes predicted to be found in the most 
enriched cellular components and their corresponding statistical values (Adapted from KEGG, 2013). 
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3.4.6. Pathway Analysis 
When a KEGG pathway analyses was carried out in STRING, by inputting the ten putative 
genes, their directly interacting genes (which totalled 79 genes) and TFs, most of the genes 
were mapped to the Natural killer cell-mediated cytotoxicity (11 genes) and Oxidative 
phosphorylation pathways (9 genes) for FDR<0.01) as shown in figure 3.18, the most 
enriched pathways were selected. These enriched pathways were confirmed by DAVID, 
which additionally mapped 18 genes to signalling by GPCR. It was interesting to note that 
many of the genes in STRING were also mapped to the mitochondrial proton-transporting 
adenosine triphosphate (ATP) synthase complex. Signalling pathways (previously associated 
with the GOI) modulate ATP production via mitochondrial oxidative phosphorylation 
(Fosslien, 2008). Altered signal transduction is known to directly affect mitochondrial 
proteins, while mitochondrial dysfunction has been highlighted as one of the recurrent 
features of neoplastic cells (Solaini et al., 2010). Hence, many of the GOI were predicted to 
participate in diverse cancer metabolic pathways. 
3.4.7. A Gene Profile for cervical cancer diagnosis 
However, no single biomarker has to date been effective in the diagnosis or treatment of 
cervical cancer (Folgueira et al., 2005); most likely because cancers are complex diseases 
which are often also multigenic in nature. Several studies have revealed that considering a 
gene profile (a combination of many genes) may be more effective in implicating/diagnosing 
a specific disease, as opposed to using a single gene common to many biological processes 
(Folgueira et al., 2005). Although the number of genes enriched for these pathways seem 
small, if even one of the candidate genes can be positively implicated in a cervical cancer 
pathway and its co-expression with another candidate gene as well as transcriptional co-
regulation by PPARγ can be verified, then a possible gene profile for cervical cancer can be 
established. Since the probability that a set of the same genes can be associated with all 
cancers is very low, combining the GOI as biomarkers in a cervical cancer diagnostic tool can 
be very promising. Bioinformatics have been invaluable in predicting genes and their 
functions that could previously not be identified using quantitative genetics data (Guan et al., 
2012). However, since microarray data and Bioinformatics algorithms in general may be 
affected by “noise” that may generate errors, this data must be empirically verified (Rajeevan 
et al., 2001). 
 
 
 
 
 Figure 3.18: The Natural Killer cell-mediated cytoxocity was a one of the most enriched pathways (Adapted from KEGG, 2013). 
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3.5. Discussion and Conclusion 
Understanding how genes are expressed and regulated in various tissues or under various 
conditions can help elucidate the molecular mechanisms of tissue development and function 
(Liu et al., 2008). The changes in gene expression can be identified or evaluated by in silico 
gene expression analysis. Gene expression profiling is a technology that is used to identify 
genes that are active in a sample of tissues or cells, for both diseased and normal states. Gene 
expression profiling allows for the sub-classification of tumours by providing diagnostic and 
prognostic information of genes that are differentially expressed in tumours (Thomas et al., 
2013). The availability of large amounts of sequence data, coupled with the advances in 
computational biology provides an ideal framework for in silico gene expression analysis 
(Murray et al., 2007). Although in silico gene identification remains a difficult task, public 
(freely available) and private (subscription) expressed sequence tag (EST) databases 
represent an important source for biomarker or target discovery (Terstappen and Reggiani, 
2001). These databases contain short sequence information of expressed genes; this leads to 
their identification and is indicative of the encoded proteins (Marra et al., 1998).  
 
The analysis of gene expression patterns derived from large EST databases have become a 
valuable tool in the discovery of prognostic and diagnostic markers. Sequence data derived 
from a variety of cDNA libraries provides a wealth of information for identifying genes that 
can be used for the development of pharmaceutical products as well as potential diagnostic 
biomarkers (Fannon, 1996). The tissue specificity of a gene is a measure of the relative 
distribution of gene expression across major tissue types in the human body. Tissue-specific 
genes enable an assay to detect small increases in the serum protein levels which can be 
unambiguously attributed to a neoplastic lesion or disease onset in the affected organ 
(Vasmatzi et al., 2007). According to Vasmatzi et al (2007), the discovery of novel serum 
biomarkers must not only identify differentially expressed genes encoding products with 
selected cellular localization but should also identify genes with high specificity in the tissue 
type of interest. The 29 remaining genes were further investigated for tissue-specificity in 
TiGER and GeneHub-GEPIS to identify genes specific to cervical cancer.  
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After the cross-cancer analysis, only ten putative genes with sufficient specificity remained 
(Figures 3.4-3.13). Guan et al (2012) demonstrated that prediction performance is 
significantly improved when incorporating tissue-specific networks as opposed to global 
functional data. By accounting for tissue-specificity one can identify more accurate candidate 
disease genes (Guan et al., 2012) and bypass redundant laboratory work (Zang et al., 2004). 
Bioinformatics analysis investigating potential protein-protein interactions and cellular 
pathways were performed for the ten candidate genes. This was done to identify if there are 
any commonalities between the genes products and if they are involved in a cancer pathway 
or pathways related to cancer such as apoptosis and cell cycle regulation. Based on the 
protein interactions between the genes; some genes can be indirectly implicated in pathways 
based on the fact that these genes interact with proteins involved in those particular pathways. 
Proteins have the ability to form a wide range of direct and indirect interactions with each 
other that can be conceptualized as networks. Analysing genes as a network increases its 
statistical power in human genetics and can assist in predicting diseased phenotypes 
(Szklarczyk et al., 2011).  
 
The interactions that are generated can be conceptualized as networks; this allows the 
genome to be seen as more than a static collection of distinct genomic functions (Skrabanek 
et al., 2008). STRING provides a source for all functional links between proteins. STRING’s 
main strengths are that it has a unique comprehensiveness; it provides a confidence score and 
an interactive user interface (Szklarczyk et al., 2011). In STRING analysis only one 
interaction was observed for the ten putative genes and since not much information was 
drawn from the protein-protein interaction studies, further in silico analysis was conducted. 
Network knowledge can give rise to understanding the biological function and dynamic 
behaviour of cellular systems, generating biological hypothesis about putative biomarkers, 
therapeutic targets or deregulated pathways in cancer. Cancer-related proteins have a higher 
ratio of promiscuous structural domains, making them more prone to interact with other 
proteins. In fact, they have a large number of interacting proteins and occupy a central 
position in the networks (Sanz-Pamplona et al., 2012). Gene co-expression network analysis 
identifies groups of genes highly correlated to each other in expression levels across multiple 
samples. Genes that are functionally related to each other are believed to express similarly 
and thus have high correlations between their expression profiles. So, functionally similar 
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genes group together in gene co-expression networks. In this study 90% of the genes were 
shown to be co-expressed. Co-expression studies are conducted because there is evidence that 
co-expressed genes may be functionally related, for instance, genes encoding the various 
subunits of a complex protein will have similar expression patterns (Heyer et al., 1999). 
According to Mostafavi et al (2008), two genes are linked if their expression levels are 
similar across a specific condition in a gene expression study. The process of regulation of 
gene transcription is controlled by a group of regulators called transcription factors (TFs). 
TFs facilitate the final steps in the relay of information from the cell surface to the nucleus 
and the gene. This is accomplished by the interaction of the TFs with specific DNA elements, 
these elements are usually situated upstream of the sequence that encodes the gene (Eckert et 
al., 2013). Transcription factors are cellular components that regulate gene expression and 
their activities subsequently control cell function and cellular response to the environment 
(Vaquerizas, 2009).  
 
A constructive approach to establishing a gene regulatory network is to identify the 
regulatory components such as the TFs that may induce the expression of a set of co-
expressed genes underlying a biological process or diseased phenotype (Whitfield et al., 
2012). If the TFs regulating the candidate genes are known to be oncogenic, the genes could 
possibly be associated with cancer. In order to establish a connection between the putative 
genes through a common regulatory element, an analysis was conducted so as to determine if 
all the ten putative genes shared a common transcription factor. According to Jung et al 
(2005), PPARγ shown to be associated with most of the candidate genes, is down-regulated 
in newly transforming cervical neoplasia. The genes PPARγ regulates can therefore possibly 
serve in the early diagnosis of cervical cancer. Interestingly, a link between PPARγ and 
C/EPB was established by demonstrating that a decrease in PPARγ also facilitated a decrease 
in the levels of C/EPB. C/EBPα is a differentiation-inducing transcription factor. 
Furthermore, loss of function or inactivation of C/EBPα is commonly associated with 
squamous cell line cancers and most of the cells affected in cervical cancer are squamous 
cells (Koschmieder, 2009). This could therefore further contribute to the specificity of the 
candidate biomarkers for cervical cancer (which was already demonstrated by the tissue 
specificity analysis).  
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Similarly, the HPV oncoproteins E6 has been shown to neutralize p53, effectively reducing 
its levels and its subsequent ability to effectively suppress tumour formation (Tommasino et 
al., 2003). The rationale of this study is to find biomarkers that can detect cervical cancer in 
its pre-invasive stage and the HPV oncogenes E6 and E7 are responsible for many of the 
changes that occur when the neoplastic tissue forms in the cervix. Therefore establishing 
which genes and/or transcription factors are targeted by these oncogenes, it will be possible 
to use those genes/transcription factors or a combination thereof to design a diagnostic tool 
specific for cervical cancer detection. By performing a network-based analyses based on gene 
variants and their interacting genes, one can explore how sub-network level features 
contribute to the phenotype of a complex disease such as cancer (Okser, 2013). Signalling 
pathways are activated by extracellular proteins (ligands), which bind their specific cell 
surface receptors which  dimerize or oligomerize at the cell surface to begin the intracellular 
signalling phase (Darnell Jnr, 2002). GPCR’s constitute the largest family of cell surface 
molecules responsible for converting extracellular stimuli into intracellular signals and have 
emerged as key players in tumourigenesis and metastasis (Dorsam and Gutkind, 2007).  
 
Events such as signal transduction are often targeted by oncogenes to sustain growth signals 
for uncontrolled proliferation (Chial, 2008). Hence, it is highly likely that the GOI are 
targeted by the HPV E6 and E7 oncogenes for dysregulation. TFs participate at the ends of 
signal transduction and stress-response pathways by up or down regulating certain genes. All 
primary and 39 modifier genes leading to cancer partake in at least one of these two pathways 
(Nebert, 2002). Since the annotated molecular function of the GOI also predicted their 
participation in one of the critical cancer pathways (signal transduction), this further 
strengthens their possible implication in cancer-related pathways. However, this does not 
mean that they can be easily detected in bodily fluids, which is necessary for a biomarker 
based test to be non-invasive. Hence, their cellular localization was also considered. More 
specifically, most genes were predicted to be secreted into the extracellular space or to be 
localized in the extracellular region and on the cell surface. This is very promising since the 
targeted genes are those that facilitate the entry of cervical cancer biomarkers into the 
circulatory system. Nevertheless, events such as cell surface binding and signal transduction 
are normal biological processes that do not generally translate into cancer. Although, it is 
worthwhile to reiterate that 90% of the GOI’s were shown to be co-expressed, while all of the 
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GOI were regulated by the same element showing possible co-regulation and co-expression. 
As previously stated, the general consensus is that there is likely to be a relationship between 
co-expression and co-regulation and that co-expressed and/or co-regulated genes are likely to 
function in the same metabolic pathway (Emmert-Streib and Glazko, 2011). By considering 
pathways one can observe gene sets that function in a coordinated manner to define a 
biological process (Emmert-Streib and Glazko, 2011). KEGG stores higher order functional 
information in the form of pathways showing graphical representations of cellular processes 
and metabolic processes (Kanehisa and Goto, 2000). Natural killer cells are known to target 
foreign and cancer cells for apoptosis via multiple mechanisms. If any of these genes from 
this pathway are mutated or deregulated it could therefore negatively influence their ability to 
induce cancer cells to undergo apoptosis. Similarly the genes involved in oxidative 
phosphorylation could make for ideal targets for oncogenes since a wide spectrum of 
oxidative phosphorylation deficit has been associated with tumourigenesis (Solaini et al., 
2010).  
 
This study managed to discover and identify putative biomarkers to be further validated using 
molecular methodologies. Combining biological data mining, text mining and in silico gene 
enrichment techniques proved to be effective in classifying genes and linking them to 
cervical cancer. The advent of microarray based technology has helped study the expression 
patterns of more than 40,000 genes at a time. Several groups have used microarray based 
technology to look for differentially expressed genes in the different stages of cervical 
tumourigenesis. Few studies have followed up and validated the microarray data in a large 
number of genes (Rajkumar et al., 2011). However, in silico methods need to be coupled with 
in-vitro work to confirm the in-silico approach and also establish the confidence of the 
identified putative markers in a biological system. 
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CHAPTER 4: Differential Expression Analysis of Putative Biomarkers Using Molecular 
Techniques 
4.1. Background 
Gene expression analysis is increasingly important in various biological research fields. 
Understanding the patterns of expressed genes is expected to provide insight into the complex 
regulatory networks and will probably lead to identification of genes implicated in disease. 
Quantifying gene expression levels can yield valuable clues about the function of a gene, for 
instance, accurate measurements of gene expression can identify the type of cells or tissues 
where a particular gene is expressed, reveal individual gene expression levels in defined 
biological states and detect alterations in gene expression levels in response to specific 
biological stimuli (Fraga et al., 2008). This section of the study is aimed at validating the ten 
putative genes identified in chapter 2 by in silico expression analysis. This was accomplished 
by means of molecular expression profiling using qPCR in cervical cancer cell lines, other 
types of cancer as well as non-cancerous cell lines. 
 
4.1.1. Quantitative real-time PCR (qPCR) 
Real-time polymerase chain reaction (PCR) has gained popularity in the past few years and 
has become the most widely used technique in modern molecular biology. This technique 
depends on fluorescence-based detection of amplicon DNA and permits the kinetics of PCR 
amplification to be monitored in real time, making it possible to quantify nucleic acids with 
extraordinary ease and precision (Guescini et al., 2008). Quantitative real-time PCR (qPCR) 
has become a very versatile technique to examine expression changes of one or more genes 
of interest in various pathological states such as cancer. This method offers a broad range of 
advantages over standard methods such as Northern blot and semi-quantitative PCR due to its 
specificity, sensitivity, simplicity, costs and high-throughput. Thus, it has become the most 
emerging tool for absolute and relative quantification of mRNA transcription levels (Jacob et 
al., 2013). This technique is very sensitive for the detection and quantification of gene 
expression levels particularly for low abundance mRNA in tissues that have low mRNA 
concentrations and to elucidate small changes in mRNA expression levels (Pfaffl et al., 
2002). PCR can be broken into three major steps (Figure 4.1): exponential phase, log-linear 
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phase and plateau phase. During the first 10-15 cycles (linear ground phase), the PCR is at 
the initiation stage and emission of fluorescence at each cycle has not risen above background 
and during this time the baseline fluorescence is calculated. At the exponential phase, the 
amount of fluorescence has reached a threshold where it is significantly higher than the 
background levels. In the log-linear phase, the PCR reaches its optimal amplification period 
with the PCR product doubling after every cycle in ideal reaction conditions. Lastly, the 
plateau stage is reached when reaction components become limited and the fluorescence 
intensity is no longer useful for data calculation (Wong and Medrano, 2005).  
 
 
 
Figure 4.1: Graph illustrating the phases of the PCR amplification curve, adapted from Fraga 
et al., 2008.  
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4.1.2. Quantitation Strategies in qPCR 
There are two strategies used to quantify gene expression in qPCR viz.: absolute 
quantification and relative quantification. Absolute quantitation relies on a standard curve 
which is generated by using serially diluted standards of known concentration. The standard 
curve produces a linear relationship between the cycle threshold (Ct) and initial amounts of 
total RNA or cDNA, allowing the determination of the concentration of unknowns based on 
their Ct values. The Ct is defined as the number of cycles required for the fluorescent signal 
to cross the threshold (i.e. exceeds background level). Ct levels are inversely proportional to 
the amount of target nucleic acid in the sample (i.e. the lower the Ct level the greater the 
amount of target nucleic acid in the sample) (Wong and Medrano, 2005). In relative 
quantitation strategy changes in gene expression are measured based on either an external 
standard or a reference sample known as a calibrator. When a calibrator is used, the results 
are expressed as a target reference ratio (Wong and Medrano, 2005). This method depends on 
the comparison between expression of a target gene versus a reference gene and the 
expression of the same gene in target sample versus reference samples (Yuan et al., 2006). 
This chapter aimed at testing the ten target genes identified in chapter 2 by in silico 
methodology, by generating expression profiles across an array of cancer cell lines in order to 
identify putative biomarker significantly expressed in cervical cancer.  
 
This was achieved by utilising various molecular techniques such as cell culture, RNA 
extraction, synthesis of cDNA and qPCR. In order to calculate the expression of a target gene 
in relation to a suitable reference gene, various mathematical models have been established. 
These models can ascertain relative expression levels either without real-time PCR efficiency 
correction as shown in equation 4.1 or with kinetic PCR efficiency correction in equations 4.2 
and 4.3 (Pfaffl, 2001). Existing models are capable of determining a single transcription 
difference between one control and one sample, e.g. LightCycler Relative Quantification 
Software, or permit a group-wise comparison of up to one hundred samples, e.g. Relative 
Expression Software Tool (REST) and REST-XL (Pfaffl, 2001). 
Equation 4.1 
R = 2 
- [ΔCp sample - ΔCp control]
 
R = 2 
- ΔΔCp
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Equation 4.2 
Ratio =          (Etarget) ΔCp target (control – sample) 
             ________________________________ 
                     (Eref) ΔCp ref (control – sample) 
 
 
Equation 4.3 
 
Ratio =             (Etarget)
 ΔCp target (MEAN control – MEAN sample)
 
                      ________________________________________________ 
                         (Eref) 
ΔCp ref (MEAN control – MEAN sample) 
 
 
 
The relative expression ratio of a target gene is calculated on the basis of its actual real-time 
PCR efficiency (E) or on a static E of 2, and the crossing point difference (ΔCp) of one 
unknown sample versus one control. The relative computation procedure, using either REST 
or REST-XL, is based on the mean Cp of the investigated groups (Equation 4.3) (Pfaffl, 
2004). 
 
4.1.3. Amplification Efficiency 
An imperative consideration when doing relative quantification is amplification efficiency of 
the PCR reaction. Techniques that have been previously used to calculate gene expression 
have been established on the hypothesis that the amplification efficiency of the reaction is 
ideal, indicating the doubling of the PCR product concentration during each cycle within the 
exponential phase of the reaction (Gibson et al., 1996). Even so, various PCR reactions lack 
perfect amplification efficiencies and calculations without an appropriate correction factor 
may substantially miscalculate the initial concentration (Liu and Saint, 2002). Generally, the 
reactions amplification efficiency is calculated using data collected from a relative standard 
curve with equation 4.4 (Rasmussen, 2001). 
Equation 4.4 Efficiency  
(E) = [10(-1/slope)]-1 
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4.1.4 Data Evaluation 
The Pfaffl model (2002) calculates gene expression by combining gene quantification and 
normalisation into a single calculation. The model makes use of amplification efficiencies of 
the target and reference genes which are also used for normalisation to correct for differences 
between two assays. The Pfaffl method makes use of excel based software known as REST® 
which automates data analysis using this model. REST uses a pairwise Fixed Reallocation 
Randomisation test to calculate result significance and is also able to indicate if the reference 
gene is suitable for normalisation. Expression ratios are calculated by the REST software 
based on Ct values of the target gene relative to the reference gene and based on the results, 
the software generates a plot of the expression ratios for all samples involved (Wong and 
Medrano, 2005).  
 
The aim of this chapter was to validate the putative biomarkers that were identified using an 
in silico approach described in chapter 2. This was accomplished by using various molecular 
techniques including cell culture, mRNA extraction cDNA synthesis and qPCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
114 
 
4.2. Materials and Methods 
Cell Culture Media and Reagents  
Dulbecco's Minimal Essential Medium (DMEM)                                   Invitrogen 
Dimethyl Sulphoxide (DMSO)                                   Sigma 
Eagle's Minimal Essential Medium (EMEM)                                   Sigma 
Fetal Bovine Serum (FBS)                                   Invitrogen 
Leibovitz's L-15 Medium                                   Sigma 
McCoy's 5a Medium Modified                                    Sigma 
MCDB                                   Sigma 
Phosphate Saline Buffer (PBS)                                   Invitrogen 
Roswell Park Memorial Institute Medium (RPMI) 1640                                   Sigma 
  
Materials and Suppliers  
Agarose             Whitehead Scientific 
Bovine Serum Albumin    Roche 
Cell culture media and reagents    Invitrogen 
Diethylpyrocarbonate (DEPC) 
Ethanol 
Ethylene Diamine Tetra-acetic acid (EDTA)  
Gel Loading Dye (6X)          
Hydrochloric Acid 
 
Sigma 
Merck 
Merck 
Merck 
Fermentas 
 
 
 
 
  
115 
 
KAPA Taq extra hotstart readymix KAPABiosystems 
KAPA SYBR FAST qPCR kit KAPABiosystems 
Nuclease free water   
Nucleospin® Tripep kit 
Oligonucleotides 
Sodium Dodecyl Sulphate (SDS) 
SYBR® Safe DNA Gel stain 
SYBR® Fast Master Mix (2x) ABI Prism 
Sodium Hydroxide 
Transcriptor First Strand cDNA Synthesis Kit 
TEMED (N, N, N’, N’-Tetra methylethylene-diamine)            
Tris [Hydroxymethyl] aminoethane (Tris) 
Tris (2-carboxyethyl) phosphine (TCEP) 
Trypsin 
Merck 
Fermentas 
Macherey-Nagel 
Inqaba Biotech 
Promega 
Invitrogen 
Lasec 
Merck 
Roche 
Sigma 
Merck 
Sigma 
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4.2.1. Cell Culture Approach 
4.2.1.1. Cell Lines and Media 
All the cell lines that were used during the course of this research were purchased from ATCC 
(American Type Culture Collection), shown in table 4.1. The cells were cultured in their 
respective growth medium per instructions of the supplier. Cell lines used in this study are 
adherent and semi-adherent.  
Table 4.1: List of cell lines used in this research study 
Cell line Origin Growth medium 
HeLa 
CaSki 
HT-3 
HPV18 cervical cancer 
HPV16 cervical cancer 
Cervix Carcinoma 
DMEM + 10% FBS 
DMEM + 10% FBS 
McCoy's 5a + 10% FBS 
A549 Lung carcinoma EMEM + 10% FBS 
MCF-7 Breast adenocarcinoma DMEM + 10% FBS 
KMST-6 Normal skin cell line DMEM + 10% FBS 
SK-OV-3 
CAOV3 
           Ovarian Carcinoma McCoy's 5a + 10% FBS 
DMEM + 10% FBS 
T-84 Colorectal adenocarcinoma DMEM-F12 +10% FBS 
 
4.2.1.2. Starting Cell Culture from frozen Cells: 
Frozen cryovials were placed in a water bath at 37ºC, for 1-2minutes, until defrosted. Slowly, 
drop by drop, cells were diluted in pre-warmed media (table 4.1) in a 15 mL tube and then 
centrifuged for 5-10 minutes. The supernatant was removed (as much as possible); making 
sure the pellet was not disturbed so as to remain intact. The pellet was then ressuspended in 
the respective media and the entire tube’s content transferred to a 25 cm2 Flask (T25). The 
flask was then incubate at 37ºC with 5% CO2 for 24 hours, after which all the medium was 
removed and replaced with new medium to ensure no DMSO remained in the cells. 
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4.2.1.3. Maintenance of Human Cells 
A schedule of cell maintenance, feeding and passaging was adopted to maintain appropriate 
cell density, nutrient concentration and pH levels in cultures. Cells were best passaged when 
growing logarithmically, at 70 to 80 % confluency. A schedule used for routine maintenance, 
every 2 days medium was changed if the confluency was below 40-50% and every day until 
70-80 % confluency was reached upon which the cells were passaged. 
 
4.2.1.4. Sub-Cultivating 
All the media (table 4.1) was pre-warmed to 37ºC. The culture was inspected for 
contamination. If no contamination was present and the cells were at 70-80% confluence, the 
medium was aspirated with a sterile Pasteur pipette and the cells were washed with 5 mL of 
PBS to remove any residual medium (~15 seconds). After the PBS was aspirated with a 
sterile Pasteur pipette, 1 mL of 0.05% trypsin-EDTA (TE) was added, evenly dispersed over 
the surface by gently rocking the flask. The flask was then placed in the incubator with the 
cap screwed tightly. After 2 minutes the flask was taken to the microscope to check the 
progress of the detachment. When the cells were detached, 5 mL of new media was added, 
rinsing the surface of the flask to inactivate the trypsin. The cells were collected by 
centrifugation at 3000 xg. 
 
4.2.1.5. Changing Medium 
Cells were fed with their respective media; the culture was inspected under the microscope to 
ensure no contamination was present. The old medium was aspirated from the flask with a 
sterile Pasteur pipette and 5 mL of new medium was added. The freezing down of cells was 
subsequent to trypsinisation of cells. Centrifugation was done at 3000 xg for 3 min. The 
supernatant was then discarded and the pellet resuspended in 90% complete medium and 
10% DMSO. The resuspended cells were aliquoted as 1ml fractions into cryotubes and stored 
at -150
o
C. 
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4.3. Analytical Laboratory Techniques 
4.3.1. Extraction of RNA 
Cells were prepared prior to RNA extraction as described in section 3.2.1; the cell pellet was 
washed with PBS and then collected by centrifugation at 3000 xg. The nucleospin kit was 
used to isolate RNA and proteins respectively according to the manufacturer instructions. 
However for the purposes of this research only RNA extraction will be the focus. The cells 
were lysed by adding buffer RP1 (350 μl) and 3.5 μl, of 20mM Tris (2-carboxyethyl) 
phosphine (TCEP) to the cell pellet and were vortex vigorously for a minute. The cells were 
washed with 350 μl 70% ethanol and were transferred to a new Eppendorf; the pellet was 
collected by centrifugation at 11 000 xg for 30sec. The silica membrane was desalted by 
adding 350 μl MDB and the pellet was collected by centrifugation at 11 000 xg. A 1: 100 
stock solution of recombinant deoxyribonuclease (rDNAse) in reaction buffer of rDNAse was 
added to the RNA silica membrane of the column. Thereafter the DNA was digested by 
adding 95 μl DNase reaction mixture; the cells were incubated at room temperature for 15 
min. The silica membrane was washed and dried by adding 200 μl RA2 (wash 1), then 600 μl 
RA3 (wash 2) and lastly 250 μl RA3 for 30 secs and 2min at 11 000 xg respectively.  
Furthermore, the RNA was eluted using 60 μl RNAse free water and centrifuged at 11000 xg 
for 1 minute. The concentration and quality of RNA was assessed using the Nanodrop ND-
1000 spectrometer (NanoDrop Technologies) and all RNA samples were stored at -20
0
C.  
 
4.3.2. Agarose Gel Electrophoresis of RNA 
Agarose gels were prepared by dissolving agarose powder in 1X TBE buffer prepared with 
Diethylpyrocarbonate (DEPC) water by heating until agarose was dissolved. The solution 
was cooled and 0.8X SYBR safe gel stain was added. The solution was then poured into a gel 
tray and the tray was placed into the electrophoresis tank filled with 1X TBE buffer.  RNA 
samples were prepared by mixing 1 part of the RNA with 6X loading dye and heated for 2-5 
minutes at 95
0
C. After loading the gel was electrophoresed for 60 minutes at 100 V and the 
RNA was visualised using the UVP system from Bio-Rad.  
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4.3.3. cDNA Synthesis 
The cDNA was synthesized using the Transcriptor First Strand cDNA synthesis kit (Roche) 
according to the manufacturer’s instructions. All the reagents were kept on ice throughout the 
experiment. The template primer mixture was prepared with the following reagents in a 
sterile, nuclease-free, thin walled PCR tube as shown in table 4.2 to a final volume of 13μL.  
 
Table 4.2: Reagents for Template Primer Mix 
Reagent Final Concentration 
RNA 1 μg 
Anchored-oligo (dT) 18 Primer 2.5 μM 
PCR grade H2O Variable 
 
 
Once all the reagents in table 4.2 were mixed, the reaction mixture was heated for 10 minutes 
at 65
0
C in a pre-heated thermal block cycler to denature the template. The reaction mixture 
was immediately cooled and the remaining reagents were added as specified in the following 
table 4.3. 
 
Table 4.3: Reagents for final cDNA Synthesis Mixture 
Reagents Final Concentration 
Transcriptor Reverse Transcriptase reaction buffer 1 X 
Protector RNAse inhibitor 20 U 
Deoxynucleotide Mix 1 mM each 
Transcriptor Reverse Transcriptase 10 U 
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Once all the reagents in table 4.3 were added, they were carefully mixed and the tube 
centrifuged briefly to collect the sample to the bottom of the tube. The tube was placed in the 
thermal block cycler and the RT reaction mixture was incubated for 33 minutes at 55
0
C. The 
Transcriptor Reverse Transcriptase was inactivated by heating the mixture for 5 minutes at 
85
0
C and the tube was placed on ice in order to stop the reaction. The cDNA was quantified 
using the Nanodrop ND-1000 Spectrophotometer (Nanodrop Technologies). The cDNA was 
stored at -20
0
C. 
 
4.3.4. Primer Design 
Gene specific oligonucleotides were designed for cDNA amplification and oligonucleotide 
sequences are shown in table 4.4. Each oligonucleotide was designed to be 20bp long using 
the NCBI primer design algorithm (www.ncbi.nlm.nih.gov). The oligonucleotide sequences 
were sent for synthesis to Inqaba biotech (http://www.inqababiotec.co.za/). Once the 
oligonucleotides were synthesized, a 100 μM stock solution of the oligonucleotides was 
prepared by re-suspending the pellet into 1x TE buffer (10 mM Tris, pH 7.5 to 8.0, 1 mM 
EDTA). The concentrated oligonucleotides stocks were stored at -20
0
C. 
 
Table 4.4: Oligonucleotide sequences for PCR amplification of cDNA 
Primer  Forward Sequences (5’-3’) Reverse Sequence (5’-3’) length(bp) 
Gene 1 GTTCTTCGATGAGCCCACCA GCAGACTTTTCCCCGGTACA 193 
Gene 2 CTAGAGGACCTGGGGACACG CGTTGTAGGCACGGTTGTTG 288 
Gene 3 GGCCACTTCGTCCACCTACT TTCCAATTGGTCCAGGTCGT 295 
Gene 4 GAACCTGGAGCGGATTACCC AGATACACCTCCACCAGGCT' 84 
Gene 5 TCCAGATATTGCCAGGGATGC CCTCATAGGTAGCCACAGCAG 192 
Gene 6 CCTGCTTCCTTTAGCGTGAAC GGTCCTTGTCACTGGCTCTT 290 
Gene 7 TAGCTCTGACTGGGCTGACT TAGCTCTGACTGGGCTGACT 289 
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Gene 8 GCCAAGGAAAAACGAGGCTG AGGCCATTCTTGTCGCTGAA 98 
Gene 9 TCTCTGAGCAGGAATCCTTTGT GCTACAGCGATGAAGCAGCA 261 
Gene 10 TGATGAGATTGGCGTGGCTT AGGATACCTGGCCTCCACAT 190 
PTEN CTCAGCCGTTACCTGTGTGT AGGTTTCCTCTGGTCCTGGT 129 
HpRT-1  TGCTCGAGATGTGATGAAGG TCCCCTGTTGACTGGTCATT  
GAPDH ACCCACTCCTCCACCTTTG CTCTTGTGCTCTTGCTGGG  
 
 
4.3.5. PCR Amplification of cDNA 
In order to verify reverse transcription and accessibility of cDNA for PCR, PCR was 
performed as shown in table 4.5. In this PCR, sequences from the 5’ and 3’ end of the 
candidate genes were amplified. The amplified PCR products were visualized for the 
expected size on a 2 % Agarose gel. The gel was stained with SYBR safe DNA stain and 1X 
TBE was used as the electrophoresis buffer (see section 4.3.2). 
 
Table 4.5: Standard PCR Reaction Composition 
Reagent  Final Concentration 
2X KAPA Taq Extra Hotstart ReadyMix with 
dye (2 mM MgCl2 at  1X) 
1 X 
Forward Primer  10 μM 
Reverse Primer  10 μM 
PCR-grade water Variable 
Template DNA  250 ng 
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The reaction mixture was cycled with the following parameters as shown by table 4.6 
 
Table 4.6: PCR cycling protocol 
Step Temperature Duration Cycles 
Initial Denaturation 95 °C 5 min 1 
Denaturation 95
 
°C 30 sec  
20-40 Annealing Primer Specific 30 sec 
Extension 72
 
°C 45 sec 
Final Extension 72
 
°C 10 min 1 
Hold 4
 
°C α 1 
 
4.3.6. Quantitative Real-Time PCR (qPCR) Protocol 
Expression levels of the ten selected genes were assessed with quantitative real-time PCR 
(qPCR). PTEN was added to the panel as a positive control as it is a gene that has been 
shown to be expressed in cervical cancer. Two housekeeping genes, GAPDH and HPRT were 
used as reference genes. All reactions were performed on the LightCycler® 480 System 
(Roche Applied Science) instrument. The reactions were prepared as outlined in table 4.7: 
Table 4.7: Reagents for a standard qPCR reaction 
Reagents Final Concentration 
SYBR GreenI Master Mix (10X) 1X 
Forward Primer (100 μM) 10 μM 
Reverse Primer (100 μM) 10 μM 
cDNA 250 ng 
PCR Grade dH2O Variable 
Final Volume 20 μl 
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The reactions were performed using the selected candidate genes; a positive control (PTEN), 
a calibrator (a cocktail of cDNA from all cell lines) and a no-template control (water). An 18 
µl aliquot of reaction mastermix was transferred to each well of the white 96 well plates. A 2 
µl aliquot of cDNA (250 ng) from various cancer cell lines was then added as the PCR 
template. A negative control was set up for each run containing 2 µl of PCR-grade water as a 
substitute for cDNA. The white 96 well plates were sealed with clear sealing foil for the 
LightCycler® 480 system and cycled on the LightCycler® 480 instrument according to the 
parameters in table 4.8. The evaluating parameters selected for data analysis were 
fluorescence (d[F1]/dT), melting temperature (Tm) and crossing point (Cp). The Second 
Derivative Maximum algorithm was employed for Cp determination where Cp was measured 
at the maximum increase of fluorescence.  
 
Table 4.8: qPCR Run Protocol 
Detection Format Block Type Reaction Volume 
SYBR® Green 96 well 20 μl 
Program Name Cycles Analysis Mode 
Pre-incubation 1 None 
Amplification 45 Quantification 
Melting Curve 1 Melting Curves 
Cooling 1 None 
Program Name Target (°C) Acquisition Mode Hold (hh:mm:ss) 
Pre-Incubation 95 None 00:10:00 
 
Amplification 
95 None 00:00:30 
Primer 
dependent 
None 00:00:20 
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72 Single 00:00:01 
 
Melting Curve 
95 None 00:00:30 
65 None 00:01:00 
97 Continuous 5-10 acquisitions/
0
C 
Cooling 40 None 00:00:30 
 
 
Specificity of real-time PCR primers was determined by amplification plots, melting 
temperature, and melting curve analysis using LightCycler Software, Version 1.5 (Roche 
Diagnostics). The standard or calibration curves were generated by the LightCycler software 
using serially diluted cDNA standards (250 ng to 0.25 ng) was quantified in each real-time 
PCR run and each dilution was amplified in duplicate. Data on expression levels for 
housekeeping genes were obtained in the form of crossing points or cycle threshold (Cp/Ct). 
Data acquisition was done through pairwise comparison using the geometric mean. The PCR 
efficiencies were calculated using the REST® software and all Ct values were taken into 
consideration according to the following equation: E=10[-1/slope] (Pfaffl 2001). The 
expression levels of all genes were determined relative to the housekeeping genes using the 
following equation: 
 
 
R=     (Etarget) 
ΔCptarget (MEAN control- MEAN sample) 
 
        (Ereference)
 ΔCpreference (MEAN control- MEAN sample) 
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4.4. Results and Discussion
 
The relative expression levels of the ten candidate genes identify through in silico 
methodologies were determined across an array of cancer cell lines using qPCR. 
Housekeeping genes (HKGs) / endogenous controls were selected to compensate for the 
inevitable sample variations observed in qPCR experiments. These variances such as 
preparation of RNA from biological samples, even the conversion step can affect the 
reliability of the qPCR results, thus, the consistency and reliability of qPCR experiments is 
significantly improved by including endogenous controls (Pfaffl, 2004). There are several 
alternative techniques used to normalize qPCR experiments, however the most commonly 
used strategy is normalization to an internal reference or a housekeeping gene. Housekeeping 
genes are widely used as reference genes since their expression is assumed to be stable. The 
ideal reference gene must be constitutively expressed and unregulated regarding the 
experimental conditions, treatment, and stage of the disease. It should be expressed at a 
similar level as the target gene (Nestorov et al., 2013).  
 
Therefore the selection of reliable housekeeping genes would correct sample-sample 
variations; hence display constant expression in all tissues under variable conditions, 
allowing a comparative analysis across all samples (Kubista et al., 2006). The most 
recommended and mostly used reference genes in qPCR studies are GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase), BA (B-Actin), HPRT1 (hypoxanthine 
phosphoribosyltransferase1), and UBC (ubiquitin C), to highlight a few (Nestorov et al., 
2013). However for this research only GAPDH and HPRT1 were used as reference genes 
since they are also present in all nucleated cell types and essential for cell survival (Pfaffl, 
2001). 
 
4.4.1. Amplification Curve and Melting Curve Analysis 
To investigate the expression levels of the ten target genes, eleven cell lines, of which three 
were cervical cancer as shown in table 4.2.1 were used and this was carried out as described 
in section 4.3.6. Before proceeding with qPCR analysis, it is imperative to verify that the 
PCR amplification is specific under the actual qPCR conditions. This was done in the Roche 
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LightCycler® 480 using the melting curve analysis feature. It is good laboratory practise to 
perform melting curve analysis after each real-time PCR run as a quality control step, as it is 
used to distinguish target amplicons from PCR artifacts such as primer-dimers or misprimed 
products (Fraga et al., 2008). The KAPA SYBR FAST qPCR kit optimized for LightCycler® 
480 uses SYBR® Green I dye chemistry to detect and quantitate the accumulation of an 
amplicon. SYBR Green represents the simplest and the most economical choice for real-time 
PCR product detection. This fluorogenic intercalating dye emits a strong fluorescent signal 
upon binding to double-stranded DNA (dsDNA) while unbound dye in solution exhibits little 
undetectable fluorescence. SYBR Green I can be used with any pair of primers, for any 
target, with no need for any additional fluorescence-labelled oligonucleotide (Nestorov et al., 
2013).   
 
The major drawback of using this dye is that both specific and nonspecific PCR products are 
detected, because SYBR green will bind to any double-stranded DNA in the reaction, 
including primer-dimers and other nonspecific reaction products, leading to overestimation of 
the target sequence concentration (Nestorov et al., 2013). Melting peaks are generated by 
plotting the negative derivative (-dF/dT) of the melting curve. From figure 4.2, it can be 
observed from the amplification curves that there was no non-specific background 
amplification. Furthermore, the melting curve analysis shows specific, single, narrow, and 
distinctive melting peaks (Nolan et al, 2006). As indicated by the figure only the target 
products were amplified. Each amplification product for the target genes demonstrated a 
specific and characteristic melting curve. No primer dimerization or nonspecific products 
were generated for the applied number of amplification cycles for the respective target genes. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Amplification curve and melting peak of GAPDH and target gene 10. 
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4.4.2. Generation of an Absolute Standard Curve 
The standard curve method is the most common approach in determining relative 
quantification, where the standard curve is generated for both the target and reference gene of 
choice (Sharkey et al., 2004) (Livak, 1997). The standard or calibration curves were 
generated by the Roche LightCycler software. The quantity of each target gene is mainly 
determined by means of a standard curve and subsequently expressed relative to a reference 
gene and they were used to calculate the efficiency of qPCR (Figure 4.3). To generate a 
standard curve, the serially diluted cDNA standard (250 ng to 0.25 ng) was quantified in each 
real-time PCR run. Each dilution was amplified in duplicate or triplicate. For each standard, 
the concentration was plotted against the cycle number at which the fluorescence signal 
increased above the threshold value (Ct) or crossing point (Cp). The gradient generated by 
each standard curve was used in the equation: Efficiency (E) = 10
-1/slope
 - 1 to determine the 
reaction efficiency (Rasmussen, 2001), with table 4.9 showing the efficiency and gradient of 
the housekeeping gene (GAPDH) and candidate genes.  
 
Table 4.9: qPCR efficiencies and standard curve gradients of target genes 
 Efficiency (E) Gradient 
GAPDH 1.99 -3.35 
Gene 1 1.94 -3.47 
Gene 2 1.92 -3.52 
Gene 3 1.93 -3.50 
Gene 4 1.92 -3.52 
GENE 5 1.97 -3.52 
Gene 6 1.97 -3.39 
Gene 7 1.95 -3.45 
Gene 8 1.94 -3.48 
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Gene 9 1.92 -3.52 
GENE 10 1.95 -3.45 
PTEN 1.94 -3.47 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Standard curves of the housekeeping gene (GAPDH) and one of the target genes (gene 10) 
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4.4.3. qPCR data Analysis and Quantification of Gene Expression 
Gene expression was quantified using the Pfaffl model which combines gene quantification 
and normalization and was calculated with the aid of Microsoft Excel based application, 
Relative Expression Software Tool  (REST-348) - Version 1 (Pfaffl et al., 2002). For this 
mathematical model, it is essential to determine the crossing point (Cp) value of each 
transcript. Given that Cp values decrease linearly with an increasing target quantity, Cp 
values could be used as a quantitative measurement of the input target number (Heid et al., 
1996). This method involved comparing the Cp values of the investigated transcripts with a 
control. The Cp values of both the control and the genes of interest were normalized to an 
appropriate housekeeping gene. REST-384 calculates relative expression using the statistical 
model Pair Wise Fixed Reallocation Randomization Test. For each sample, Cp values for the 
reference and target genes were randomly reallocated to the control and sample groups. 
Differences in gene expression levels between control and samples were evaluated in group 
means for statistical significance by randomization tests (Pfaffl et al., 2002). Descriptive 
statistics such as the sample means, minimal (Min) and maximal (Max) values, standard 
deviation (SD), and coefficient of variance expressed as a percentage (CV%), of the derived 
Cp values were computed for each investigated gene to determine intra-sample variation. 
 
 
An analysis was done to evaluate the specificity of the putative genes for cervical cancer by 
analysing their expression patterns in three different cervical cancer cell lines; six different 
cancer cell lines and one non-cancerous cell line (refer to table 4.2.1). The normal skin 
fibroblast cell line, KMST-6 was used as a non-cancerous cell line since there is no non-
cancerous cell line for the cervix tissue. The ten putative genes were relatively measured in 
the various cancer types against the KMST-6 cell line which served as a control using the 
Pfaffl method as depicted in figure 4.4. Differential expression of the genes was observed 
across all cancer cell lines, with gene 5 and gene 8 being significantly highly expressed in 
cervical cancer cell lines: Hela, Caski and HT-3 in comparison to other cancer cell lines. 
Furthermore, gene 10 is also highly differentially expressed in the cervical cancer when 
compared to other cancer types. Genes 5, 8 and 10 thus have the highest potential to be 
biomarkers for cervical cancer. This study was designed to identify genes that were 
differentially expressed during cervical cancer development, meaning genes that were either 
up-regulated or down-regulated.  
 
 
 
 
 Figure 4.4: Relative expression ration plot of the ten putative genes across various cancer cell lines. 
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The data obtained from the in silico tissue specificity analysis in section 3.4, corresponds 
with the data acquired using qPCR analysis. Genes 5, 8 and 10 were shown to be highly 
specific to the cervix tissue as highlighted in figures 3.8, 3.11 and 3.13 respectively. The 
relative expression plot showed that the other putative genes were highly expressed in other 
cancer cell lines in comparison to cervical cancer cell lines. Table 4.10 represents a 
microcosm illustration of the relative expression ratio plot depicting the fold expression ratios 
of the putative genes across all cell lines. 
 
Table 4.10:  Fold expression ratios of 10 putative genes 
 Hela Caski HT3 A549 T84 MCF 7  SKOV3 Caov3 
Gene 1 1.080 1.032 -1.014 -1.014 -1.014 1.009 -1.277 -1.098 
Gene 2 1.241 1.186 1.133 1.133 1.133 1.159 -1.091 1.046 
Gene 3 1.608 1.112 1.275 -1.035 -1.035 -2.168 -1.042 5.129 
Gene 4 1.106 1.057 1.009 1.107 1.107 1.082 -1.091 -1.073 
Gene 5 9.569 6.088 3.681 3.597 2.163 1.495 1.005 2.686 
Gene 6 1.080 1.032 -1.014 -1.014 -1.014 1.009 -1.018 -1.098 
Gene 7 1.213 1.159 -1.014 -1.014 -1.014 2.485 1.005 1.022 
Gene 8 2.600 3.612 4.132 1.272 1.243 -1.307 -3.017 -1.707 
Gene 9 1.080 1.032 -1.014 1.107 1.107 1.133 -1.018 -1.098 
Gene 10 4.033 2.495 -3.531 1.883 1.033 1.009 3.311 -1.001 
PTEN 1.459 1.883 -4.659 5.452 2.726 4.532 5.428 -1.124 
  
 
The seven putative genes showed to be differentially expressed in different cancer cell lines, 
however from table 4.10 it could be deduced that gene 7 was more significantly expressed in 
MCF7 cell lines, which is a breast cancer cell line. In contrast gene 3 showed a significant 
expression in CAOV3, an ovarian cancer cell lines. Gene 3 and gene 7 could serve as 
potential biomarkers for ovarian and breast cancer respectively. The fact that some of the 
putative genes showed up-regulation in other cancer types is positive; hence this study is a 
part of a bigger research for biomarker discovery for various cancers such as breast, ovarian, 
lung and prostate cancer. These candidates will be further validated in the respective cancers 
where they showed differential expression as potential biomarkers.  
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Phosphatase and tensine homologue (PTEN) has been implicated in biomarker studies as an 
indicator for cervical cancer. PTEN a tumour-suppressor gene is involved in cellular 
differentiation, reproduction and apoptosis, as well as cellular adhesion and mobility. The 
loss or down-regulation of PTEN plays an important role in the multiple steps of 
tumourigenesis and progression of malignancies (Qi et al., 2014). According to Grigore et al, 
PTEN expression in squamous cell carcinoma is lower compared with normal cervical 
epithelium. It might be used as a marker for early diagnosis and prognosis of cervical cancer. 
In this study PTEN was included as a positive control isolated from the candidate genes 
obtained from the in-silico pipeline (Chapter 2). It’s inclusion as part of the candidate genes 
rendered as evidence of the pipeline to identify novel as well as existing biomarkers for 
cervical cancer. This meant that the putative biomarkers should have a fold change 
expression ratios similar to the positive control and even more. However from the data 
obtained it can be deduced that this biomarker was not significantly expressed in cervical 
cancer cell lines. All the candidate biomarkers were over-expressed in comparison to the 
positive control in cervical cancer, thus suggesting these genes as possible biomarkers for 
further validation. PTEN was over-expressed in other cancer cell line, with significant 
expression in SKOV3 (ovarian cancer), MCF-7 (breast cancer) and A549 (lung cancer). 
However this is not surprising because according to Loures et al, PTEN inactivation may 
play an important role in the pathogenesis of a variety of human malignancies.  
 
A study done by Eijsink et al indicated that a loss of PTEN expression frequently occurs in 
early-stage cervical cancer. Qi et al (2014) established that PTEN plays an important role in 
the occurrence and development of cervical cancer and the PTEN protein expression 
phenotype can be considered as an indicator for the pathophysiological behaviour of cervical 
cancer. The fact that our putative biomarkers showed a significant expression to the PTEN 
biomarker indicates that these genes could also play a role in early stage cervical cancer, 
especially, genes 5, 8 and 10 since they showed substantial differential expression in cervical 
cancer cell lines. From the literature studies conducted in chapter 2, there were no known 
associations of these putative genes with cervical cancer and it was not clear what their 
involvement is in cervical cancer. However, the top three candidate biomarkers, gene 5, 8 and 
10 will be discussed according to various publications.  
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Gene 5 is an 855 amino acid secreted protein that localizes to the extracellular space/ matrix, 
is not attached to membranes and contains three peptidase S1 domains. It is a Proteolytic 
enzyme or protease, which is a protein that performs a common biochemical reaction, the 
hydrolysis of peptide bonds. Proteases act as highly specific processing enzymes and perform 
a selective and limited cleavage of specific substrates. These proteolytic processing events 
are essential for the regulation of multiple events such as cell cycle progression, tissue 
morphogenesis and remodelling, cell proliferation and migration, ovulation, angiogenesis, 
haemostasis, apoptosis, and autophagy. Consistent with these diverse and essential roles of 
proteases in living organisms, structural changes in these enzymes or alterations in their 
expression patterns underlie many pathological conditions such as metabolic diseases, 
neurodegenerative disorders, cardiovascular alterations, arthritis, and cancer (Cal et al., 
2005).  
 
Most of the well-characterized members of the S1 family of serine proteases are either 
secreted enzymes or exocytosed from secretory vesicles into the extracellular environment. A 
structurally distinct group of S1 serine proteases, termed broadly as the membrane-anchored 
serine proteases, has emerged that are synthesized with amino- or carboxy-terminal 
extensions that serve to anchor their serine protease catalytic domains directly at the plasma 
membrane. Additional membrane-anchored serine proteases of the S1 family each possess an 
amino-terminal signal peptide and enter the secretory pathway. Surface localization studies 
demonstrate that membrane-anchored serine proteases normally localize to the cell surface 
and are differentially distributed on apical or basolateral surfaces of polarized cells in patterns 
unique for each protease (Antalis et al., 2011). 
 
 
Gene 8 is a 29-amino acid COOH-terminally, highly conserved but unique neuroendocrine 
peptide originally isolated from intestine. This gene mediates biological effects by interacting 
with high-affinity cell surface receptors. Expression of gene 8 peptides has been detected in 
pheochromocytoma, pituitary adenoma, neuroblastic tumours, gastrointestinal cancer, 
squamous cell carcinoma, brain tumours, melanoma, breast cancer and embryonal carcinoma. 
In several cancers and tumour cell lines expression of gene 8 receptors has been shown as 
well. Expression of peptide or receptors has been correlated with tumour stage or subtypes of 
pituitary adenoma, neuroblastic tumours, colon carcinoma and squamous cell carcinoma. 
Gene 8 and its receptors are promising targets for diagnosis and treatment of several types of 
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tumours. There are several explanations for a possible influence of the circulating levels of 
gene 8 on cancer growth. For instance, circulating levels may be influenced by cancer growth 
as a result of altered expression of gene 8 in cancer tissues. As gene 8 is an inhibitory factor 
in regulating cell proliferation the protection mechanism would be increased with the cancer 
growth. Gene 10 is an aminoacyl-tRNA synthetase (ARS) that links the amino acid glycine to 
its corresponding tRNA prior to protein translation and is one of three bifunctional ARS that 
are active within both the cytoplasm and mitochondria (McMillan et al., 2014). Gene 10 
catalyzes the attachment of glycine to tRNA-gly in the cytoplasm and mitochondria and thus 
plays an essential role in protein synthesis. Park et al (2012) have implicated secreted 
extracellular gene10 in immune surveillance against cancer. Gene 10 is secreted by 
macrophages in response to FAS ligand that is released from tumor cells and acts as a 
cytokine with a distinct role against specific tumor cells, this enzyme is essential for protein 
synthesis in all cells and tissues. ARS are being increasingly recognized as having important 
secondary functions that include regulation of transcription, translation, splicing and 
apoptosis. ARS mutations have been implicated in a wide range of human diseases 
(McMillan et al., 2014). 
 
 
4.5. Conclusion 
A critical step in the biomarker discovery pipeline is validation of biomarkers. Before any 
biological entity can be stated as a biomarker all required tests must be done in order to prove 
that the entity is fit for such a purpose. There are some limitations in array technologies even 
though they are comprehensive and relatively accurate in analysing gene expression and have 
been used in numerous human malignancy studies. Microarray results are influenced by 
various external factors such as RNA extraction. Consequently, differentially expressed genes 
in such preliminary discovery efforts need to be confirmed using alternative methods such as 
qPCR (Hu et al., 2006). Even though microarray technology is growing broadly, qPCR is still 
one of the best methods used extensively for gene expression studies in tissue samples 
(Pfaffl, 2001) and as such was used in this study. Quantitative real time PCR has the 
capability to quantify rare transcripts and small changes in gene expression. The difference in 
gene expression has the ability to shed light on the role of a gene or gene product in a 
particular process. Changes in gene expression of a particular gene or a group of genes can be 
indicative of a diseased state as the body tries to maintain homeostasis (Pfaffl, 2001). 
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This research study intended to validate the ten putative genes identified using an in silico 
approach in cervical cancer cell lines in comparison to a non-cancerous cervical cell line and 
relative to other cancer types. However, at present there are no non- cancerous cervical cell 
line, therefore normal fibroblast cell lines were used instead. A postulation established for 
this study was based on the theory that genes differentially expressed in cervical cancer 
compared to normal, non-diseased state might shed light into the progression and diagnosis of 
this disease. Further evaluation of the expression levels of these genes in other cancer types 
may lead into understanding which genes could possibly be explored as putative biomarkers 
for diagnostic and therapeutic purposes in cervical cancer and if new discoveries can be 
uncovered to better understand the role of these genes in other cancers. This aim was 
achieved by evaluating the expression levels of these genes using qPCR.  The gene 
expression levels of the ten putative genes were evaluated across various cancer cell lines 
represented in table 4.2. The results from qRT-PCR were analysed using the REST-384© 
software package through Pfaffl model (Pfaffl, 2001). The software tested for significant 
results by means of randomisation test and target genes with a p-value less than 0.05 were 
deemed as showing significant gene expression in cancer cells relative to the calibrator 
(KMST-6). 
 
A relative expression ratio plot was generated using the software as shown in figure 4.3. The 
gene expression levels for all cancer types were measured relative to a normal fibroblast cell. 
Three genes: 5, 8 and 10 showed a significant differential expression in cervical cancer 
comparative to other cancer types.  It was noted that five genes: 1, 6, 7, 9, and 10 were down-
regulated in HT3 (cervical cancer), with gene 10 being significantly down-regulated. This 
correlates with the design of the study to identify biomarkers differentially expressed in 
cervical cancer. Furthermore, it was interesting to observe that the expression of these 
putative genes had an expression ratio significantly above PTEN, a gene reported as a 
biomarker for cervical cancer. This suggested that these genes might play a role in cervical 
cancer development and be stronger indicators of disease onset and or progression compared 
to PTEN. The genes that showed slight expression in cervical cancer cannot be disregarded to 
have no significant role in cervical cancer. As it has been documented cancer is a 
heterogeneous disease and is very complex; hence some genes are expressed at basal levels at 
one point during the course of cancer development (Mishra and Verma, 2010).  
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Studies performed on cell lines can be limiting due to that analysis on tissues is outside a 
biological system. The assumption that some genes could be expressed at one point or stage 
of the disease state at which the tissue was isolated may not necessarily present the holistic 
process of cancer. These genes can be further defined in other cancer types, thus these genes 
were further investigated in other cancer types to evaluate if they will display a similar profile 
as they have in cervical cancer. The expression ratios exhibited by the putative genes 
revealed the need to understand mechanism at which these genes are associated to other 
cancers. As depicted in figure 4.3 it was clear that although these genes were differentially 
overexpressed across all cancer types, none were specific to one type of cancer. Therefore, 
the other seven genes (1, 2, 3, 4, 6, 7, and 9), showed overexpression in other cancer types in 
comparison to cervical cancer. Gene 3 was over-expressed in an ovarian cancer cell line 
(CAOV3). 
 
It is evident that the genes presented in this study were expressed ubiquitously across all 
cancer types that were investigated. Some genes showed upregulated expression in cervical 
cell lines while other genes remained unchanged. The genes highlighted yellow in table 4.10 
were of interest as they exhibited overexpression above PTEN.  The study brought about an 
understanding that the red highlighted genes (gene 3 and 7) showed upregulated expression in 
ovarian and breast cancer respectively. It also managed to prioritise genes significantly 
overexpressed in cervical cancer and may be pursued further as biomarkers for cervical 
cancer. These studies serve as basis for future investigations to determine whether these 
candidate genes can be exploited as potential biomarkers for diagnosis of cancers in general, 
as well as, for specific cancers. Thus, they could also serve as potential drug targets for 
cancer treatment. 
 
 
 
 
 
 
 
 
 
 
  
136 
 
4.6. References 
1. Antalis, T.M., Bugge, T., and Wu, Q. 2011. Membrane-anchored serine proteases in 
health and disease. Prog Mol Biol Transl Sci, 99: 1–50.  
2. Cal, S., Quesada, V., Llamazares, M., Díaz-Perales, A., Garabaya, C., and López-
Otín, C. 2005. Human Polyserase-2, a Novel Enzyme with Three Tandem Serine 
Protease Domains in a Single Polypeptide Chain. Journal of biological chemistry, 
280(3): 1953–1961.  
3. Eijsink, J.J., Noordhuis, M.G., ten Hoor, K.A., et al. 2010. The epidermal growth 
factor receptor pathway in relation to pelvic lymph node metastasis and survival in 
early-stage cervical cancer. Hum Pathol, 41:1735-1741. 
4. Fraga, D., Meulia, T., and Fenster, S. 2008.  Real-Time PCR. Current Protocols 
Essential Laboratory Techniques, 10.3.1-10.3.34. 
5. Guescini, M., Sisti, D., Rocchi, M.B.L., Stocchi, L., and Stocchi, V. 2008. A new 
real-time PCR method to overcome significant quantitative inaccuracy due to slight 
amplification inhibition. BMC Bioinformatics, 9(326):1-12.  
6. Grigore, M., Teleman, S., Ungureanu, D., and Mares, A. 2013. Molecular markers in 
cervical screening – a promise for the future. Revista Română de Medicină de 
Laborator, 21(2/4): 231-239. 
7. Heid, C. A., Stevens, J., Livak, K.J., and Williams, P.M. 1996. Real-time quantitative 
PCR. Genome Research, 6:986-994. 
8. Hu, N., Qian, L., Hu, Y., Shou, J-Z., Wang, C., Giffen, C., Wang, Q-H., Wang, Y., 
Goldstein, A.M., Emmert-Buck, M. and Taylor, P.R. 2006. Quantitative real-time RT-
PCR validation of differential mRNA expression of SPARC, FADD, Fascin, 
COL7AI, CK4, TGM3, ECMI, PPL and EVPL in esophageal squamous carcinoma. 
BMC Cancer, 6(33), pp. doi: 10.1186/1471. 
9. Jacob, F., Rea Guertler, R., Naim, S., Nixdorf, S., Fedier, A., Hacker, N.F., and 
Heinzelmann-Schwarz, V. 2013. Careful Selection of Reference Genes Is Required 
for Reliable Performance of RT-qPCR in Human Normal and Cancer Cell Lines. 
PLOS ONE, 8(3):1-8.  
 
 
 
 
  
137 
 
10. Kubista, M., Andrade, J.M., Bengtsson, M., Forootan, A., Jonák, J., Lind, K., 
Sindelka, R., Sjöback, R., Sjögreen, B., Strömbom, L., Ståhlberg, A., Zoric, N. 2006. 
The real-time polymerase chain reaction.  Mol Aspects Med, 27: 95-125. 
11. Livak, K. J. 1997. ABI Prism 7700 Sequence Detection System, User Bulletin 2. PE 
Applied Biosystems, Foster City, CA. 
12. Loures, L.F., Cândido, E.B., Vidigal, P.V.T., Seabra, M.A.L., Cunha de Marco, L.A., 
and da Silva-Filho, A.L. 2014. PTEN expression in patients with carcinoma of the 
cervix and its association with p53, Ki-67 and CD31. Rev Bras Ginecol Obstet; 
36(5):205-10. 
13. Nestorov, J., Matic, G., Elakovic, I., Nikola Tanic, N. 2013. Gene expression studies: 
how to obtain accurate and reliable data by quantitative real-time RT PCR. J Med 
Biochem; 32 (4):325-338.  
14. Nolan, T., Hands, R. E., and Bustin, S. A. 2006. Quantification of mRNA using 
realtime RT-PCR. Nature Protocols, 1:1559-1582. 
15. Park, M.C., Kanga, T., Jina, Min Han, J., Bum Kim, S., Park, Y.J., Cho, K., Park, 
Y.W., Guo, M., He, W., Yang, X.L., Schimmel, P., and Kim, S. 2012. Secreted 
human glycyl-tRNA synthetase implicated in defense against ERK-activated 
tumorigenesis. PNAS, 640–647. 
16. Pfaffl, M.W. 2001. A new mathematical model for relative quantification in real-time 
RT-PCR. Nucleic Acids Research, 29(9):2003-2007. 
17. Pfaffl, M.W. 2004. Quantification strategies in Real Time PCR. In A-Z of 
Quantitative PCR. Ed S.A Bustin. International University Line. California, pp.87-
112. 
18. Pfaffl, M.W., Horgan, G.W., and Dempfle, L. 2002. Relative expression software tool 
(REST©) for group-wise comparison and statistical analysis of relative expression 
results in real-time PCR. Nucleic Acids Research, 30(9):1-10. 
19. Qi, Q., Ling, Y., Zhu, M., Zhou, L., Wan, M., Bao, Y., and Liu, Y. 2014. Promoter 
region methylation and loss of protein expression of PTEN and significance in 
cervical cancer. Biomedical Reports, 2: 653-658.  
 
 
 
 
  
138 
 
20. Rasmussen, R. P. 2001. Quantification on the LightCycler. In Meuer, S., C. Wittwer, 
K. Nakagawara. (Eds.). Rapid cycle real-time PCR, methods and applications. pp. 21-
34. Springer Press. Heidelberg. 
21. Sharkey, F. H., Banat, I. M., and Marchant, R. 2004. Detection and quantification of 
gene expression in environmental bacteriology. Applied and Environmental 
Microbiology, 70:3795-3806. 
22. Wong, M.L., and Medrano, J.F. 2005. Real-time PCR for mRNA quantitation. 
BioTechniques, 39(1):1-11.  
23. Yuan, J.S., Reed, A., Chen, F., and Stewart Jr, C.N. 2006. Statistical analysis of real-
time PCR data. BMC Bioinformatics, 7(85):1-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
139 
 
CHAPTER 5: General Discussion and Future Directions 
Cancer is emerging as an under-recognised global threat to human development. It is 
estimated that there will be 22.2 million new cases of cancer and 12.7 million cancer-related 
deaths worldwide in 2030(Ginsburg, 2013). More than half of new cases and two-thirds of 
cancer deaths will occur in low and middle-income countries, where access to early, accurate 
diagnosis and quality care are woefully lacking. The increasing burden of cancer has 
especially harsh consequences for women due to gender discrimination, cultural taboos and 
stigma, all of which conspire to limit women’s choices to seek care even when it is available 
(Ginsburg, 2013). In South Africa however, women, especially black women, present with 
advanced cancer–too late for them to be cured. Not only the World Health Organisation, but 
also the Cancer Association of South Africa (CANSA) stresses prevention and early detection 
as the best way to fight the disease (Maree and Wright, 2010).  Early diagnosis of cancer is 
difficult because of the lack of specific symptoms in early disease and the limited 
understanding of aetiology and oncogenesis (Cho, 2007).  
 
One of the main reasons for high death rates in cancer patients is due to the lack of well-
validated and clinically useful biomarkers with adequate sensitivity and specificity to detect 
this disease at early stages. However, cervical cancer is curable when detected early before 
the development of metastasis. Development of cervical cancer is a multi-step process 
initiated by persistent infection with high-risk human papillomavirus, which in a limited 
number of cases progresses via cervical intraepithelial neoplasia to invasive cervical cancer 
that usually spans 10-20 years, which offers a period of several years to detect the tumour in 
an early stage and to interfere with the natural cause of the disease.  
 
All South African women have access to cervical cancer screening at primary health clinics 
however the screening uptake is only approximately 20%, thus most women present with late 
cervical cancer. A study conducted by Van Schalkwyk et al (2008), revealed that women 
were willing to be diagnosed but were failed by the health care system, with their initial 
interaction with the health care system not resulting in prompt diagnosis or treatment and 
they repeatedly had to go back before being diagnosed  (Issah et al., 2011). Early detection of 
CC can therefore significantly reduce the mortality associated with this malignancy. 
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However, current screening methods including Pap smear test, colposcopy, pathological and 
preoperative diagnosis either lack the required sensitivity and specificity or are costly and 
invasive. Some biomarkers such as the CEA levels and tumour-associated gene mutations 
have only shown some prognostic or predictive value (Cho, 2007). There is therefore an 
urgent need for developing new diagnostic/screening tests and identifying putative 
biomarkers to diagnose, predict and monitor the progress of CC and eventually find more 
efficient drug targets for this disease.  
 
The aim of this study was to discover biomarkers that could aid in the early diagnosis of 
cervical cancer. A diagnostic system that can detect biomarkers that are found in bodily fluids 
can serve as a less invasive, inexpensive and specific and sensitive method for detection. The 
in silico approach used in this study was successful in identifying genes that are associated 
with cervical cancer as well as those who have not yet been associated with the disease thus 
verifying that data obtained from this pipeline was reliable. The methodology employed in 
chapter two allowed for genes to be proficiently prioritised based on various categorical 
levels. The results indicated that this pipeline can save time and can be incorporated in 
biomarker discovery studies successfully. A study done by Prassas et al (2012), used a 
similar bioinformatic approach to identify proteins with tissue-specific expression for 
biomarker discovery, their study managed to identify previously studied cancer biomarkers. 
This study identified ten putative biomarkers and they were verified in each step of 
elimination and were confidently selected for further validation.   
 
Databases house vast amounts of information therefore for biomarker identification in silico 
approaches were carefully selected to uncover the wealth of information. Furthermore each 
tool employed in this study was able to prioritize and discriminate between data that was 
required for the next step of the study and eliminate those that were not. This required the 
user to establish parameters of inclusion or exclusion and these were defined in Chapter 2. 
The study made use of multistep processes which involved data mining, literature mining, 
refinement and annotation tools that have led to the identification of putative biomarkers for 
cervical cancer. The identification of candidate biomarkers on a small scale as opposed to 
wet-bench techniques could lead to more biomarkers being identified in shorter periods of 
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time (Magni et al., 2010). Understanding genes on the transcriptional level gives new insight 
into how the genes are regulated; it can also implicate them in various pathways and can 
indicate similar protein-protein interactions. The in silico pipeline proved to be valuable in 
extracting complex candidate gene lists. Most of the genes were predicted to be enriched for 
various cancer-associated processes by Gene Ontology (DAVID), protein-protein interactions 
(STRING) and pathway analysis (KEGG). The GOI were predicted to be transcriptionally 
coupled to PPARγ (down-regulated in pre-invasive cervical cancer) and to be interacting with 
PCNA, thereby showing potential value for providing an early diagnosis of cervical cancer. 
Ninety percent (90%) of the GOI were co-expressed, while many genes participated in 
cancer-related pathways. This could implicate their possible role in a coordinated cervical 
cancer pathway. Lastly, their potential tissue specificity and sensitivity was also 
demonstrated by various in silico analyses. This section of the study successfully implicated 
the ten cell surface gene products in cancer based on their regulatory elements, interacting 
proteins and pathway analysis. The in silico biomarker discovery should be a continuous 
study in a quest to identify potential novel genes since microarray databases are frequently 
updated. Further bioinformatics studies should be done between the putative biomarkers and 
known clinical biomarkers for cervical cancer. Gene expression profiles should also be 
established by combining the candidate genes with their interacting proteins for early 
diagnosis. Further investigation of the GOI and their regulatory elements through projects 
such as the ENCODE Consortium could also provide valuable insights and help to map a 
possible cervical cancer pathway. 
 
It is well accepted that in silico prediction of biomarkers should not be separated from in-
vitro validation in a biological system. With that in mind, a molecular approach was 
employed to confirm gene expression patterns of the ten putative biomarkers which were 
identified using an in silico approach. An important aspect of cancer aetiology lies in the 
stepwise accumulation of genetic and epigenetic changes. These changes contribute to the 
development of cancer and they vary between different cancer types and stages, tissues and 
individual (Sadikovic et al., 2008). Bioinformatics approach in conjunction with 
experimental validation provided a powerful combination to carry out this research study. 
qPCR significantly simplifies and accelerates the process of producing reproducible and 
reliable quantification of target genes transcription.  
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The study revealed that PTEN was differentially expressed in CC cell lines and it is therefore 
being investigated as a potential biomarker for the prognosis of CC. However, the PTEN 
biomarker was significantly overexpressed in A549 (lung cancer), MCF7 (breast cancer) and 
SKOV3 (ovarian cancer), thus making this biomarker not to be specific and sensitive for 
cervical cancer. The study also revealed that the ten putative genes were differentially 
expressed in the cancer cell lines as compared to the non-cancerous cell line (KMST6). Three 
genes were shown to be potential biomarkers for cervical cancer, gene 5, gene 8 and gene 10.  
Gene 3 was upregulated in ovarian cancer and gene 7 was overexpressed in breast cancer.  In 
conclusion, the work presented in this thesis has revealed several candidate putative 
biomarkers that need to be tested on samples from cervical cancer patients in combination 
with known cervical cancer biomarkers used in clinical settings.  
 
Further studies could include confirming the expression of protein products of differentially 
expressed gene candidates in media of various human cell lines (cancer and non-cancerous) 
using western blots. Furthermore, the presence of these proteins could be investigated in 
cervical cancer patient samples using ELISA. This study may open avenues into nano-
diagnostics by using nano-devices. Biomarkers can exist in small quantities in biological 
fluids and may be masked by other proteins. The application of nanotechnology can ensure 
the detection of these biomarkers on a nano-scale. By combining nanotechnology in the form 
of gold nanoparticles, the study can be used to develop a lateral flow device for the detection 
of CC as shown in Figure 5.1. This has the potential for a diagnostic test to be developed that 
is more cost effective and can rapidly be adopted into clinical practice. Also, it may be 
possible to test for these biomarkers in serum or other bodily fluids thus avoiding invasive 
diagnostic tests.
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 5.1: A nanotechnology lateral flow assay where ligands will bind to the biomarkers for a positive result. 
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